91探花
Back to
Scientia Professor Gregory Dore

Scientia Professor Gregory Dore

Professor

2001聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 PhD聽 聽聽聽聽聽聽聽聽聽聽聽聽聽聽 University of New South Wales

1997聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 MPH聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 University of Sydney

1995聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 FRACP 聽聽聽聽聽聽聽聽聽聽聽 Royal Australasian College of Physicians

1987聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 BSc聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 University of New South Wales

1987聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 MBBS聽聽聽聽聽聽聽聽聽聽聽聽聽 University of New South Wales

Medicine & Health
The Kirby Institute

Professor Dore is Head, Viral Hepatitis Clinical Research Program, Kirby Institute, 91探花 Sydney, and Infectious Diseases Physician, St Vincent鈥檚 Hospital, Sydney, Australia. He has been involved in viral hepatitis and HIV epidemiological and clinical research, clinical care and public health policy for 25 years. He has developed extensive national and international collaborations and is internationally recognized in the areas of HCV natural history and epidemiology, therapeutic strategies for acute and chronic HCV infection, particularly among people who inject drugs, and HCV elimination strategies.

He has received large-scale public sector research funding from U.S. National Institutes for Health and Australian National Health and Medical Research Council (NHMRC).

Professor Dore has been President of the Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM), a member of NHMRC Council, and is an NHMRC Leadership Fellow (L3).

Professor Dore established the St Vincent鈥檚 Hospital viral hepatitis service in 1999 and led its development into one of the leading national and international hepatitis C treatment services, with a particular focus on marginalised populations including people who inject drugs and homeless persons.
Phone
02 9385 0900
E-mail
gdore@kirby.unsw.edu.au
Location
Wallace Wurth Building 91探花 Sydney
  • Books | 2009
    2009, Hepatitis C: An Expanding Perspective, Dore GJ; Dore G; Lloyd AROLA, (eds.), IP Communications, East Hawthorn
  • Book Chapters | 2021
    Hajarizadeh B; Martinello M; Dore G, 2021, 'HCV Elimination in Australia', in Hepatitis C: Epidemiology, Prevention and Elimination Volume 1, Springer,
    Book Chapters | 2020
    Dore GJ; Martinello M, 2020, 'Global elimination of hepatitis C virus by 2030: The optimistic view', in Clinical Dilemmas in Viral Liver Disease, Second Edition, pp. 238 - 243,
    Book Chapters | 2019
    Martinello M; Hajarizadeh B; Grebely J; Matthews G; Dore G, 2019, 'Cure and Control: What Will It Take to Eliminate HCV?', in Sofia M (ed.), HCV: The Journey from Discovery to a Cure: Volume II, Springer International Publishing, pp. 447 - 490,
    Book Chapters | 2017
    Martinello MK; Grebely J; Dore G, 2017, 'Protease, polymerase and assembly inhibitors for the treatment of hepatitis C virus infection', in Kucers' The Use of Antibiotics A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set, CRC Press
    Book Chapters | 2010
    Thein H-H; Dore GJ, 2010, 'Cognitive Function, Mood and Health-Related Quality of Life in Hepatitis C Virus-Infected Individuals', in Handbook of Disease Burdens and Quality of Life Measures, Springer New York, pp. 3299 - 3326,
    Book Chapters | 2009
    Boesecke C; Dore GJ; Cooper DA, 2009, 'AIDS: Clinical Manifestations', in Encyclopedia of Life Sciences (eLS), John Wiley & Sons, Ltd., Chichester, pp. 1 - 10,
    Book Chapters | 2009
    Dore GJ; Temple-Smith M; Lloyd AROLA, 2009, 'Future challenges for hepatitis C', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, edn. 1, IP Communications, East Hawthorn, pp. 433 - 452,
    Book Chapters | 2009
    Dore GJ, 2009, 'Initial assessment and clinical monitoring of people with hepatitis C', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, edn. 1, IP Communications, East Hawthorn, pp. 156 - 169
    Book Chapters | 2009
    Dore GJ, 2009, 'Therapy decision-making for people with chronic hepatitis C', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, edn. 1, IP Communications, East Hawthorn, pp. 181 - 191
    Book Chapters | 2009
    Grebely J; Dore GJ, 2009, 'Acute hepatitis C infection', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, edn. 1, IP Communications, East Hawthorn, pp. 230 - 253
    Book Chapters | 2009
    Loveday S; Dore GJ, 2009, 'Improving quality of life for people with hepatitis C', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, edn. 1, IP Communications, East Hawthorn, pp. 172 - 180
    Book Chapters | 2009
    Matthews G; Dore GJ, 2009, 'HIV and hepatitis C co-infection', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, edn. 1, IP Communications, East Hawthorn, pp. 308 - 329
    Book Chapters | 2009
    Thein HH; Dore GJ, 2009, 'Natural history of hepatitis C virus infection', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, edn. 1, IP Communications, East Hawthorn, pp. 76 - 89
    Book Chapters | 2008
    Nguyen VT; Dore GJ, 2008, 'Prevalence and epidemiology of hepatitis B', in Matthews G; Robotin M (ed.), B positive: All you wanted to know about hepatitis B: A guide for primary care providers, edn. 1st, Australasian Society for HIV Medicine (ASHM), Darlinghurst, Australia, pp. 13 - 23,
    Book Chapters | 2003
    Dore GJ; Cooper DA, 2003, 'AIDS : Clinical Manifestations', in , Wiley,
    Book Chapters | 2001
    Dore GJ, 2001, 'Initial assessment and clinical monitoring of people with hepatitis C', in Crofts N; Dore G; Locarnini S (ed.), Hepatitis C: An Australian Perspective, edn. 1, IP Communications, Melbourne, pp. 129 - 139
    Book Chapters | 2001
    Dore GJ, 2001, 'Natural history of hepatitis C infection', in Crofts N; Dore G; Locarnini S (ed.), Hepatitis C: An Australian Perspective, edn. 1, IP Communications, Melbourne, pp. 82 - 100
    Book Chapters | 2001
    Dore GJ, 2001, 'Theapy decision-making for people with chronic hepatitis C', in Crofts N; Dore G; Locarnini S (ed.), Hepatitis C: An Australian Perspective, edn. 1, IP Communications, Melbourne, pp. 172 - 182
    Book Chapters | 2000
    Correll PK; MacDonald MA; Dore GJ, 2000, 'Hepatitis C infection in indigenous communities in Australia', in Hepatitis C: Informing Australia`s Response, edn. Original, Commonwealth Department of Health and Aged Care, Canberra, pp. 47 - 60
    Book Chapters | 2000
    Dore GJ, 2000, 'Natural history of hepatitis C virus infection', in Hepatitis C: Informing Australia`s Response, edn. Original, Commonwealth Department of Health and Aged Care, Canberra, pp. 95 - 118
    Book Chapters | 2000
    MacDonald MA; Correll PK; Dore GJ, 2000, 'Occupational exposure to hepatitis C in health care settings', in Hepatitis C: Informing Australia`s Response, edn. Original, Commonwealth Department of Health and Aged Care, Canberra, pp. 119 - 135
  • Journal articles | 2025
    Artenie A; Trickey A; Looker KJ; Stone J; Lim AG; Fraser H; Degenhardt L; Dore GJ; Grebely J; Cunningham EB; Hazarizadeh B; Low-Beer D; Luhmann N; Webb P; Hickman M; Vickerman P, 2025, 'Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis', The Lancet Gastroenterology and Hepatology, 10, pp. 315 - 331,
    Journal articles | 2025
    Byrne CD; Dore GJ, 2025, 'Metabolic dysfunction-associated steatotic liver disease a multisystem disease: Assessing the cost effectiveness of pharmacotherapies', Journal of Hepatology,
    Journal articles | 2025
    Carson JM; Dore GJ, 2025, 'Learning From the Gaps: Rethinking Hepatitis C Virus Retreatment for People Who Inject Drugs.', Clin Infect Dis,
    Journal articles | 2025
    Dore GJ, 2025, 'Monitoring hepatitis C elimination among people who inject drugs: A broader approach is required', International Journal of Drug Policy, 137,
    Journal articles | 2025
    Jacka BP; Cheng QL; Schiavone B; Darley DR; Kelleher AD; Dore GJ; Matthews GV, 2025, 'Trajectories of health-related quality of life two years after mild/moderate COVID-19 infection in pre-Omicron era', Open Forum Infectious Diseases,
    Journal articles | 2025
    Sazzad HMS; Li H; Hajarizadeh B; Horsburgh BA; Grebely J; Dore GJ; Bull RA; Lloyd AR; Rodrigo C, 2025, 'Estimating the impact of direct acting antiviral therapy on the prevalence of hepatitis C virus infection using phylogenetics', Virus Research, 355,
    Journal articles | 2025
    Stevens A; Lafferty L; Treloar C; Cunningham EB; Dore GJ; Grebely J; Marshall AD, 2025, 'Acceptability of hepatitis C testing using point-of-care testing and dried blood spot collection among people at risk of hepatitis C infection', International Journal of Drug Policy, 137, pp. 104720 - 104720,
    Journal articles | 2025
    Tillakeratne S; Valerio H; Alavi M; Hajarizadeh B; Martinello M; George J; Matthews G; Grebely J; Pearson SA; Dore GJ, 2025, 'Trends in cause-specific mortality among people with hepatitis C virus in New South Wales, Australia', International Journal of Drug Policy, 139,
    Journal articles | 2025
    Wheeler A; Masters J; Pradhan A; Roth JM; Degenhardt L; Dore GJ; Matthews GV; Cunningham EB; Peacock A; Colledge-Frisby S; Grebely J; Hajarizadeh B; Martinello M, 2025, 'Prevalence of Injection-Related Bacterial and Fungal Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis', Open Forum Infectious Diseases, 12,
    Journal articles | 2025
    Young C; Singh M; Jackson KJL; Field MA; Peters TJ; Angioletti-Uberti S; Frenkel D; Ravishankar S; Gupta M; Wang JJ; Agapiou D; Faulks ML; Al-Eryani G; Luciani F; Gordon TP; Reed JH; Danta M; Carr A; Kelleher AD; Dore GJ; Matthews G; Brink R; Bull RA; Suan D; Goodnow CC, 2025, 'A triad of somatic mutagenesis converges in self-reactive B cells to cause a virus-induced autoimmune disease', Immunity, 58, pp. 412 - 430.e10,
    Journal articles | 2024
    Bah R; Sheehan Y; Li X; Dore GJ; Grebely J; Lloyd AR; Hajarizadeh B; Bah R; Li C; Byrne M; Butler T; Musarurwa B; Hooshmand E; Simpson A; Alrayyani M; Price N; Groom M, 2024, 'Prevalence of blood-borne virus infections and uptake of hepatitis C testing and treatment in Australian prisons: the AusHep study', The Lancet Regional Health - Western Pacific, 53,
    Journal articles | 2024
    Bah R; Sheehan Y; Li X; Price N; Butler T; Dore GJ; Grebely J; Lloyd AR; Hajarizadeh B, 2024, 'Challenges and facilitators in repeated bio-behavioural surveys for blood-borne virus infections in Australian prisons', International Journal of Drug Policy,
    Journal articles | 2024
    Bin Usman Shah SH; Alavi M; Hajarizadeh B; Matthews GV; Martinello M; Danta M; Amin J; Law MG; George J; Valerio H; Dore GJ, 2024, 'Corrigendum to 鈥淭rends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales鈥 [JHEP Reports 4 (2022)] (JHEP Reports (2022) 4(10), (S2589555922001240), (10.1016/j.jhepr.2022.100552))', JHEP Reports, 6,
    Journal articles | 2024
    Broady TR; Valerio H; Alavi M; Wheeler A; Silk D; Martinello M; Conway A; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Treloar C; Grebely J, 2024, 'Factors associated with experiencing stigma, discrimination, and negative health care treatment among people who inject drugs', International Journal of Drug Policy, 128,
    Journal articles | 2024
    Chaganti J; Poudel G; Cysique LA; Dore GJ; Kelleher A; Matthews G; Darley D; Byrne A; Jakabek D; Zhang X; Lewis M; Jha N; Brew BJ, 2024, 'Blood brain barrier disruption and glutamatergic excitotoxicity in post-acute sequelae of SARS COV-2 infection cognitive impairment: potential biomarkers and a window into pathogenesis', Frontiers in Neurology, 15,
    Journal articles | 2024
    Cheng Q; Valerio H; Cunningham EB; Shih STF; Silk D; Conway A; Treloar C; Murray C; Henderson C; Amin J; Read P; Dore GJ; Grebely J; Bath N; Milat A; Dunlop A; Holden J; Leadbeatter K; Day E; Habraken N; Dawson O; Degenhardt L; Scott C; Tillakeratne S; Marks P; Jayasinghe I; Martinez M; Reid H; Gleeson V; Van Dyk J; Mercade GE; Marshall AD; Obeid S; Wheeler A; Hooshyar SH; Catlett B; Verich A; Erratt A; Wheeler A; Ezard N; Reid D; Gorton C; Hayllar J; Lam T; Datta P; Wade A; Spruce S; Cock V; Cornwell M; Zohrab K; Christmass M; Connelly C; Cooper A; Montebello M; Cherry R; Dyer J; Arawal S; Press E; Horasak N; Lewis R; Carthew A; Morris D; Donohue K; Griffiths K; Lana JD; Shin S; Graf C; Hampson A; Qian S; Brown D; Lautier A; Curran C; Burns C; Raidu R; Stolzenhein K; Brabender W; Somes K; Abram N; Turne R; Larter S; Goodberg F; Luksza J; Hall M; Hazelwood S; Ismay C; McClurg B; Mincham C; Barlow K; Hoskins A; Salisbury K; Markham J; Talmet J; Dunn S; Mitchell A; McKinnon A; Smyth F; Snell L; Laing E; Clark M; Dorigo J, 2024, 'Health-Related Quality of Life of People Who Inject Drugs: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage Study', Value in Health, 27, pp. 216 - 225,
    Journal articles | 2024
    Farooq A; Valerio H; Wheeler A; Martinello M; Henderson C; Silk D; Degenhardt L; Read P; Dore GJ; Grebely J; Cunningham EB, 2024, 'Needle and syringe sharing among people who have recently injected drugs in Australia: The ETHOS Engage Study', Drug and Alcohol Review, 43, pp. 1019 - 1028,
    Journal articles | 2024
    Farrell M; Shahbazi J; Chambers M; Byrne M; Gholami J; Zahra E; Grebely J; Lintzeris N; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Weiss R; Rodgers C; Cook J; Degenhardt L, 2024, '96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial', International Journal of Drug Policy, 127,
    Journal articles | 2024
    Grebely J; Matthews S; Causer LM; Feld JJ; Cunningham P; Dore GJ; Applegate TL, 2024, 'We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what?', Expert Review of Molecular Diagnostics, 24, pp. 177 - 191,
    Journal articles | 2024
    Hajarizadeh B; Carson JM; Byrne M; Grebely J; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Lloyd AR; Dore GJ, 2024, 'Incidence of hepatitis C virus infection in the prison setting: The SToP-C study', Journal of Viral Hepatitis, 31, pp. 21 - 34,
    Journal articles | 2024
    MacLachlan JH; Allard N; Tran L; Savage A; Adamson E; Price V; Pearce C; Dore GJ; Cowie BC, 2024, 'Uptake of guideline-based testing for chronic viral hepatitis in Australian primary care: retrospective analysis of electronic medical record data', Australian journal of primary health, 30,
    Journal articles | 2024
    Maher L; Wand H; Heard S; Starr M; Zolala F; Kemp R; Cunningham P; Drummer H; Hellard M; Kaldor J; Dore G, 2024, 'Utilising Integrated Bio-behavioural Surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey', International Journal of Drug Policy, 131,
    Journal articles | 2024
    Maher L; Wand H; Heard S; Starr M; Zolala F; Kemp R; Cunningham P; Drummer H; Hellard M; Kaldor J; Dore G, 2024, 'Utilising integrated bio-behavioural surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey.', Int J Drug Policy, pp. 104576,
    Journal articles | 2024
    Marshall AD; Conway A; Cunningham EB; Valerio H; Silk D; Alavi M; Tillakeratne S; Wade A; Lam T; Zohrab K; Dunlop A; Connelly C; Cock V; Burns C; Henderson C; Christmass M; Dore GJ; Grebely J, 2024, 'A Pilot Randomised Controlled Trial Involving Financial Incentives to Facilitate Hepatitis C Treatment Uptake Among People Who Inject Drugs: ETHOS Engage Study', Viruses, 16,
    Journal articles | 2024
    Marshall AD; Rance J; Dore GJ; Grebely J; Treloar C, 2024, 'Applying a stigma and time framework to facilitate equitable access to hepatitis C care among women who inject drugs: The ETHOS Engage Study', International Journal of Drug Policy, 129,
    Journal articles | 2024
    Marshall AD; Willing AR; Kairouz A; Cunningham EB; Wheeler A; O'Brien N; Perera V; Ward JW; Hiebert L; Degenhardt L; Hajarizadeh B; Colledge S; Hickman M; Jawad D; Lazarus JV; Matthews GV; Scheibe A; Vickerman P; Dore GJ; Grebely J; Sargsyants N; Suleymanova L; Salkic N; Simonova M; Nemeth-Blazic T; Mravcik V; Kivimets K; Salupere R; Butsashvili M; Soselia G; Makara M; Tolmane I; Jancorien臈 L; Stratulat S; Flisiak R; Gheorghe L; Cernat R; Lakhov A; Stanevich O; Jarcuska P; Peck-Radosavljevic M; Robaeys G; 脴vrehus A; Foster G; Sutinen J; Farkkila M; Rautiainen H; Vuoti S; Nikolova D; Pawlotsky JM; Rockstroh J; Sypsa V; Papatheodoridis G; Olafsson S; Feeney E; Teti E; Seguin-Devaux C; Pocock J; Reiff S; McDougall N; Van der Valk M; Dalgard O; Tato Marinho R; Dillon J; Peters E; Bojovic K; Mati膷i膷 M; K氓berg M; Bruggmann P; Healy B; Chong VH; Yi S; Tucker J; Pasaribu LR; Tanaka J; Ashley EA; Abu Hassan MR; Mohammed NS; Chan HK; Gidaagaya S; Kyi KP; Hyung Joon K; Chin B; Baladjay PC; Kao JH; Wansom T; da Cruz B; Flower B; Ehsan E; Al Mahtab M; Khandu L; Bhadoria AS; Alavi M; KC P; Hamid S; Biryukov S; Alymbaeva D; Alaei A; Bakieva S; Flichman D, 2024, 'Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions', The Lancet Gastroenterology and Hepatology, 9, pp. 366 - 382,
    Journal articles | 2024
    Martinello M; Carson JM; Post JJ; Finlayson R; Baker D; Read P; Shaw D; Bloch M; Doyle J; Hellard M; Filep E; Hosseini-Hooshyar S; Dore GJ; Matthews GV, 2024, 'Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014-2023)', Open Forum Infectious Diseases, 11,
    Journal articles | 2024
    McKetin R; Degan TJ; Saunders L; Nguyen L; Dore G; Shoptaw S; Farrell M; Degenhardt L; Kelly PJ; Turner A; Clare PJ; Dean OM; Arunogiri S; Colledge-Frisby S; Koeijers J; Goodman-Meza D; Sinclair B; Reid D; Hill H; Hayllar J; Christmass M; Cordaro F; Lundin R; Liaw W; Liu D; Holyoak E; Wu BTF; Keygan J; Kontogiannis A; Palmer L; Morrison C; Wrobel A; Hyland B; Byrne M; Russell S; Zahra E; Berk M, 2024, 'A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial', Trials, 25,
    Journal articles | 2024
    Murdock NA; Alajaji NE; Schaefer R; Boone CA; Campo RE; Dore GJ; Gandhi M; Gorospe JR; Gulick RM; Hodder SL; Liu J; Rhee MS; Rooney JF; Vannappagari V; Wilkin T; Miller V, 2024, 'Long-acting HIV Treatments: Study Design, Logistics, and Access', Open Forum Infectious Diseases, 11,
    Journal articles | 2024
    Phetsouphanh C; Jacka B; Ballouz S; Jackson KJL; Wilson DB; Manandhar B; Klemm V; Tan HX; Wheatley A; Aggarwal A; Akerman A; Milogiannakis V; Starr M; Cunningham P; Turville SG; Kent SJ; Byrne A; Brew BJ; Darley DR; Dore GJ; Kelleher AD; Matthews GV, 2024, 'Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection', Nature Communications, 15,
    Journal articles | 2024
    Price O; Dietze P; Maher L; Dore GJ; Sutherland R; Salom C; Bruno R; Crawford S; Degenhardt L; Larney S; Peacock A, 2024, 'High COVID-19 vaccine uptake following initial hesitancy among people in Australia who inject drugs', Vaccine, 42, pp. 2877 - 2885,
    Journal articles | 2024
    Price O; Swanton R; Grebely J; Hajarizadeh B; Webb P; Peacock A; Dore GJ; Cowie BC; Vickerman P; Degenhardt L, 2024, 'Vaccination coverage among people who inject drugs: A systematic review', International Journal of Drug Policy, 127,
    Journal articles | 2024
    Ryan H; Dore GJ; Grebely J; Byrne M; Cunningham EB; Martinello M; Lloyd AR; Hajarizadeh B, 2024, 'Hepatitis C treatment outcome among people in prison: The SToP-C study', Liver International, 44, pp. 2996 - 3007,
    Journal articles | 2024
    Shih STF; Stone J; Martin NK; Hajarizadeh B; Cunningham EB; Kwon JA; McGrath C; Grant L; Grebely J; Dore GJ; Lloyd AR; Vickerman P; Chambers GM, 2024, 'Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination', Open Forum Infectious Diseases, 11,
    Journal articles | 2024
    Tillakeratne S; Pearson SA; Alavi M; Hajarizadeh B; Martinello M; Law M; George J; Amin J; Matthews G; Grebely J; Dore GJ; Valerio H, 2024, 'Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, Australia', The Lancet Regional Health - Western Pacific, 51,
    Journal articles | 2024
    Valerio H; Alavi M; Marshall AD; Hajarizadeh B; Amin J; Law M; Tillakeratne S; George J; Degenhardt L; Grebely J; Matthews GV; Dore GJ, 2024, 'Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population-based study', Drug and Alcohol Review, 43, pp. 1080 - 1092,
    Journal articles | 2024
    Valerio H; Marshall AD; Conway A; Treloar C; Carter L; Martinello M; Henderson C; Amin J; Read P; Silk D; Degenhardt L; Prain B; Alavi M; Dore GJ; Grebely J, 2024, 'Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage study', International Journal of Drug Policy, 127,
    Journal articles | 2024
    Yeoh YKJ; Dore GJ; Lockart I; Danta M; Flynn C; Blackmore C; Levy MT; George J; Alavi M; Hajarizadeh B, 2024, 'Temporal change in aetiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients in New South Wales, Australia', Internal Medicine Journal, 54, pp. 602 - 612,
    Journal articles | 2023
    Alter HJ; Barnes E; Biondi MJ; Cox AL; Eberts JD; Feld JJ; Liang TJ; Morrison J; Rice CM; Shoukry NH; Thomas DL; Van Gennip J; Weijer C; Aghemo A; Akiyama M; Ali M; Bader R; Bailey JR; Balaban Y; Banerjee S; Bartenschlager R; Baumert TF; Berenguer M; Bhadoria AS; Bonanni P; Bonella AE; Bruggmann P; Bruneau J; Bull RA; Butsashvili M; Cahn P; Caplan AL; Chappell RY; Chisari F; Chung R; Cooke G; Cox AL; Dalgard O; Dao DY; Darzi A; Dieterich D; Dillon JF; Dore GJ; Doyle JS; Drummer HE; Durbin AP; Dusheiko G; Eyal N; Ferguson K; Flisiak R; Forns X; Foster GR; Foung S; Gal-Tanamy M; Gane E; Gehring AJ; George J; Ghany MG; Gilbert DT; Glaze K; Goodman KW; Grebely J; Hamid S; Haybron DM; Holton R; Ignarro LJ; Jackson T; Jamieson D; Jollimore J; Karaba A; Klein M; Lauer G; Law M; Lemon SM; Liang TJ; Liu L; Lohmann V; Mak LY; Marinho RT; Marsh AA; Miller L; Negro F; Nguyen BV; Page K; Paterson K; Pedrana A; Pietschmann T; Pinker S; Plotkin S; Ray SC; Reau N; Remak WM; Ridruejo E; Roberts RJ, 2023, 'Joint statement in support of hepatitis C human challenge studies', The Lancet Gastroenterology and Hepatology, 8, pp. 967 - 969,
    Journal articles | 2023
    Carson J; Barbieri S; Matthews GV; Dore GJ; Hajarizadeh B, 2023, 'Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016-2021', Hepatology Communications, 7, pp. e0125,
    Journal articles | 2023
    Carson JM; Barbieri S; Cunningham E; Mao E; van der Valk M; Rockstroh JK; Hellard M; Kim A; Bhagani S; Feld JJ; Gane E; Thurnheer MC; Bruneau J; Tu E; Dore GJ; Matthews GV; Martinello M, 2023, 'Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study', Journal of the International AIDS Society, 26, pp. e26168,
    Journal articles | 2023
    Carson JM; Barbieri S; Matthews GV; Dore GJ; Hajarizadeh B, 2023, 'Corrigendum to 鈥楴ational trends in retreatment of HCV due to reinfection or treatment failure in Australia鈥 (J Hepatol [2023] 260鈥270) (Journal of Hepatology (2023) 78(2) (260鈥270), (S016882782203118X), (10.1016/j.jhep.2022.09.011))', Journal of Hepatology, 78, pp. 1084,
    Journal articles | 2023
    Carson JM; Barbieri S; Matthews GV; Dore GJ; Hajarizadeh B, 2023, 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia', Journal of Hepatology, 78, pp. 260 - 270,
    Journal articles | 2023
    Casey JL; Dore GJ; Grebely J; Matthews GV; Cherepanov V; Martinello M; Marks P; Janssen HLA; Hansen BE; Kaul R; MacParland SA; Gehring AJ; Feld JJ, 2023, 'Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C聽virus infection', Journal of Viral Hepatitis, 30, pp. 64 - 72,
    Journal articles | 2023
    Cheng Q; Bajis S; Cunningham E; Shih STF; Schulz M; Marshall AD; Martin NK; Miners A; Hajarizadeh B; Wiseman V; Dore GJ; Grebely J, 2023, 'Health-related quality of life among people who inject drugs in Australia', Quality of Life Research, 32, pp. 3195 - 3207,
    Journal articles | 2023
    Cheng Q; Cunningham EB; Shih S; Amin J; Bruneau J; Artenie AA; Powis J; Litwin AH; Cooper C; Dalgard O; Hellard M; Bruggmann P; Marks P; Lacombe K; Stedman C; Read P; Hajarizadeh B; Dunlop AJ; Conway B; Feld JJ; Dore GJ; Grebely J; Dore G; Crawford S; Swan T; Byrne J; Coordinating Centre鈥擜manda Erratt ML; Marks P; Shaw I; Siriragavan S; Quiene S; Petoumenos K; Schmid P; Castro E; Moriggia A; Daulouede JP; Fraser C; Feld J; Gane E; Matthews G; Kronborg I; Shaw D; Norton B; Thurnheer MC; Weltman M; Dillon J; Kessler S; Knapp C; Oprandi L; Messina P; Pantic M; Le Cam M; Maitre C; Andreassen J; Melkeraaen I; Tollefsen MM; Pagarigan H; Milne R; Mason K; Kaznowski D; Zou L; Bouchard R; Kotsoros B; Muir M; Milloy J; Oliver V; Noonan T; Sevehon A; Hazelwood S; Hall M; Hagenauer M; Liddle R; Ferguson C; Agyemang L; Patel H; Soloway I; Cerocchi O; Lacalamita M; Fragomeli V; Gilliver R; Lothian R; Cleary S; Johnston L; Middleton S; D'Amico R; McGovern B; Anderson J; Zhong Z; Keane F; Tatsch F; Brainard D; McHutchison J, 2023, 'Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs', Value in Health, 26, pp. 883 - 892,
    Journal articles | 2023
    Colledge-Frisby S; Ottaviano S; Webb P; Grebely J; Wheeler A; Cunningham EB; Hajarizadeh B; Leung J; Peacock A; Vickerman P; Farrell M; Dore GJ; Hickman M; Degenhardt L, 2023, 'Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review', The Lancet Global Health, 11, pp. e673 - e683,
    Journal articles | 2023
    Conway A; Treloar C; Crawford S; Degenhardt L; Dore GJ; Farrell M; Hayllar J; Grebely J; Marshall AD, 2023, '鈥淵ou'll come in and dose even in a global pandemic鈥: A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic', International Journal of Drug Policy, 114,
    Journal articles | 2023
    Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J, 2023, 'Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis', International Journal of Drug Policy, 111,
    Journal articles | 2023
    Cysique LA; Jakabek D; Bracken SG; Allen-Davidian Y; Heng B; Chow S; Dehhaghi M; Staats Pires A; Darley DR; Byrne A; Phetsouphanh C; Kelleher A; Dore GJ; Matthews GV; Guillemin GJ; Brew BJ, 2023, 'The kynurenine pathway relates to post-acute COVID-19 objective cognitive impairment and PASC', Annals of Clinical and Translational Neurology, 10, pp. 1338 - 1352,
    Journal articles | 2023
    Degenhardt L; Webb P; Colledge-Frisby S; Ireland J; Wheeler A; Ottaviano S; Willing A; Kairouz A; Cunningham EB; Hajarizadeh B; Leung J; Tran LT; Price O; Peacock A; Vickerman P; Farrell M; Dore GJ; Hickman M; Grebely J, 2023, 'Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review', The Lancet Global Health, 11, pp. e659 - e672,
    Journal articles | 2023
    Feld JJ; Bruneau J; Dore GJ; Ghany MG; Hansen B; Sulkowski M; Thomas DL, 2023, 'Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations', Clinical Infectious Diseases, 77, pp. S262 - S269,
    Journal articles | 2023
    Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P, 2023, 'Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study', International Journal of Drug Policy, 114,
    Journal articles | 2023
    Grebely J; Markus C; Causer LM; Silk D; Comben S; Lloyd AR; Martinez M; Cunningham EB; O'Flynn M; Dore GJ; Matthews S, 2023, 'A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia', The Lancet Gastroenterology and Hepatology, 8, pp. 204 - 207,
    Journal articles | 2023
    Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2023, 'Recomendaciones para el manejo de la infecci贸n por el virus de la hepatitis C entre usuarios de drogas por v铆a parenteral', International Journal of Drug Policy, 111,
    Journal articles | 2023
    Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2023, 'Recommandations pour la prise en charge de l'infection par le virus de l'h茅patite C chez les usagers de drogues par injection', International Journal of Drug Policy, 111, pp. 101669,
    Journal articles | 2023
    Hajarizadeh B; Kairouz A; Ottaviano S; Ireland J; Willing A; Cunningham E; Webb P; Colledge-Frisby S; Wheeler A; Leung J; Tran LT; Price O; Vickerman P; Farrell M; Hickman M; Dore GJ; Bergenstr枚m A; Degenhardt L; Grebely J, 2023, 'Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review', The Lancet Global Health, 11, pp. e1885 - e1898,
    Journal articles | 2023
    Hobday S; Valerio H; Combo T; Monaghan R; Scott C; Silk D; Murray C; Read P; Henderson C; Degenhardt L; Treloar C; Dore GJ; Grebely J; Martinello M, 2023, 'Evaluating the prevalence of current hepatitis C infection and treatment among Aboriginal and Torres Strait Islander peoples who inject drugs in Australia: The ETHOS engage study', Drug and Alcohol Review, 42, pp. 1617 - 1632,
    Journal articles | 2023
    Iversen J; Wand H; McManus H; Dore GJ; Maher L, 2023, 'Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies', Addiction, 118, pp. 901 - 911,
    Journal articles | 2023
    Jessica HB; Carson J; Scott M; Patricia C; Nelson R; Helen VG; Phillip R; Hanson J; Robert M; Matthews G; Dore GJ; Martinello M; Read P, 2023, 'Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real-world cohort (REACH-C)', Journal of Viral Hepatitis, 30, pp. 386 - 396,
    Journal articles | 2023
    Koopsen J; Matthews G; Rockstroh J; Applegate TL; Bhagani S; Rauch A; Grebely J; Sacks-Davis R; Ingiliz P; Boesecke C; Rebers S; Feld J; Bruneau J; Martinello M; Hellard M; Dore GJ; Schinkel J; van der Valk M; Adams T; Amjad S; Appelhans C; Becker B; Bouchard R; Braun D; Bruelisauer C; Calcagnile S; Carroll A; Cerocchi O; Chronister K; Cordes C; Dore G; Evans F; Fedele S; Ferguson C; Fraser C; Ganase B; Gane E; George V; Gerlach C; Gilleece Y; Gilliver R; Grube C; Gustafson J; Haas A; Hagenauer M; Harris M; Helder J; Hirter D; Hull M; Katz S; Kim A; Kotsoros B; Lacalamita M; Lindergard G; Lutz T; Macabodbod L; Manz M; Marks P; Messina P; Mohrmann K; Monnich C; Moon J; Moriggia A; Morris G; Morrish T; Nelson M; Oliver V; Patterson J; Peters M; Petoumenos K; Porretta H; Raymode P; Read P; Reece S; Saidi A; Sasadeusz J; Scherler P; Schr枚der R; Selfridge M; Sevehon A; Shaw D; Sulkowski M; Tamaddoni M; Thunder O; Thurnheer MC; Tu E; Ustianowski A; Witele E, 2023, 'Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis', The Lancet Microbe, 4, pp. e622 - e631,
    Journal articles | 2023
    Martinello M; Bhagani S; Shaw D; Orkin C; Cooke G; Gane E; Iser D; Ustianowski A; Kulasegaram R; Stedman C; Tu E; Grebely J; Dore GJ; Nelson M; Matthews GV, 2023, 'Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study', JHEP Reports, 5,
    Journal articles | 2023
    Martinello M; Carson JM; Van Der Valk M; Rockstroh JK; Ingiliz P; Hellard M; Nelson M; Lutz T; Bhagani S; Kim AY; Hull M; Cordes C; Moon J; Feld JJ; Gane E; Rauch A; Bruneau J; Tu E; Applegate T; Grebely J; Dore GJ; Matthews GV, 2023, 'Reinfection incidence and risk among people treated for recent hepatitis C virus infection', AIDS, 37, pp. 1883 - 1890,
    Journal articles | 2023
    Martinello M; Solomon SS; Terrault NA; Dore GJ, 2023, 'Hepatitis C', The Lancet, 402, pp. 1085 - 1096,
    Journal articles | 2023
    Morpeth SC; Venkatesh B; Totterdell JA; McPhee GM; Mahar RK; Jones M; Bandara M; Barina LA; Basnet BK; Bowen AC; Burke AJ; Cochrane B; Denholm JT; Dhungana A; Dore GJ; Dotel R; Duffy E; Dummer J; Foo H; Gilbey TL; Hammond NE; Hudson BJ; Jha V; Jevaji PR; John O; Joshi R; Kang G; Kaur B; Kim S; Das SK; Lau JSY; Littleford R; Marsh JA; Marschner IC; Matthews G; Maze MJ; McArthur CJ; McFadyen JD; McMahon JH; McQuilten ZK; Molton J; Mora JM; Mudaliar V; Nguyen V; O'Sullivan MVN; Pant S; Park JE; Paterson DL; Price DJ; Raymond N; Rees MA; Robinson JO; Rogers BA; Ryu W-S; Sasadeusz J; Shum O; Snelling TL; Sommerville C; Trask N; Lewin SR; Hills TE; Davis JS; Roberts JA; Tong SYC, 2023, 'A Randomized Trial of Nafamostat for Covid-19.', NEJM Evid, 2, pp. EVIDoa2300132,
    Journal articles | 2023
    Price O; Maher L; Dietze PM; Bruno R; Crawford S; Sutherland R; Salom C; Dore GJ; Peacock A, 2023, 'COVID-19 vaccine attitudes and facilitators among people in Australia who inject drugs', Drug and Alcohol Review, 42, pp. 1066 - 1077,
    Journal articles | 2023
    Razavi-Shearer DM; Gamkrelidze I; Pan CQ; Jia J; Berg T; Gray RT; Lim YS; Chen CJ; Ocama P; Desalegn H; Abbas Z; Abdallah AR; Aghemo A; Ahmadbekova S; Ahn SH; Aho I; Akarca US; Al Masri NM; Alalwan AM; Alavian SM; Al-Busafi SA; Aleman S; Alfaleh FZ; Alghamdi AS; Al-Hamoudi WK; Aljumah AA; Al-Naamani K; Al-Rifai A; AlSerkal YM; Altraif IH; Amarsanaa J; Anderson M; Andersson MI; Armstrong P; Asselah T; Athanasakis K; Baatarkhuu O; Ben-Ari Z; Bensalem A; Bessone F; Biondi MJ; Bizri ARN; Blach S; Braga WSM; Brand茫o-Mello CE; Brosgart CL; Brown KA; Brown RS; Bruggmann P; Brunetto MR; Buti M; Cabezas J; Casanovas T; Chae C; Chan HLY; Cheinquer H; Chen PJ; Cheng KJG; Cheon ME; Chien CH; Choudhuri G; Christensen PB; Chuang WL; Chulanov V; Cisneros Garza LE; Coffin CS; Contreras FA; Coppola N; Cornberg M; Cowie B; Cramp ME; Craxi A; Crespo J; Cui F; Cunningham CW; Dalgard O; De Knegt RJ; De Ledinghen V; Dore GJ; Drazilova S; Duberg AS; Egeonu S; Elbadri M; El-Kassas M; El-Sayed MH; Estes C; Etzion O; Farag E; Ferradini L; Ferreira PRA; Flisiak R; Forns X; Frankova S; Fung J; Gane EJ; Garcia V; Garcia-Samaniego J; Gemilyan M; Genov J; Gheorghe LS, 2023, 'Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study', The Lancet Gastroenterology and Hepatology, 8, pp. 879 - 907,
    Journal articles | 2023
    Schiavone B; Dore GJ; Stone E; Matthews GV; Darley DR, 2023, 'An update on long COVID and its management', Medicine Today, 24, pp. 37 - 43
    Journal articles | 2023
    Shah SHBU; Alavi M; Hajarizadeh B; Matthews G; Valerio H; Dore GJ, 2023, 'Liver-related mortality among people with hepatitis B and C: Evaluation of definitions based on linked healthcare administrative datasets', Journal of Viral Hepatitis, 30, pp. 520 - 529,
    Journal articles | 2023
    Shah SHBU; Valerio H; Hajarizadeh B; Alavi M; Matthews G; Dore G, 2023, 'Cascade of care among people with an HBV notification in New SouthWales, Australia, including diagnosis, specialist assessment, and treatment uptake', JOURNAL OF HEPATOLOGY, 78, pp. S910 - S910
    Journal articles | 2023
    Shah SHBU; Valerio H; Hajarizadeh B; Matthews G; Alavi M; Dore GJ, 2023, 'Cascade of care among people with hepatitis B in New South Wales, Australia', Journal of Viral Hepatitis, 30, pp. 926 - 938,
    Journal articles | 2023
    Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J, 2023, 'A 鈥榦ne-stop-shop鈥 point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study', Journal of Hepatology, 79, pp. 635 - 644,
    Journal articles | 2023
    Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon JA; Lloyd AR; Dore GJ; Wiseman V; Grebely J, 2023, 'Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis', The Lancet Regional Health - Western Pacific, 36,
    Journal articles | 2023
    Stone J; Lim AG; Dore GJ; Borquez A; Geddes L; Gray R; Grebely J; Hajarizadeh B; Iversen J; Maher L; Valerio H; Martin NK; Hickman M; Lloyd AR; Vickerman P, 2023, 'Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study', Liver International, 43, pp. 569 - 579,
    Journal articles | 2023
    Yousafzai MT; Alavi M; Valerio H; Hajarizadeh B; Grebely J; Dore GJ, 2023, 'Hepatitis C care cascade before and during the direct-acting antiviral eras in New South Wales, Australia: A population-based linkage study', Journal of Viral Hepatitis, 30, pp. 250 - 261,
    Journal articles | 2022
    Adhikari A; Abayasingam A; Rodrigo C; Agapiou D; Pandzic E; Brasher NA; Fernando BSM; Keoshkerian E; Li H; Kim HN; Lord M; Popovic G; Rawlinson W; Mina M; Post JJ; Hudson B; Gilroy N; Dwyer D; Sasson SC; Grubor-Bauk B; Lloyd AR; Martinello M; Bull RA; Tedla N; Kaldor J; Dore G; Sorrell T; Bartlett A; Lemberg D; Di Girolamo N; Byrne M; Hammoud M; Sultan R; Konecny P; Matthews G; Shek D; Holdaway S; Mitsa-Kos K; How-Chow D; Lagunday R; Robinson S; Terrill L; Joshi N; Li Y; Gill S; Sevehon A, 2022, 'Longitudinal Characterization of Phagocytic and Neutralization Functions of Anti-Spike Antibodies in Plasma of Patients after Severe Acute Respiratory Syndrome Coronavirus 2 Infection', Journal of Immunology, 209, pp. 1499 - 1512,
    Journal articles | 2022
    Bartlett SR; Verich A; Carson J; Hosseini-Hooshyar S; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Martinez M; Marks P; Dore GJ; Matthews GV; Applegate T; Martinello M; Hosseini Hooshyar S, 2022, 'Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort', Health Science Reports, 5,
    Journal articles | 2022
    Blach S; Terrault NA; Tacke F; Gamkrelidze I; Craxi A; Tanaka J; Waked I; Dore GJ; Abbas Z; Abdallah AR; Abdulla M; Aghemo A; Aho I; Akarca US; Alalwan AM; Blom MA; Al-Busafi SA; Aleman S; Alghamdi AS; Al-Hamoudi WK; Aljumah AA; Al-Naamani K; Serkal YMA; Altraif IH; Anand AC; Anderson M; Andersson MI; Athanasakis K; Baatarkhuu O; Bakieva SR; Ben-Ari Z; Bessone F; Biondi MJ; Bizri ARN; Brand茫o-Mello CE; Brigida K; Brown KA; Brown RS; Bruggmann P; Brunetto MR; Busschots D; Buti M; Butsashvili M; Cabezas J; Chae C; Ivanova VC; Chan HLY; Cheinquer H; Cheng KJ; Cheon ME; Chien CH; Chien RN; Choudhuri G; Christensen PB; Chuang WL; Chulanov V; Cisneros LE; Coco B; Contreras FA; Cornberg M; Cramp ME; Crespo J; Cui F; Cunningham CW; Abou LD; Dalgard O; Dao DY; Ledinghen VD; Derbala MF; Deuba K; Dhindsa K; Djauzi S; Drazilova S; Duberg AS; Elbadri M; El-Sayed MH; Esmat G; Estes C; Ezzat S; F盲rkkil MA; Ferradini L; Ferraz MLG; Ferreira PRA; Kanizaj TF; Flisiak R; Frankova S; Fung J; Gamkrelidze A; Gane EJ; Garcia V; Garc铆a-Samaniego J; Gemilyan M; Genov J; Gheorghe LS; Gholam PM; Goldis A; Gottfredsson M; Gray RT; Grebely J; Gschwantler M, 2022, 'Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study', The Lancet Gastroenterology and Hepatology, 7, pp. 396 - 415,
    Journal articles | 2022
    Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B, 2022, 'Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study', Clinical Infectious Diseases, 75, pp. 1809 - 1819,
    Journal articles | 2022
    Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Davies J; Doyle JS; Yee J; Martinello M; Marks P; Matthews GV; Dore GJ; Post J; Batey R; Smart J; Dawson O; Hill S; Douglas M; Montebello M; Collie P; Hallinan R; Snelgar G; Baker D; Galhenage S; Soo TM; Bopage R; Faros J; Cooper L; Nelson R; Shaw D; Wilson M; Pratt W; Hinton S; Wade A; Van Gessel H; Davidson L; Dibdin M; Lucas M; Ahmad R; Smith D; Tan K; Roder C; Harney B; Holdaway S; Walsh J; Fox P; Mousavi R; Lam W; Dahal RP; Habel P; Gilliver R; Silins E; Ackerman J; Deacon R; Hall E; Everson A; Stewart J; Milner M; Ferguson C; Tate-Baker J; Bradshaw J; Duncan G; Baluran G; Watson B; Hey C; Hickey R; Orme C; Miczkova S, 2022, 'Retreatment for hepatitis C virus direct-acting antiviral therapy virological failure in primary and tertiary settings: The REACH-C cohort', Journal of Viral Hepatitis, 29, pp. 661 - 676,
    Journal articles | 2022
    Catlett B; Hajarizadeh B; Cunningham E; Wolfson-Stofko B; Wheeler A; Khandaker-Hussain B; Feld JJ; Martr贸 E; Chevaliez S; Pawlotsky JM; Bharat C; Cunningham PH; Dore GJ; Applegate T; Grebely J, 2022, 'Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review', Journal of Infectious Diseases, 226, pp. 1005 - 1021,
    Journal articles | 2022
    Catlett B; Starr M; Machalek DA; Danwilai T; Palmer M; Kelly A; Kaldor J; Dore GJ; Darley D; Matthews G; Cunningham PH, 2022, 'Evaluation of serological assays for SARS-CoV-2 antibody testing from dried blood spots collected from cohorts with prior SARS-CoV-2 infection: SARS-CoV-2 detection from dried blood spots', Journal of Clinical Virology Plus, 2,
    Journal articles | 2022
    Chidwick K; Myton R; Rodgers A; Jun M; Dartnell J; Balcomb A; Dore G, 2022, 'A cluster randomized controlled trial of a MedicineInsight Educational Quality Improvement Programme to improve the diagnosis and treatment of chronic hepatitis C in general practice (the EQUIP-HEPC trial)', Journal of Viral Hepatitis, 29, pp. 135 - 146,
    Journal articles | 2022
    Conway A; Read P; Gilliver R; McNaughton T; Valerio H; Cunningham EB; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Grebely J, 2022, 'Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study', Viruses, 14,
    Journal articles | 2022
    Conway A; Valerio H; Alavi M; Silk D; Treloar C; Hajarizadeh B; Marshall AD; Martinello M; Milat A; Dunlop A; Murray C; Prain B; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Christmass M; Wade A; Montebello M; Dore GJ; Grebely J, 2022, 'A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study', Viruses, 14,
    Journal articles | 2022
    Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Valencia BM; Bajis S; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J, 2022, 'Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, 7, pp. 426 - 445,
    Journal articles | 2022
    Farrell M; Shahbazi J; Byrne M; Grebely J; Lintzeris N; Chambers M; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Nicholas T; Weiss R; Rodgers C; Cook J; Degenhardt L, 2022, 'Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence', International Journal of Drug Policy, 100,
    Journal articles | 2022
    Grebely J; Dore GJ; Altice FL; Conway B; Litwin AH; Norton BL; Dalgard O; Gane EJ; Shibolet O; Nahass R; Luetkemeyer AF; Peng CY; Iser D; Gendrano IN; Kelly MM; Hwang P; Asante-Appiah E; Haber BA; Barr E; Robertson MN; Platt H, 2022, 'Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy A Cohort Study', Annals of Internal Medicine, 175, pp. 1221 - 1229,
    Journal articles | 2022
    Hern谩ndez-Mitre MP; Tong SYC; Denholm JT; Dore GJ; Bowen AC; Lewin SR; Venkatesh B; Hills TE; McQuilten Z; Paterson DL; Morpeth SC; Roberts JA, 2022, 'Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review', Clinical Pharmacokinetics, 61, pp. 1331 - 1343,
    Journal articles | 2022
    Hosseini-Hooshyar S; Alavi M; Martinello M; Valerio H; Tillakeratne S; Matthews GV; Dore GJ, 2022, 'Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study', Journal of Viral Hepatitis, 29, pp. 271 - 279,
    Journal articles | 2022
    Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua NZ; Fierer DS; Chromy D; Rockstroh JK; Martin TCS; Ingiliz P; Hung CC; Dore GJ; Martinello M; Matthews GV, 2022, 'Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression', The Lancet HIV, 9, pp. e414 - e427,
    Journal articles | 2022
    Howe AYM; Rodrigo C; Cunningham EB; Douglas MW; Dietz J; Grebely J; Popping S; Sfalcin JA; Parczewski M; Sarrazin C; de Salazar A; Fuentes A; Sayan M; Quer J; Kjellin M; Kileng H; Mor O; Lennerstrand J; Fourati S; Di Maio VC; Chulanov V; Pawlotsky JM; Harrigan PR; Ceccherini-Silberstein F; Garcia F; Martinello M; Matthews G; Fernando FF; Esteban JI; M眉llhaupt B; Wiesch JSZ; Buggisch P; Neumann-Haefelin C; Berg T; Berg CP; Schattenberg JM; Moreno C; Stauber R; Lloyd A; Dore G; Applegate T; Ignacio J; Garcia-Cehic D; Gregori J; Rodriguez-Frias F; Rando A; Gozlan Y; Angelico M; Andreoni M; Babudieri S; Bertoli A; Cento V; Coppola N; Crax矛 A; Paolucci S; Parruti G; Pasquazzi C; Perno CF; Teti E; Vironet C; Lannerg氓rd A; Duberg AS; Aleman S; Gutteberg T; Soulier A; Gourgeon A; Chevaliez S; Pol S; Carrat F; Salmon D; Kaiser R; Knopes E; Gomes P; de Kneght R; Rijnders B; Poljak M; Lunar M; Usubillaga R; Seguin_Devaux C; Tay E; Wilson C; Wang DS; George J; Kok J; P茅rez AB; Chueca N; Garc铆a-Deltoro M; Mart铆nez-Sapi帽a AM; Lara-P茅rez MM; Garc铆a-Bujalance S; Ald谩miz-Echevarr铆a T; Vera-M茅ndez FJ; Pineda JA; Casado M; Pascasio JM; Salmer贸n J; Alados-Arboledas JC; Poyato A; T茅llez F; Rivero-Ju谩rez A, 2022, 'Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals', JHEP Reports, 4, pp. 100462,
    Journal articles | 2022
    Lafferty L; Rance J; Byrne M; Milat A; Dore GJ; Grebely J; Lloyd AR; Treloar C, 2022, '鈥淵ou need a designated officer鈥 鈥 Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting', International Journal of Drug Policy, 106,
    Journal articles | 2022
    Lazarus JV; Picchio CA; Byrne CJ; Crespo J; Colombo M; Cooke GS; Dore GJ; Grebely J; Ward JW; Dillon JF, 2022, 'A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination', Seminars in Liver Disease, 42, pp. 159 - 172,
    Journal articles | 2022
    Lazarus JV; Romero D; Kopka CJ; Karim SA; Abu-Raddad LJ; Almeida G; Baptista-Leite R; Barocas JA; Barreto ML; Bar-Yam Y; Bassat Q; Batista C; Bazilian M; Chiou ST; del Rio C; Dore GJ; Gao GF; Gostin LO; Hellard M; Jimenez JL; Kang G; Lee N; Mati膷i膷 M; McKee M; Nsanzimana S; Oliu-Barton M; Pradelski B; Pyzik O; Rabin K; Raina S; Rashid SF; Rathe M; Saenz R; Singh S; Trock-Hempler M; Villapol S; Yap P; Binagwaho A; Kamarulzaman A; El-Mohandes A; Barreto M; Abdulla S; Addleman S; Aghayeva G; Agius R; Ahmed M; Ramy MA; Aide P; Aleman S; Alfred JP; Ali S; Aliaga J; Aloudat T; Alqahtani SA; Al-Salman J; Amuasi JH; Agrawal A; Anwar W; Araujo-Jorge T; Artaza O; Asadi L; Awuku Y; Baker M; Barberia L; Bascolo E; Belcher P; Bell L; Benzaken A; Bergholtz E; Bhadelia N; Bhan A; Bilodeau S; Bitr谩n R; Bluyssen P; Bosman A; Bozza FA; Brinkmann MM; Brown A; Mellado B; Bukusi E; Bullen C; Buonanno G; Burgess R; Butler M; Byakika-Kibwika P; Cabieses B; Carlsson G; Cascini F; Chabala C; Chakroun M; Cheng KK; Chetty A; Chumachenko D; Consalves G; Conway Morris A; Cordie A; Corrah T; Crabtree-Ram铆rez B; Dashdorj N; Davidovitch N, 2022, 'A multinational Delphi consensus to end the COVID-19 public health threat', Nature, 611, pp. 332 - 345,
    Journal articles | 2022
    Lockart I; Yeo MGH; Hajarizadeh B; Dore G; Danta M; Abe K; Carrat F; Lusivika-Nzinga C; Degasperi E; Di Marco V; Hou J; Howell J; Janjua NZ; Wong S; Kumada T; Lleo A; Persico M; Lok AS; Wei L; Yang M; Nabatchikova E; Nguyen MH; Antonio Pineda J; Reig M; Shiha G; Yu ML; Tsai PC, 2022, 'HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis', Hepatology, 76, pp. 139 - 154,
    Journal articles | 2022
    Marshall AD; Conway A; Cunningham EB; Valerio H; Silk D; Alavi M; Wade A; Lam T; Zohrab K; Dunlop A; Connelly C; Christmass M; Cock V; Burns C; Henderson C; Wiseman V; Dore GJ; Grebely J, 2022, 'Willingness of people who inject drugs to participate in a randomised controlled trial involving financial incentives to initiate hepatitis C treatment', Drug and Alcohol Dependence, 235,
    Journal articles | 2022
    Oliu-Barton M; Pradelski BSR; Algan Y; Baker MG; Binagwaho A; Dore GJ; El-Mohandes A; Fontanet A; Peichl A; Priesemann V; Wolff GB; Yamey G; Lazarus JV, 2022, 'Elimination versus mitigation of SARS-CoV-2 in the presence of effective vaccines', The Lancet Global Health, 10, pp. e142 - e147,
    Journal articles | 2022
    Phetsouphanh C; Darley DR; Wilson DB; Howe A; Munier CML; Patel SK; Juno JA; Burrell LM; Kent SJ; Dore GJ; Kelleher AD; Matthews GV, 2022, 'Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection', Nature Immunology, 23, pp. 210 - 216,
    Journal articles | 2022
    Phetsouphanh C; Khoo WH; Jackson K; Klemm V; Howe A; Aggarwal A; Akerman A; Milogiannakis V; Stella AO; Rouet R; Schofield P; Faulks ML; Law H; Danwilai T; Starr M; Munier CML; Christ D; Singh M; Croucher PI; Brilot-Turville F; Turville S; Phan TG; Dore GJ; Darley D; Cunningham P; Matthews GV; Kelleher AD; Zaunders JJ, 2022, 'High titre neutralizing antibodies in response to SARS鈥揅oV鈥2 infection require RBD鈥搒pecific CD4 T cells that include proliferative memory cells', Frontiers in Immunology, 13,
    Journal articles | 2022
    Shah SHBU; Alavi M; Hajarizadeh B; Matthews GV; Martinello M; Danta M; Amin J; Law MG; George J; Valerio H; Dore GJ, 2022, 'Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales', JHEP Reports, 4,
    Journal articles | 2022
    Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J; ETHOS Engage Study Group , 2022, 'Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.', Int J Drug Policy, 105, pp. 103706,
    Journal articles | 2022
    Valerio H; Conway A; Alavi M; Treloar C; Silk D; Murray C; Henderson C; Amin J; Read P; Degenhardt L; Christmass M; Montebello M; Dore GJ; Grebely J, 2022, 'Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study', International Journal of Drug Policy, 110,
    Journal articles | 2022
    Wheeler A; Valerio H; Cunningham EB; Martinello M; Barocas JA; Colledge-Frisby S; Treloar C; Amin J; Henderson C; Read P; Matthews GV; Dunlop AJ; Gorton C; Hayllar J; Alavi M; Murray C; Marks P; Silk D; Degenhardt L; Dore GJ; Grebely J, 2022, 'Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study', Drug and Alcohol Dependence, 237,
    Journal articles | 2022
    Yee J; Carson JM; Hajarizadeh B; Hanson J; O鈥橞eirne J; Iser D; Read P; Balcomb A; Doyle JS; Davies J; Martinello M; Marks P; Dore GJ; Matthews GV; Hanson J; Marks P; Byrne M; Post J; Batey R; Smart J; Dawson O; Hill S; Douglas M; Montebello M; Collie P; Hallinan R; Snelgar G; Baker D; Galhenage S; Soo TM; Bopage R; Faros J; Cooper L; Nelson R; Shaw D; Davies J; Wilson M; Pratt W; Hinton S; Wade A; Van Gessel H; Davidson L; Dibdin M; Lucas M; Ahmad R; Smith D; Tan K; Roder C; Harney B; Holdaway S; Walsh J; Fox P; Mousavi R; Lam W; Dahal RP; Habel P; Gilliver R; Silins E; Ackerman J; Deacon R; Hall E; Everson A; Milner M; Ferguson C; Tate-Baker J; Bradshaw J; Duncan G; Baluran G; Watson B; Hey C; Hickey R; Orme C; Miczkova S, 2022, 'High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study', Hepatology Communications, 6, pp. 496 - 512,
    Journal articles | 2022
    Yousafzai MT; Alavi M; Valerio H; Hajarizadeh B; Grebely J; Dore GJ, 2022, 'Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia', Viruses, 14, pp. 1496,
    Journal articles | 2021
    Abid A; Uddin M; Muhammad T; Awan S; Applegate T; Dore GJ; Cloherty G; Hamid S, 2021, 'Evaluation of hepatitis C virus core antigen assay in a resource-limited setting in Pakistan', Diagnostics, 11,
    Journal articles | 2021
    Alavi M; Moghanibashi-Mansourieh A; Radfar SR; Alizadeh S; Bahramabadian F; Esmizade S; Dore GJ; Sedeh FB; Deilamizade A, 2021, 'Coordination, cooperation, and creativity within harm reduction networks in Iran: COVID-19 prevention and control among people who use drugs', International Journal of Drug Policy, 93,
    Journal articles | 2021
    Applegate T; Bajis S; Catlett B; Cunningham P; Dore G; Grebely J; Hajarizadeh B, 2021, 'Evaluation of the Aptima HCV Quant Dx Assay for Hepatitis C Virus RNA Detection from Fingerstick Capillary Dried Blood Spot and Venepuncture-Collected Samples', Journal of Infectious Diseases,
    Journal articles | 2021
    Busingye D; Chidwick K; Simpson V; Dartnell J; J Dore G; Balcomb A; Blogg S; Dore G, 2021, 'The changing characteristics of patients with chronic hepatitis C prescribed direct acting antiviral medicines in general practice since listing of the medicines on the Australian Pharmaceutical Benefits Scheme', JGH Open, 5, pp. 813 - 819,
    Journal articles | 2021
    Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Davies J; Doyle JS; Yee J; Martinello M; Marks P; Dore GJ; Matthews GV, 2021, 'Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort', International Journal of Drug Policy, 96,
    Journal articles | 2021
    Catlett B; Bajis S; Starr M; Dore GJ; Hajarizadeh B; Cunningham PH; Applegate TL; Grebely J, 2021, 'Evaluation of the Aptima HCV Quant Dx Assay for Hepatitis C Virus RNA Detection from Fingerstick Capillary Dried Blood Spot and Venepuncture-Collected Samples', Journal of Infectious Diseases, 223, pp. 818 - 826,
    Journal articles | 2021
    Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Christmass M; Dunlop A; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Treloar C; Dore GJ; Grebely J, 2021, 'Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study', International Journal of Drug Policy, 96,
    Journal articles | 2021
    Cunningham EB; Hajarizadeh B; Amin J; Hellard M; Bruneau J; Feld JJ; Cooper C; Powis J; Litwin AH; Marks P; Dalgard O; Conway B; Moriggia A; Stedman C; Read P; Bruggmann P; Lacombe K; Dunlop A; Applegate TL; Matthews GV; Fraser C; Dore GJ; Grebely J, 2021, 'Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection among People Who Inject Drugs', Clinical Infectious Diseases, 72, pp. 1392 - 1400,
    Journal articles | 2021
    Darley D; Matthews G; Dore G; Wilhelm K; Plit M; Stone E; Byrne A; Tonga K; Andresen D; Kelleher A; Cysique L; Cunningham P; Brew B, 2021, 'Persistent symptoms up to four months after community and hospital- managed SARS- CoV- 2 infection', Medical Journal of Australia,
    Journal articles | 2021
    Darley DR; Dore GJ; Byrne A; Plit M; Brew BJ; Kelleher A; Matthews GV, 2021, 'Limited recovery from post-acute sequelae of SARS-CoV-2 (PASC) at eight months in a prospective cohort', ,
    Journal articles | 2021
    Darley DR; Dore GJ; Byrne AL; Plit ML; Brew BJ; Kelleher A; Matthews GV, 2021, 'Limited recovery from post-acute sequelae of sars-cov-2 at 8 months in a prospective cohort', ERJ Open Research, 7,
    Journal articles | 2021
    Dore G; Levy M, 2021, 'Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients with Difficult to Cure Characteristics', Clinical Infectious Diseases,
    Journal articles | 2021
    Dore G, 2021, 'Australian COVID-19 response: Lessons and future directions', Journal and Proceedings of the Royal Society of New South Wales, 154, pp. 78 - 84,
    Journal articles | 2021
    Dore GJ; Bajis S, 2021, 'Author Correction: Hepatitis C virus elimination: laying the foundation for achieving 2030 targets (Nature Reviews Gastroenterology & Hepatology, (2021), 18, 2, (91-92), 10.1038/s41575-020-00392-3)', Nature Reviews Gastroenterology and Hepatology, 18, pp. 143,
    Journal articles | 2021
    Dore GJ; Bajis S, 2021, 'Hepatitis C virus elimination: laying the foundation for achieving 2030 targets', Nature Reviews Gastroenterology and Hepatology, 18, pp. 91 - 92,
    Journal articles | 2021
    Dore GJ; Cowie B, 2021, 'Global Hepatitis B Virus Elimination by 2030: China Is Pivotal and Instructive', Clinical Infectious Diseases, 72, pp. 753 - 754,
    Journal articles | 2021
    Dore GJ, 2021, 'Elimination of hepatitis c in australia by 2030: A decade and counting', Australian Prescriber, 44, pp. 36 - 37,
    Journal articles | 2021
    Grebely J; Tran L; Degenhardt L; Dowell-Day A; Santo T; Larney S; Hickman M; Vickerman P; French C; Butler K; Gibbs D; Valerio H; Read P; Dore GJ; Hajarizadeh B, 2021, 'Association between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection among People Who Inject Drugs: A Systematic Review and Meta-analysis', Clinical Infectious Diseases, 73, pp. E107 - E118,
    Journal articles | 2021
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ; Loveday S; Tamaddoni M; Obeid S; Estivill Mercade G; Martinez M; Donnelly R; Bowman J; Trevethan L; Lagios K; Murrell T; Bath N; Tawil V; Stevens A; Topp L; Churchill A; Pinnock K; Drew S; Harrod M; Smith A; Williams R; Cooper B; Somes K; Burns C; Kaur A; Lobo C; Conroy K; McCredie L; Caf茅 C; Anlezark J; Rawlinson W; Yeang M; Wynn M; Willenborg C, 2021, 'Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study', The Lancet Gastroenterology and Hepatology, 6, pp. 533 - 546,
    Journal articles | 2021
    Hamid S; Abid A; Dore GJ, 2021, 'Identifying the lower age limit for hepatitis C screening in large elimination programmes in highly endemic areas', The Lancet Gastroenterology and Hepatology, 6, pp. 89 - 90,
    Journal articles | 2021
    Jin F; Dore GJ; Matthews G; Luhmann N; Macdonald V; Bajis S; Baggaley R; Mathers B; Verster A; Grulich AE, 2021, 'Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, 6, pp. 39 - 56,
    Journal articles | 2021
    Kwon JA; Dore GJ; Hajarizadeh B; Alavi M; Valerio H; Grebely J; Guy R; Gray RT, 2021, 'Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications', PLoS ONE, 16,
    Journal articles | 2021
    Lafferty L; Rance J; Dore GJ; Grebely J; Lloyd AR; Treloar C, 2021, 'Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel', International Journal of Drug Policy, 98,
    Journal articles | 2021
    Lafferty L; Rance J; Dore GJ; Lloyd AR; Treloar C, 2021, 'The role of social capital in facilitating hepatitis C treatment scale-up within a treatment-as-prevention trial in the male prison setting', Addiction, 116, pp. 1162 - 1171,
    Journal articles | 2021
    Lim AG; Stone J; Hajarizadeh B; Byrne M; Chambers GM; Martin NK; Grebely J; Dore GJ; Lloyd AR; Vickerman P, 2021, 'Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons', Hepatology, 74, pp. 2366 - 2379,
    Journal articles | 2021
    Liu B; Jayasundara D; Pye V; Dobbins T; Dore GJ; Matthews G; Kaldor J; Spokes P, 2021, 'Whole of population-based cohort study of recovery time from COVID-19 in New South Wales Australia', The Lancet Regional Health - Western Pacific, 12,
    Journal articles | 2021
    Lockart I; Hajarizadeh B; Alavi M; Davison S; Prakoso E; Levy MT; George J; Dore GJ; Danta M, 2021, 'Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival', Journal of Viral Hepatitis, 28, pp. 710 - 718,
    Journal articles | 2021
    Lockart I; Hajarizadeh B; Buckley N; Davison S; Prakoso E; Levy MT; George J; Dore GJ; Danta M, 2021, 'All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy', Journal of Gastroenterology and Hepatology (Australia), 36, pp. 3515 - 3523,
    Journal articles | 2021
    Marriott D; Beresford R; Mirdad F; Stark D; Glanville A; Chapman S; Harkness J; Dore GJ; Andresen D; Matthews GV, 2021, 'Concomitant Marked Decline in Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Other Respiratory Viruses among Symptomatic Patients Following Public Health Interventions in Australia: Data from St Vincent's Hospital and Associated Screening Clinics, Sydney, NSW', Clinical Infectious Diseases, 72, pp. E649 - E651,
    Journal articles | 2021
    Matthews GV; Bhagani S; Van der Valk M; Rockstroh J; Feld JJ; Rauch A; Thurnheer C; Bruneau J; Kim A; Hellard M; Shaw D; Gane E; Nelson M; Ingiliz P; Applegate TL; Grebely J; Marks P; Martinello M; Petoumenos K; Dore GJ; Marks P; Feld J; Amjad S; Tu E; Tamaddoni M; Thurnheer MC; Gilleece Y; Fraser C; Moriggia A; Lutz T; Moon J; Read P; Ustianowski A; Cordes C; Sasadeusz J; Hull M; Braun D, 2021, 'Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection', Journal of Hepatology, 75, pp. 829 - 839,
    Journal articles | 2021
    Ogrunc M; Martinez-Zamudio RI; Ben Sadoun P; Dore G; Schwerer H; Pasero P; Lemaitre JM; Dejean A; Bischof O, 2021, 'Retraction notice to: USP1 regulates cellular senescence by controlling genomic integrity (Cell Reports (2016) 15(7) (1401鈥1411), (S2211124716304466), (10.1016/j.celrep.2016.04.033))', Cell Reports, 34,
    Journal articles | 2021
    Palmer AY; Wilkinson A; Aitken C; Dietze P; Dore GJ; Maher L; Sacks-Davis R; Stoove M; Wilson D; Hellard M; Scott N, 2021, 'Estimating the number of new hepatitis C infections in Australia in 2015, prior to the scale-up of direct-acting antiviral treatment', Journal of Gastroenterology and Hepatology (Australia), 36, pp. 2270 - 2274,
    Journal articles | 2021
    Papaluca T; Roberts SK; Strasser SI; Stuart KA; Farrell G; Macquillan G; Dore GJ; Wade AJ; George J; Hazeldine S; O'Beirne J; Wigg A; Fisher L; McGarity B; Sawhney R; Sinclair M; Thomas J; Valiozis I; Weltman M; Wilson M; Woodward A; Ahlenstiel G; Haque M; Levy M; Prewett E; Sievert W; Sood S; Tse E; Valaydon Z; Bowden S; Douglas M; New K; O'Keefe J; Hellard M; Doyle J; Stoove M; Thompson AJ, 2021, 'Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients with Difficult to Cure Characteristics', Clinical Infectious Diseases, 73, pp. E3288 - E3295,
    Journal articles | 2021
    Phetsouphanh C; Darley D; Wilson D; Howe A; Ling Munier M; Patel S; Juno J; Burrell L; Kent S; Dore G; Kelleher A; Matthews G, 2021, 'Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection', ,
    Journal articles | 2021
    Prince DS; Pipicella JL; Fraser M; Alvaro F; Maley M; Foo H; Middleton PMC; Davison SA; Dore GJ; McCaughan GW; Levy MT, 2021, 'Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or 鈥榬e-diagnose鈥 infections is effective in Australia', Journal of Viral Hepatitis, 28, pp. 121 - 128,
    Journal articles | 2021
    Rance J; Lafferty L; Treloar C; Loveday S; Dore G; Lloyd A; Grebely J; Butler T; Martin N; Chambers G; Byrne M; Donnelly R; McGrath C; Bowman J; Trevethan L; Grant L; Murrell T; Bath N; Harrod M; Churchill A; Pinnock K; Cairnduff S, 2021, 'Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 鈥榮urveillance and treatment of prisoners with hepatitis C鈥 project (SToP-C)', Harm Reduction Journal, 18, pp. 46,
    Journal articles | 2021
    Rance J; Lafferty L; Treloar C; Loveday S; Dore G; Lloyd A; Grebely J; Butler T; Martin N; Chambers G; Byrne M; Donnelly R; McGrath C; Bowman J; Trevethan L; Grant L; Murrell T; Bath N; Harrod M; Churchill A; Pinnock K; Cairnduff S, 2021, 'Expert stakeholder perspectives on the acceptability of treatment-as-prevention in prison: a qualitative substudy of the 鈥楽urveillance and Treatment of Prisoners with Hepatitis C鈥 project (SToP-C)', Addiction, 116, pp. 2761 - 2769,
    Journal articles | 2021
    Stafford F; Dore GJ; Clackett S; Martinello M; Matthews GV; Grebely J; Balcomb AC; Hajarizadeh B, 2021, 'Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program', Medical Journal of Australia, 215, pp. 332 - 333,
    Journal articles | 2021
    Stephens J; Bradley C; Elliott S; Dore G; Grebely J; Alavi M; Kennedy B; Tong S; Ward J, 2021, '843Hepatitis C in South Australia and Northern Territory: a population-based linkage study', International Journal of Epidemiology, 50,
    Journal articles | 2021
    Stephens J; Bradley C; Elliott S; Dore G; Grebely J; Alavi M; Kennedy B; Tong S; Ward J, 2021, 'Hepatitis C in South Australia and Northern Territory: a population-based linkage study', INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 50,
    Journal articles | 2021
    Tea F; Stella AO; Aggarwal A; Darley DR; Pilli D; Vitale D; Merheb V; Lee FXZ; Cunningham P; Walker GJ; Fichter C; Brown DA; Rawlinson WD; Isaacs SR; Mathivanan V; Hoffmann M; P枚hlman S; Mazigi O; Christ D; Rockett RJ; Sintchenko V; Hoad VC; Irving DO; Dore GJ; Gosbell IB; Kelleher AD; Matthews GV; Brilot F; Turville SG, 2021, 'SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants', PLoS Medicine, 18,
    Journal articles | 2021
    Valerio H; Alavi M; Law M; McManus H; Tillakeratne S; Bajis S; Martinello M; Matthews GV; Amin J; Janjua NZ; Krajden M; George J; Degenhardt L; Grebely J; Dore GJ, 2021, 'Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study', Clinical Infectious Diseases, 73, pp. 2037 - 2044,
    Journal articles | 2021
    Valerio H; Alavi M; Law M; Tillakeratne S; Amin J; Janjua NZ; Krajden M; George J; Matthews GV; Hajarizadeh B; Degenhardt L; Grebely J; Dore GJ, 2021, 'High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia', Journal of Hepatology, 74, pp. 293 - 302,
    Journal articles | 2021
    Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore G; Grebely J, 2021, 'Progress towards Elimination of Hepatitis C Infection among People Who Inject Drugs in Australia: The ETHOS Engage Study', Clinical Infectious Diseases, 73, pp. E69 - E78,
    Journal articles | 2021
    Yousafzai MT; Bajis S; Alavi M; Grebely J; Dore GJ; Hajarizadeh B, 2021, 'Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis', Journal of Viral Hepatitis, 28, pp. 1340 - 1354,
    Journal articles | 2020
    Artenie AA; Cunningham EB; Dore GJ; Conway B; Dalgard O; Powis J; Bruggmann P; Hellard M; Cooper C; Read P; Feld JJ; Hajarizadeh B; Amin J; Lacombe K; Stedman C; Litwin AH; Marks P; Matthews GV; Quiene S; Erratt A; Bruneau J; Grebely J, 2020, 'Patterns of drug and alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis c virus treatment with directacting antiviral therapies: An international study', Clinical Infectious Diseases, 70, pp. 2369 - 2376,
    Journal articles | 2020
    Bajis S; Applegate TL; Grebely J; Matthews GV; Dore GJ, 2020, 'Novel hepatitic C virus (HCV) diagnosis and treatment delivery systems: Facilitating HCV elimination by thinking outside the clinic', Journal of Infectious Diseases, 222, pp. S758 - S772,
    Journal articles | 2020
    Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ; Peolim L; How-Chow D; Telenta J; Harvey P; Jones S; Dunlop A; Treloar C; Samuel Y; Poeder F; Crawford S; Baxter A; Keats J; Mowat Y; Silk D; Micallef M; Tamaddoni M; Marks P; Lamoury F; Jayasinghe I; Reid H; Cunningham EB; Bartlett S; Jacka B; Erratt A; Jauncey M; Collie P; Lam T; Gilliver R; Hazelwood S; Houlihan N; Burns C; Lewis R; Morris D; Donohue K; Carthew A; Horasak N; Cherry R; Shin S; Peterson D; Sellwood T; McKeown W; Pritchard-Jones J; Smyth F; Adey S; Clark K; Grebely J; Hajarizadeh B; Edwards M, 2020, 'Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study', Journal of Viral Hepatitis, 27, pp. 281 - 293,
    Journal articles | 2020
    Boettiger DC; Salazar-Vizcaya L; Dore GJ; Gray RT; Law MG; Callander D; Lea T; Rauch A; Matthews GV, 2020, 'Can Australia Reach the World Health Organization Hepatitis C Elimination Goal by 2025 among Human Immunodeficiency Virus-positive Gay and Bisexual Men?', Clinical Infectious Diseases, 70, pp. 106 - 113,
    Journal articles | 2020
    Cunningham EB; Hajarizadeh B; Amin J; Litwin AH; Gane E; Cooper C; Lacombe K; Hellard M; Read P; Powis J; Dalgard O; Bruneau J; Matthews GV; Feld JJ; Dillon JF; Shaw D; Bruggmann P; Conway B; Fraser C; Marks P; Dore GJ; Grebely J, 2020, 'Adherence to once-daily and twice-daily direct-acting antiviral therapy for Hepatitis C infection among people with recent injection drug use or current opioid agonist therapy', Clinical Infectious Diseases, 71, pp. E115 - E124,
    Journal articles | 2020
    Dalgard O; Litwin A; Dore G; Shibolet O; Grebely J; Nahass R; Altice F; Conway B; Gane E; Luetkemeyer A; Peng C-Y; Iser D; Gendrano IN; Kelly MM; Haber B; Platt HL; Puenpatom A, 2020, 'Patient-reported outcomes among people receiving opioid agonist therapy and treatment for hepatitis C virus infection: results from CO-STAR', JOURNAL OF HEPATOLOGY, 73, pp. S356 - S356,
    Journal articles | 2020
    Dore G; Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Mcmanus H; Butler T; Vickerman P; Martin N; Mchutchison J; Brainard D; Treloar C; Lloyd A, 2020, 'Declining HCV incidence following rapid HCV treatment scale-up in a prison network in Australia: Evidence of treatment as prevention from the SToP-C study', JOURNAL OF HEPATOLOGY, 73, pp. S127 - S127,
    Journal articles | 2020
    Dore GJ; Danta M; Matthews GV, 2020, 'Hepatocellular carcinoma risk with antivirals for chronic hepatitis B: no longer confounding', The Lancet Gastroenterology and Hepatology, 5, pp. 1028 - 1029,
    Journal articles | 2020
    Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; M眉llhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E, 2020, 'Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial', Journal of Hepatology, 72, pp. 431 - 440,
    Journal articles | 2020
    Dore GJ; Martinello M; Alavi M; Grebely J, 2020, 'Global elimination of hepatitis C virus by 2030: why not?', Nature Medicine, 26, pp. 157 - 160,
    Journal articles | 2020
    Dore GJ; Matthews GV, 2020, 'Universal screening for hepatitis C virus infection should be linked to universal treatment access', Nature Reviews Gastroenterology and Hepatology, 17, pp. 321 - 322,
    Journal articles | 2020
    Dore GJ; Trooskin S, 2020, 'People with hepatitis C who inject drugs 鈥 Underserved, not undeserving', New England Journal of Medicine, 383, pp. 608 - 611,
    Journal articles | 2020
    Dore GJ; Valerio H; Grebely J, 2020, 'Creating an environment for equitable access to direct-acting antiviral therapy for people who inject drugs with hepatitis C', Liver International, 40, pp. 2353 - 2355,
    Journal articles | 2020
    Douglas MW; Tay ESE; Wang DS; Ong ATL; Wilson C; Phu A; Kok J; Dwyer DE; Bull RA; Lloyd AR; Applegate TL; Dore GJ; Howe AY; Harrigan R; George J, 2020, 'Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance', Hepatology Communications, 4, pp. 904 - 915,
    Journal articles | 2020
    Geddes L; Iversen J; Wand H; Esmaeili A; Tsui J; Hellard M; Dore G; Grebely J; Dietze P; Bruneau J; Prins M; Morris MD; Shoukry NH; Lloyd AR; Kim AY; Lauer G; Cox AL; Page K; Maher L; Lloyd A; Dore G; Dietze P, 2020, 'Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection', Clinical Infectious Diseases, 70, pp. 123 - 131,
    Journal articles | 2020
    Grebely J; Catlett B; Catlett B; Jayasinghe I; Valerio H; Hajarizadeh B; Verich A; Cunningham P; Martinello M; Tillakeratne S; Silk D; Dore GJ; Applegate TL, 2020, 'Time to Detection of Hepatitis C Virus Infection with the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis', Journal of Infectious Diseases, 221, pp. 2043 - 2049,
    Journal articles | 2020
    Grebely J; Read P; Cunningham EB; Weltman M; Matthews GV; Dunlop A; Montebello M; Martinello M; Gilliver R; Marks P; Applegate TL; Dore GJ, 2020, 'Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial', Health Science Reports, 3,
    Journal articles | 2020
    Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J, 2020, 'Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis', Journal of Hepatology, 72, pp. 643 - 657,
    Journal articles | 2020
    He S; Lockart I; Alavi M; Danta M; Hajarizadeh B; Dore GJ, 2020, 'Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma', Alimentary Pharmacology and Therapeutics, 51, pp. 34 - 52,
    Journal articles | 2020
    Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV, 2020, 'Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV', AIDS, 34, pp. 1347 - 1358,
    Journal articles | 2020
    Iranpour N; Dore GJ; Martinello M; Matthews GV; Grebely J; Hajarizadeh B, 2020, 'Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: A retrospective cohort study', Sexual Health, 17, pp. 223 - 230,
    Journal articles | 2020
    Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L, 2020, 'Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy', International Journal of Drug Policy, 83, pp. 102837,
    Journal articles | 2020
    Lafferty L; Rance J; Grebely J; Dore GJ; Lloyd AR; Treloar C, 2020, 'Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting', International Journal of Drug Policy, 77,
    Journal articles | 2020
    Larance B; Byrne M; Lintzeris N; Nielsen S; Grebely J; Degenhardt L; Shahbazi J; Shanahan M; Lancaster K; Dore G; Ali R; Farrell M; Treloar C, 2020, 'Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: Protocol for the CoLAB study', BMJ Open, 10, pp. e034389,
    Journal articles | 2020
    Marshall AD; Grebely J; Dore GJ; Treloar C, 2020, 'Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists鈥擳he practitioner experience', Drug and Alcohol Dependence, 206,
    Journal articles | 2020
    Martinello M; Bajis S; Dore GJ, 2020, 'Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation', Gastroenterology Clinics of North America, 49, pp. 253 - 277,
    Journal articles | 2020
    Martinello M; Hajarizadeh B; Dore GJ, 2020, 'Hepatitis C elimination in Australia: progress and challenges', Medical Journal of Australia, 212, pp. 362 - 363,
    Journal articles | 2020
    Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews GV, 2020, 'Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection', Hepatology, 72, pp. 7 - 18,
    Journal articles | 2020
    Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV, 2020, 'Moving towards Hepatitis C microelimination among people living with human immunodeficiency virus in Australia: The CEASE study', Clinical Infectious Diseases, 71, pp. 1502 - 1510,
    Journal articles | 2020
    Tea F; Stella AO; Aggarwal A; Darley DR; Pilli D; Vitale D; Merheb V; Lee FXZ; Cunningham P; Walker GJ; Brown DA; Rawlinson WD; Isaacs SR; Mathivanan V; Hoffman M; P枚hlmann S; Dwyer DE; Rockett R; Sintchenko V; Hoad VC; Irving DO; Dore GJ; Gosbell IB; Kelleher AD; Matthews GV; Brilot F; Turville SG, 2020, 'SARS-CoV-2 neutralizing antibodies; longevity, breadth, and evasion by emerging viral variants', ,
    Journal articles | 2020
    Trooskin SB; Dore G; Kostman J, 2020, 'We must do better: Addressing HCV treatment barriers in persons who inject drugs in the United States', Journal of Infectious Diseases, 222, pp. S773 - S781,
    Journal articles | 2020
    Valerio H; Alavi M; Matthews G; Law M; McManus H; Amin J; Janjua N; Krajden M; Tillakeratne S; Gleeson V; George J; Degenhardt L; Grebely J; Dore G, 2020, 'Opportunities to enhance linkage to hepatitis C care among people hospitalised for injection drug use-related complications: a population-based study', JOURNAL OF HEPATOLOGY, 73, pp. S807 - S808,
    Journal articles | 2019
    Abayasingam A; Leung P; Eltahla A; Bull RA; Luciani F; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Cox AL; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Lloyd A; Rodrigo C, 2019, 'Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing', Infection, Genetics and Evolution, 71, pp. 36 - 41,
    Journal articles | 2019
    Alavi M; Law MG; Dore GJ, 2019, 'Reply to: 鈥淧itfalls in measuring temporal trends for late diagnosis of viral hepatitis鈥', Journal of Hepatology, 71, pp. 1254 - 1255,
    Journal articles | 2019
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ, 2019, 'Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia', Journal of Hepatology, 71, pp. 281 - 288,
    Journal articles | 2019
    Alavi M; Poustchi H; Merat S; Kaveh-ei S; Rahimi-Movaghar A; Shadloo B; Hajarizadeh B; Grebely J; Dore GJ; Malekzadeh R, 2019, 'An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study', International Journal of Drug Policy, 72, pp. 99 - 105,
    Journal articles | 2019
    Bajis S; Grebely J; Cooper L; Smith J; Owen G; Chudleigh A; Hajarizadeh B; Martinello M; Adey S; Read P; Gilliver R; Applegate T; Treloar C; Maher L; Dore GJ, 2019, 'Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study', Journal of Viral Hepatitis, 26, pp. 969 - 979,
    Journal articles | 2019
    Bartlett SR; Applegate TL; Jacka BP; Martinello M; Lamoury FMJ; Danta M; Bradshaw D; Shaw D; Lloyd AR; Hellard M; Dore GJ; Matthews GV; Grebely J, 2019, 'A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015', Journal of the International AIDS Society, 22, pp. e25222,
    Journal articles | 2019
    Catlett B; Lamoury FMJ; Bajis S; Hajarizadeh B; Martinez D; Mowat Y; Cunningham PH; Jacka BP; Cloherty GA; Marks P; Dore GJ; Grebely J; Applegate TL, 2019, 'Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study', Journal of Viral Hepatitis, 26, pp. 1423 - 1430,
    Journal articles | 2019
    Cooke GS; Andrieux-Meyer I; Applegate TL; Atun R; Burry JR; Cheinquer H; Dusheiko G; Feld JJ; Gore C; Griswold MG; Hamid S; Hellard ME; Hou JL; Howell J; Jia J; Kravchenko N; Lazarus JV; Lemoine M; Lesi OA; Maistat L; McMahon BJ; Razavi H; Roberts TR; Simmons B; Sonderup MW; Spearman CW; Taylor BE; Thomas DL; Waked I; Ward JW; Wiktor SZ; Abdo A; Aggarwal R; Aghemo A; Al-Judaibi B; Al Mahtab M; Altaf A; Ameen Z; Asselah T; Baatarkkhuu O; Barber E; Barnes E; Boulet P; Burrows L; Butsashvili M; Chan E; Chow C; Cowie B; Cunningham C; de Araujo A; Diap G; Dore G; Doyle J; Elsayed M; Fajardo E; Gane E; Getehun A; Goldberg D; Got T; Hickman M; Hill A; Hutchinson S; Jones C; Kamili S; Khan A; Lee A; Lee TY; Malani J; Morris TM; Nayagam S; Njouom R; Ocama P; Pedrana A; Peeling R; Reddy A; Sacks J; Sarin S; Shimakawa Y; Silva M; Skala P; Taylor-Robinson S; Thompson A; Thursz M; Tonganibeia A; Wallace J; Ward J; Wolff F; Vickerman P; Yau J, 2019, 'Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission', The Lancet Gastroenterology and Hepatology, 4, pp. 135 - 184,
    Journal articles | 2019
    Dillon JF; Miller MH; Robinson EM; Hapca A; Rezaeihemami M; Weatherburn C; McIntyre PG; Bartlett B; Donnan PT; Boyd KA; Dow E, 2019, 'Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care', Journal of Hepatology, 71, pp. 699 - 706,
    Journal articles | 2019
    Dore G; Feld J; Thompson A; Martinello M; Muir A; Agarwal K; Mullhaupt B; Wedemeyer H; Lacombe K; Matthews G; Schultz M; Mercade GE; Kho D; Filep E; Petoumenos K; Marks P; Tatsch F; dos Santos AGP; Gane E, 2019, 'Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study', JOURNAL OF HEPATOLOGY, 70, pp. E110 - E110,
    Journal articles | 2019
    Dore GJ, 2019, 'HCV reinfection as a positive indication of high-risk population treatment access', Journal of Viral Hepatitis, 26, pp. 516 - 518,
    Journal articles | 2019
    Foster GR; Dore GJ; Wang S; Grebely J; Sherman KE; Baumgarten A; Conway B; Jackson D; Asselah T; Gschwantler M; Tomasiewicz K; Aguilar H; Asatryan A; Hu Y; Mensa FJ, 2019, 'Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies', Drug and Alcohol Dependence, 194, pp. 487 - 494,
    Journal articles | 2019
    Grebely J; Cunningham EB; Dalgard O; Hajarizadeh B; Conway B; Powis J; Bruneau J; Feld J; Read P; Cooper C; Amin J; Bruggmann P; Lacombe K; Stedman C; Hellard M; Marks P; Dunlop A; Moriggia A; Applegate T; Litwin A; Matthews G; Dore G, 2019, 'SAT-232-Reinfection following successful HCV DAA therapy among people with recent injecting drug use', Journal of Hepatology, 70, pp. e732 - e733,
    Journal articles | 2019
    Grebely J; Dore GJ; Alami NN; Conway B; Dillon JF; Gschwantler M; Felizarta F; H茅zode C; Tomasiewicz K; Fredrick LM; Dumas EO; Mensa FJ, 2019, 'Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1鈥6 receiving opioid substitution therapy', International Journal of Drug Policy, 66, pp. 73 - 79,
    Journal articles | 2019
    Grebely J; Larney S; Peacock A; Colledge S; Leung J; Hickman M; Vickerman P; Blach S; Cunningham EB; Dumchev K; Lynskey M; Stone J; Trickey A; Razavi H; Mattick RP; Farrell M; Dore GJ; Degenhardt L, 2019, 'Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs', Addiction, 114, pp. 150 - 166,
    Journal articles | 2019
    Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Reid H; Law M; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore G; Grebely J, 2019, 'SAT-233-Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', Journal of Hepatology, 70, pp. e733 - e733,
    Journal articles | 2019
    Hooshyar SH; Martinello M; Yee J; Bartlett S; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Marks P; Applegate T; Dore G; Matthews G, 2019, 'SAT-235-Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia', Journal of Hepatology, 70, pp. e734 - e734,
    Journal articles | 2019
    Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L, 2019, 'Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia', Journal of Hepatology, 70, pp. 33 - 39,
    Journal articles | 2019
    Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT; Dunlop A; Zekry A; Lloyd A; Duvnjak A; Treloar C; Tyrrell H; George J; Iversen J; Marriott K; Crooks L; Maher L; Douglas M, 2019, 'Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study', Journal of Viral Hepatitis, 26, pp. 83 - 92,
    Journal articles | 2019
    Lafferty L; Rance J; Treloar C, 2019, '鈥楩ighting a losing battle鈥: prisoners鈥 perspectives of treatment as prevention for hepatitis C with inadequate primary prevention measures', Drugs: Education, Prevention and Policy, 26, pp. 502 - 507,
    Journal articles | 2019
    Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Filep E; Petoumenos K; Marks P; Applegate T; Grebely J; Dore G; Nelson M; Matthews G, 2019, 'Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection', JOURNAL OF HEPATOLOGY, 70, pp. E231 - E231,
    Journal articles | 2019
    Olmstead AD; Montoya V; Chui CK; Dong W; Joy JB; Tai V; Poon AFY; Nguyen T; Brumme CJ; Martinello M; Matthews GV; Richard Harrigan P; Dore GJ; Applegate TL; Grebely J; Howe AYM, 2019, 'A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections', Infection, Genetics and Evolution, 69, pp. 76 - 84,
    Journal articles | 2019
    Read P; Gilliver R; Kearley J; Lothian R; Cunningham EB; Chronister KJ; Dore GJ, 2019, 'Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection', Journal of Viral Hepatitis, 26, pp. 1301 - 1310,
    Journal articles | 2019
    Rodrigo C; Leung P; Lloyd AR; Bull RA; Luciani F; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Cox AL; Osburn W; Kim AY; Shoukry NH; Lauer GM; Maher L; Schinkel J; Prins M; Hellard M; Eltahla AA, 2019, 'Genomic variability of within-host hepatitis C variants in acute infection', Journal of Viral Hepatitis, 26, pp. 476 - 484,
    Journal articles | 2019
    Safreed-Harmon K; Blach S; Aleman S; Bollerup S; Cooke G; Dalgard O; Dillon JF; Dore GJ; Duberg AS; Grebely J; Boe Kielland K; Midgard H; Porter K; Razavi H; Tyndall M; Weis N; Lazarus JV, 2019, 'The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination', Clinical Infectious Diseases, 69, pp. 2218 - 2227,
    Journal articles | 2019
    Safreed-Harmon K; Blach S; Aleman S; Kielland KB; Bollerup S; Cooke G; Dalgard O; Dillon J; Dore G; Du Berg A-S; Grebely J; Midgard H; Porter K; Razavi H; Tyndall M; Weis N; Lazarus J, 2019, 'The consensus hepatitis C cascade of care: Methodology and initial findings from three countries', JOURNAL OF HEPATOLOGY, 70, pp. E333 - E334,
    Journal articles | 2019
    Sharkawy RE; Bayoumi A; Metwally M; Mangia A; Berg T; Romero-Gomez M; Abate ML; Irving WL; Sheridan D; Dore GJ; Spengler U; Lampertico P; Bugianesi E; Weltman M; Mollison L; Cheng W; Riordan S; Santoro R; Gallego-Dur谩n R; Fischer J; Nattermann J; D鈥橝mbrosio R; McLeod D; Powell E; latchoumanin O; Thabet K; Najim MAM; Douglas MW; Liddle C; Qiao L; George J; Eslam M; White R; Rojas A; Bassendine M; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Grebely J; Fragomeli V; Jonsson JR, 2019, 'A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-尾1 dependent mechanisms', Scientific Reports, 9,
    Journal articles | 2018
    Alavi M; Grebely J; Hajarizadeh B; Amin J; Larney S; Law MG; George J; Degenhardt L; Dore GJ, 2018, 'Mortality trends among people with hepatitis B and C: A population-based linkage study, 1993-2012', BMC Infectious Diseases, 18,
    Journal articles | 2018
    Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio H; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ, 2018, 'Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study', Journal of Viral Hepatitis, 25, pp. 473 - 481,
    Journal articles | 2018
    Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ, 2018, 'The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study', Journal of Hepatology, 68, pp. 393 - 401,
    Journal articles | 2018
    Alavi M; Law MG; Dore GJ, 2018, 'Reply to: 鈥溾榃ho killed JR鈥: Chronic hepatitis C or alcohol use disorders?鈥', Journal of Hepatology, 68, pp. 1099 - 1100,
    Journal articles | 2018
    Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J, 2018, 'Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia', International Journal of Drug Policy, 61, pp. 23 - 30,
    Journal articles | 2018
    Bartlett SR; Fox P; Cabatingan H; Jaros A; Gorton C; Lewis R; Priscott E; Dore GJ; Russell DB, 2018, 'Demonstration of near-elimination of Hepatitis C virus among a prison population: The Lotus Glen Correctional Centre Hepatitis C Treatment Project', Clinical Infectious Diseases, 67, pp. 460 - 463,
    Journal articles | 2018
    Conway B; Dore GJ; Altice F; Litwin A; Grebely J; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng C; Gendrano I; Huang H; Chen E; Nguyen B; Wahl J; Barr E; Robertson M; Platt H, 2018, 'A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT)', Journal of the Canadian Association of Gastroenterology, 1, pp. 299 - 300,
    Journal articles | 2018
    Cunningham EB; Amin J; Feld JJ; Bruneau J; Dalgard O; Powis J; Hellard M; Cooper C; Read P; Conway B; Dunlop AJ; Norton B; Litwin AH; Hajarizadeh B; Thurnheer MC; Dillon JF; Weltman M; Shaw D; Bruggmann P; Gane E; Fraser C; Marks P; Applegate TL; Quiene S; Siriragavan S; Matthews GV; Dore GJ; Grebely J, 2018, 'Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study', International Journal of Drug Policy, 62, pp. 14 - 23,
    Journal articles | 2018
    Cunningham EB; Hajarizadeh B; Amin J; Bretana N; Dore GJ; Degenhardt L; Larney S; Luciani F; Lloyd AR; Grebely J; Dolan K, 2018, 'Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study', International Journal of Drug Policy, 54, pp. 18 - 25,
    Journal articles | 2018
    Dore G; Hoy J; Phanuphak P; Levy J; Lewin SR, 2018, 'Professor David Cooper OBITUARY', AIDS, 32, pp. 1205 - 1206,
    Journal articles | 2018
    Dore GJ; Hajarizadeh B, 2018, 'Elimination of Hepatitis C Virus in Australia: Laying the Foundation', Infectious Disease Clinics of North America, 32, pp. 269 - 279,
    Journal articles | 2018
    Dore GJ, 2018, 'Striving for hepatitis C virus elimination or control?', The Lancet Gastroenterology and Hepatology, 3, pp. 295 - 297,
    Journal articles | 2018
    Esmaeili A; Mirzazadeh A; Morris MD; Hajarizadeh B; Sacks HS; Maher L; Grebely J; Kim AY; Lauer G; Cox AL; Hellard M; Dietze P; Bruneau J; Shoukry NH; Dore GJ; Lloyd AR; Prins M; Page K, 2018, 'The Effect of Female Sex on Hepatitis C Incidence among People Who Inject Drugs: Results from the International Multicohort InC3 Collaborative', Clinical Infectious Diseases, 66, pp. 20 - 28,
    Journal articles | 2018
    Grebely J; Conway B; Cunningham EB; Fraser C; Moriggia A; Gane E; Stedman C; Cooper C; Castro E; Schmid P; Petoumenos K; Hajarizadeh B; Marks P; Erratt A; Dalgard O; Lacombe K; Feld JJ; Bruneau J; Daulouede JP; Powis J; Bruggmann P; Matthews GV; Kronborg I; Shaw D; Dunlop A; Hellard M; Applegate TL; Crawford S; Dore GJ, 2018, 'Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy', International Journal of Drug Policy, 62, pp. 94 - 103,
    Journal articles | 2018
    Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ, 2018, 'Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial', The Lancet Gastroenterology and Hepatology, 3, pp. 153 - 161,
    Journal articles | 2018
    Grebely J; Feld JJ; Wyles D; Sulkowski M; Ni L; Llewellyn J; Mir HM; Sajed N; Stamm LM; Hyland RH; McNally J; Brainard DM; Jacobson I; Zeuzem S; Bourli猫re M; Foster G; Afdhal N; Dore GJ, 2018, 'Sofosbuvir-based direct-acting antiviral therapies for HCV in people receiving opioid substitution therapy: An analysis of phase 3 studies', Open Forum Infectious Diseases, 5,
    Journal articles | 2018
    Grebely J; Puoti M; Wedemeyer H; Cooper C; Sulkowski MS; Foster GR; Berg T; Villa E; Rodriguez-Perez F; Wyles DL; Schnell G; Alami NN; Zhang Z; Dumas E; Dore GJ, 2018, 'Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in patients with chronic hepatitis C virus genotype 1 infection receiving opioid substitution therapy: A post hoc analysis of 12 clinical trials', Open Forum Infectious Diseases, 5, pp. ofy248,
    Journal articles | 2018
    Hajarizadeh B; Cunningham EB; Reid H; Law M; Dore GJ; Grebely J, 2018, 'Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, 3, pp. 754 - 767,
    Journal articles | 2018
    Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2018, 'Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia', Journal of Viral Hepatitis, 25, pp. 640 - 648,
    Journal articles | 2018
    Hezode C; Kwo P; Sperl J; Dore G; Hwang P; Long J; Talwani R; Robertson M; Haber B, 2018, 'Efficacy and safety of Elbasvir/Grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy', Journal of Hepatology, 68, pp. S264 - S265,
    Journal articles | 2018
    Lafferty L; Rance J; Grebely J; Lloyd AR; Dore GJ; Treloar C, 2018, 'Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison', Journal of Viral Hepatitis, 25, pp. 1526 - 1532,
    Journal articles | 2018
    Lamoury FMJ; Bajis S; Hajarizadeh B; Marshall AD; Martinello M; Ivanova E; Catlett B; Mowat Y; Marks P; Amin J; Smith J; Ezard N; Cock V; Hayllar J; Persing DH; Kleman M; Cunningham P; Dore GJ; Applegate TL; Grebely J, 2018, 'Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay', Journal of Infectious Diseases, 217, pp. 1889 - 1896,
    Journal articles | 2018
    Lamoury FMJ; Hajarizadeh B; Soker A; Martinez D; Quek C; Cunningham P; Catlett B; Cloherty G; Marks P; Amin J; Grebely J; Dore GJ; Applegate TL, 2018, 'Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples', Journal of Molecular Diagnostics, 20, pp. 621 - 627,
    Journal articles | 2018
    Marshall AD; Cunningham EB; Nielsen S; Aghemo A; Alho H; Backmund M; Bruggmann P; Dalgard O; Seguin-Devaux C; Flisiak R; Foster GR; Gheorghe L; Goldberg D; Goulis I; Hickman M; Hoffmann P; Jancorien臈 L; Jarcuska P; K氓berg M; Kostrikis LG; Makara M; Maimets M; Marinho RT; Mati膷i膷 M; Norris S; 脫lafsson S; 脴vrehus A; Pawlotsky JM; Pocock J; Robaeys G; Roncero C; Simonova M; Sperl J; Tait M; Tolmane I; Tomaselli S; van der Valk M; Vince A; Dore GJ; Lazarus JV; Grebely J, 2018, 'Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe', The Lancet Gastroenterology and Hepatology, 3, pp. 125 - 133,
    Journal articles | 2018
    Marshall AD; Pawlotsky JM; Lazarus JV; Aghemo A; Dore GJ; Grebely J, 2018, 'The removal of DAA restrictions in Europe 鈥 One step closer to eliminating HCV as a major public health threat', Journal of Hepatology, 69, pp. 1188 - 1196,
    Journal articles | 2018
    Marshall AD; Treloar C; Dore GJ; Grebely J, 2018, 'A239 QUALITATIVE EVALUATION OF THE DECISIONS AND EXPERIENCES OF PEOPLE WHO INJECT DRUGS WHO RECEIVED A LIVER DISEASE ASSESSMENT AS PART OF A LIVER HEALTH PROMOTION CAMPAIGN: THE LIVERLIFE STUDY', Journal of the Canadian Association of Gastroenterology, 1, pp. 419 - 419,
    Journal articles | 2018
    Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV, 2018, 'Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection', Journal of Viral Hepatitis, 25, pp. 1180 - 1188,
    Journal articles | 2018
    Martinello M; Dore GJ; Matthews GV; Grebely J, 2018, 'Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs', Infectious Disease Clinics of North America, 32, pp. 371 - 393,
    Journal articles | 2018
    Martinello M; Dore GJ; Skurowski J; Bopage RI; Finlayson R; Baker D; Bloch M; Matthews GV, 2018, 'Erratum: Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection (Open Forum Infect Diss (2016)3:2(ofw105) DOI: 10.1093/ofid/ofw105)', Open Forum Infectious Diseases, 5,
    Journal articles | 2018
    Martinello M; Hajarizadeh B; Dore GJ, 2018, 'Observations on the launch of new drugs for hepatitis C', Australian Prescriber, 41, pp. 4 - 5,
    Journal articles | 2018
    Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2018, 'Management of acute HCV infection in the era of direct-acting antiviral therapy', Nature Reviews Gastroenterology and Hepatology, 15, pp. 412 - 424,
    Journal articles | 2018
    Shepherd SJ; McDonald SA; Palmateer NE; Gunson RN; Aitken C; Dore GJ; Goldberg DJ; Applegate TL; Lloyd AR; Hajarizadeh B; Grebely J; Hutchinson SJ, 2018, 'HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype', Journal of Medical Virology, 90, pp. 120 - 130,
    Journal articles | 2018
    Waziry R; Amin J; Law M; Dore GJ, 2018, 'Reply to: 鈥淒irect antiviral agents and risk of HCC: Waiting for Godot鈥', Journal of Hepatology, 68, pp. 616 - 617,
    Journal articles | 2018
    Waziry R; Gomaa A; Waked I; Dore GJ, 2018, 'Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era', Arab Journal of Gastroenterology, 19, pp. 26 - 32,
    Journal articles | 2018
    Zeuzem S; Foster GR; Wang S; Asatryan A; Gane E; Feld JJ; Asselah T; Bourli猫re M; Ruane PJ; Wedemeyer H; Pol S; Flisiak R; Poordad F; Chuang WL; Stedman CA; Flamm S; Kwo P; Dore GJ; Sepulveda-Arzola G; Roberts SK; Soto-Malave R; Kaita K; Puoti M; Vierling J; Tam E; Vargas HE; Bruck R; Fuster F; Paik SW; Felizarta F; Kort J; Fu B; Liu R; Ng TI; Pilot-Matias T; Lin CW; Trinh R; Mensa FJ, 2018, 'Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection', New England Journal of Medicine, 378, pp. 354 - 369,
    Journal articles | 2017
    Alavi M; Amin J; Grebely J; Law MG; Janjua NZ; Krajden M; Hajarizadeh B; George J; Matthews GV; Larney S; Degenhardt L; Dore GJ, 2017, 'O23 Characterisation of populations with hepatitis C to improve access to antiviral therapy programs: a population-based linkage study', Journal of Virus Eradication, 3, pp. 9 - 9,
    Journal articles | 2017
    Bajis S; Dore GJ; Hajarizadeh B; Cunningham EB; Maher L; Grebely J, 2017, 'Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review', International Journal of Drug Policy, 47, pp. 34 - 46,
    Journal articles | 2017
    Bajis S; Lamoury F; Applegate TL; Maher L; Treloar C; Mowat Y; Schulz M; Hajarizadeh B; Marshall A; Cunningham E; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Dore GJ; Grebely J, 2017, 'P4鈥傾cceptability of point of care finger-stick and venepuncture hepatitis C virus testing among people who inject drugs and homeless people', Journal of Virus Eradication, 3, pp. 13 - 14,
    Journal articles | 2017
    Bartlett SR; Applegate T; Jacka B; Lamoury F; Bull R; Danta M; Bradshaw D; Lloyd AR; Hellard M; Dore GJ; Matthews GV; Grebely J, 2017, 'P6鈥働hylogenetic clustering of recent hepatitis C virus infection between 2004 and 2015', Journal of Virus Eradication, 3, pp. 14 - 15,
    Journal articles | 2017
    Bartlett SR; Grebely J; Eltahla AA; Reeves JD; Howe AYM; Miller V; Ceccherini-Silberstein F; Bull RA; Douglas MW; Dore GJ; Harrington P; Lloyd AR; Jacka B; Matthews GV; Wang GP; Pawlotsky JM; Feld JJ; Schinkel J; Garcia F; Lennerstrand J; Applegate TL, 2017, 'Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review', Hepatology Communications, 1, pp. 379 - 390,
    Journal articles | 2017
    Bartlett SR; Wertheim JO; Bull RA; Matthews GV; Lamoury FMJ; Scheffler K; Hellard M; Maher L; Dore GJ; Lloyd AR; Applegate TL; Grebely J, 2017, 'A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies', Journal of Viral Hepatitis, 24, pp. 404 - 411,
    Journal articles | 2017
    Blach S; Zeuzem S; Manns M; Altraif I; Duberg AS; Muljono DH; Waked I; Alavian SM; Lee MH; Negro F; Abaalkhail F; Abdou A; Abdulla M; Abou Rached A; Aho I; Akarca U; Al Ghazzawi I; Al Kaabi S; Al Lawati F; Al Namaani K; Al Serkal Y; Al-Busafi SA; Al-Dabal L; Aleman S; Alghamdi AS; Aljumah AA; Al-Romaihi HE; Andersson MI; Arendt V; Arkkila P; Assiri AM; Baatarkhuu O; Bane A; Ben-Ari Z; Bergin C; Bessone F; Bihl F; Bizri AR; Blachier M; Blasco AJ; Brandao Mello CE; Bruggmann P; Brunton CR; Calinas F; Chan HLY; Chaudhry A; Cheinquer H; Chen CJ; Chien RN; Choi MS; Christensen PB; Chuang WL; Chulanov V; Cisneros L; Clausen MR; Cramp ME; Craxi A; Croes EA; Dalgard O; Daruich JR; De Ledinghen V; Dore GJ; El-Sayed MH; Ergor G; Esmat G; Estes C; Falconer K; Farag E; Ferraz MLG; Ferreira PR; Flisiak R; Frankova S; Gamkrelidze I; Gane E; Garcia-Samaniego J; Khan AG; Gountas I; Goldis A; Gottfredsson M; Grebely J; Gschwantler M; Guimaraes Pessoa M; Gunter J; Hajarizadeh B; Hajelssedig O; Hamid S; Hamoudi W; Hatzakis A; Himatt SM; Hofer H; Hrstic I; Hui YT; Hunyady B; Idilman R; Jafri W; Jahis R; Janjua NZ; Jar膷u拧ka P; Jeruma A; Jonasson JG, 2017, 'Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study', The Lancet Gastroenterology and Hepatology, 2, pp. 161 - 176,
    Journal articles | 2017
    Boettiger DC; Law MG; Dore GJ; Guy R; Callander D; Donovan B; O'Connor CC; Fairley CK; Hellard M; Matthews G; Han A, 2017, 'Hepatitis C testing and re-testing among people attending sexual health services in Australia, and hepatitis C incidence among people with human immunodeficiency virus: Analysis of national sentinel surveillance data', BMC Infectious Diseases, 17, pp. 740,
    Journal articles | 2017
    Chronister KJ; Gilliver R; Kearley J; Lothian R; Dore GJ; Read P, 2017, 'P54鈥僒reatment adherence among people who inject drugs taking directly observed direct acting antiviral therapy at Kirketon Road Centre', Journal of Virus Eradication, 3, pp. 30 - 30,
    Journal articles | 2017
    Cunningham E; Amin J; Bretana NA; Luciani F; Degenhardt L; Larney S; Hajarizadeh B; Dore GJ; Lloyd A; Grebely J, 2017, 'P10鈥僆njecting risk behaviours among people who inject drugs in an Australian prison setting, 2005鈥2014: the HITS-p study', Journal of Virus Eradication, 3, pp. 15 - 16,
    Journal articles | 2017
    Cunningham EB; Hajarizadeh B; Bretana NA; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Dolan K; Lloyd AR; Grebely J; Haber P; Rawlinson W; Treloar C; Maher L, 2017, 'Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study', Journal of Viral Hepatitis, 24, pp. 733 - 741,
    Journal articles | 2017
    Cunningham EB; Hajarizadeh B; Dalgard O; Amin J; Hellard M; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Bruneau J; Midgard H; Bourgeois S; Thurnheer MC; Dore GJ; Grebely J; Shaw I; Siriragavan S; Horschik T; Sharma S; Eevers A; Andreassen J; Melkeraaen I; Widder N; Lesneuck K; Kotsoros B; Hazelwood S; Holland R; Axten D; Von Bibra S; Powis J; Mason K; Ryder S; Jack K; Scheidegger C; Huber C; Ferguson C; Staehelin C; Lacalamita M; Fragomeli V; Sevehon A, 2017, 'Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', BMC Infectious Diseases, 17, pp. 420,
    Journal articles | 2017
    Dore G; Grebely J; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Iser DM; Huang HC; Gendrano IN; Kelly M; Hwang P; Robertson M; Wahl J; Barr E; Platt HL, 2017, 'O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study', Journal of Virus Eradication, 3, pp. 8 - 8,
    Journal articles | 2017
    Dore GJ; Hatzakis A; Negro F; Waked I, 2017, 'Estimating HCV disease burden鈥攙olume 4 (editorial)', Journal of Viral Hepatitis, 24, pp. 4 - 7,
    Journal articles | 2017
    Dore GJ, 2017, 'Commentary on Gountas et al. (2017): Time to focus on empirical evidence for HCV treatment as prevention', Addiction, 112, pp. 1300 - 1301,
    Journal articles | 2017
    Dore GJ, 2017, 'O1 Hepatitis C: the treatment landscape in 2017', Journal of Virus Eradication, 3, pp. 1 - 1,
    Journal articles | 2017
    Eltahla AA; Rodrigo C; Betz-Stablein B; Grebely J; Applegate T; Luciani F; Schinkel J; Dore GJ; Page K; Bruneau J; Morris MD; Cox AL; Kim AY; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Lloyd AR; Bull RA, 2017, 'Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents', Journal of Viral Hepatitis, 24, pp. 37 - 42,
    Journal articles | 2017
    Eslam M; McLeod D; Kelaeng KS; Mangia A; Berg T; Thabet K; Irving WL; Dore GJ; Sheridan D; Gr酶nb忙k H; Abate ML; Hartmann R; Bugianesi E; Spengler U; Rojas A; Booth DR; Weltman M; Mollison L; Cheng W; Riordan S; Mahajan H; Fischer J; Nattermann J; Douglas MW; Liddle C; Powell E; Romero-Gomez M; George J; Metwally M; White R; Gallego-Duran R; Leung R; Mahajan N; Bassendine M; Rahme A; Rosso C; Mezzabotta L; Malik B; Matthews G; Asimakopoulos A; Applegate T; Grebely J; Fragomeli V; Jonsson JR; Santoro R, 2017, 'IFN-位3, not IFN-位4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis', Nature Genetics, 49, pp. 795 - 800,
    Journal articles | 2017
    Fortier E; Alavi M; Bruneau J; Micallef M; Perram J; Sockalingam S; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Grebely J, 2017, 'Depression, Anxiety, and Stress among People with Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia', Journal of Addiction Medicine, 11, pp. 10 - 18,
    Journal articles | 2017
    Ghinea N; Lipworth W; Day R; Hill A; Dore GJ; Danta M, 2017, 'Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries', The Lancet, 389, pp. 1268 - 1272,
    Journal articles | 2017
    Grebely J; Bruneau J; Lazarus JV; Dalgard O; Bruggmann P; Treloar C; Hickman M; Hellard M; Roberts T; Crooks L; Midgard H; Larney S; Degenhardt L; Alho H; Byrne J; Dillon JF; Feld JJ; Foster G; Goldberg D; Lloyd AR; Reimer J; Robaeys G; Torrens M; Wright N; Maremmani I; Norton BL; Litwin AH; Dore GJ, 2017, 'Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs', International Journal of Drug Policy, 47, pp. 51 - 60,
    Journal articles | 2017
    Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2017, 'O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', Journal of Virus Eradication, 3, pp. 5 - 5,
    Journal articles | 2017
    Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ, 2017, 'Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', International Journal of Drug Policy, 47, pp. 177 - 186,
    Journal articles | 2017
    Grebely J; Dore GJ; Morin S; Rockstroh JK; Klein MB, 2017, 'Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there', Journal of the International AIDS Society, 20, pp. 22146,
    Journal articles | 2017
    Grebely J; Dore GJ, 2017, 'Treatment of HCV in persons who inject drugs: Treatment as prevention', Clinical Liver Disease, 9, pp. 77 - 80,
    Journal articles | 2017
    Grebely J; Hajarizadeh B; Dore GJ, 2017, 'Direct-Acting antiviral agents for HCV infection affecting people who inject drugs', Nature Reviews Gastroenterology and Hepatology, 14, pp. 641 - 651,
    Journal articles | 2017
    Grebely J; Jacobson IM; Kayali Z; Verna EC; Shiffman ML; Hyland RH; Stamm LM; Huang KC; Brainard DM; McHutchison JG; Pol S; Chung RT; Bernstein DE; Dore G, 2017, 'SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy', Journal of Hepatology, 66, pp. S513 - S514,
    Journal articles | 2017
    Grebely J; Lamoury FMJ; Hajarizadeh B; Mowat Y; Marshall AD; Bajis S; Marks P; Amin J; Smith J; Edwards M; Gorton C; Ezard N; Persing D; Kleman M; Cunningham P; Catlett B; Dore GJ; Applegate TL, 2017, 'Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study', The Lancet Gastroenterology and Hepatology, 2, pp. 514 - 520,
    Journal articles | 2017
    Haber B; Gane E; Dore GJ; Grebely J; Altice F; Litwin AH; Dalgard O; Shibolet O; Luetkemeyer A; Nahass R; Peng C-Y; Conway B; Iser DM; Huang H-C; Gendrano IN; Kelly M; Hwang P; Robertson M; Wahl J; Barr E; Platt HL, 2017, 'HEPATITIS C VIRUS (HCV) REINFECTION AND INJECTION RISK BEHAVIOR FOLLOWING ELBASVIR/GRAZOPREVIR (EBR/GZR) TREATMENT IN PATIENTS ON OPIOID AGONIST THERAPY (OAT): CO-STAR THREE-YEAR FOLLOW-UP STUDY', GASTROENTEROLOGY, 152, pp. S1058 - S1059,
    Journal articles | 2017
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Lloyd AR; Dore GJ, 2017, 'O6 Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the StoP-C study', Journal of Virus Eradication, 3, pp. 2 - 3,
    Journal articles | 2017
    Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2017, 'P20鈥僊onitoring the uptake of hepatitis C: direct acting antiviral treatment in Australia', Journal of Virus Eradication, 3, pp. 19 - 19,
    Journal articles | 2017
    Hajarizadeh B; Grebely J; McManus H; Estes C; Razavi H; Gray RT; Alavi M; Amin J; McGregor S; Sievert W; Thompson A; Dore GJ, 2017, 'Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment', Journal of Gastroenterology and Hepatology (Australia), 32, pp. 229 - 236,
    Journal articles | 2017
    Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L, 2017, 'Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia', International Journal of Drug Policy, 47, pp. 77 - 85,
    Journal articles | 2017
    Jacobson IM; Lawitz E; Gane EJ; Willems BE; Ruane PJ; Nahass RG; Borgia SM; Shafran SD; Workowski KA; Pearlman B; Hyland RH; Stamm LM; Svarovskaia E; Dvory-Sobol H; Zhu Y; Subramanian GM; Brainard DM; McHutchison JG; Br盲u N; Berg T; Agarwal K; Bhandari BR; Davis M; Feld JJ; Dore GJ; Stedman CAM; Thompson AJ; Asselah T; Roberts SK; Foster GR, 2017, 'Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials', Gastroenterology, 153, pp. 113 - 122,
    Journal articles | 2017
    Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ, 2017, 'Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1鈥6 without cirrhosis', Journal of Hepatology, 67, pp. 263 - 271,
    Journal articles | 2017
    Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M; Conway B; Robaeys G; Swan T; Cloherty G; Marks P; Grebely J; Dore GJ; Applegate TL, 2017, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse', Journal of Clinical Virology, 92, pp. 32 - 38,
    Journal articles | 2017
    Larney S; Hickman M; Guy R; Grebely J; Dore GJ; Gray RT; Day CA; Kimber J; Degenhardt L, 2017, 'Estimating the number of people who inject drugs in Australia', BMC Public Health, 17, pp. 757,
    Journal articles | 2017
    Lubel J; Strasser S; Stuart KA; Dore G; Thompson A; Pianko S; Bollipo S; Mitchell JL; Fragomeli V; Jones T; Chivers S; Gow P; Iser D; Levy M; Tse E; Gazzola A; Cheng W; Nazareth S; Galhenage S; Wade A; Weltman M; Wigg A; MacQuillan G; Sasadeusz J; George J; Zekry A; Roberts SK, 2017, 'Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir 卤 ribavirin for hepatitis C genotype 1 鈥 final results of the REV1TAL study', Antiviral Therapy, 22, pp. 699 - 710,
    Journal articles | 2017
    Marshall AD; Grebely J; Dore GJ; Treloar C, 2017, '鈥業 didn't want to let it go too far.鈥 The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study', International Journal of Drug Policy, 47, pp. 153 - 160,
    Journal articles | 2017
    Martinello M; Dore GJ; Bopage RI; Finlayson R; Baker D; Bloch M; Filep E; Skurowski J; Lin L; Lamoury F; Bartlett S; Applegate T; Hellard M; Matthews GV, 2017, 'O7 Moving towards HCV elimination in HIV/HCV co- infection in Australia following universal access to interferon-free therapy', Journal of Virus Eradication, 3, pp. 3 - 3,
    Journal articles | 2017
    Martinello M; Grebely J; Petoumenos K; Gane E; Hellard M; Shaw D; Sasadeusz J; Applegate TL; Dore GJ; Matthews GV, 2017, 'HCV reinfection incidence among individuals treated for recent infection', Journal of Viral Hepatitis, 24, pp. 359 - 370,
    Journal articles | 2017
    Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2017, 'HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs', Current HIV/AIDS Reports, 14, pp. 110 - 121,
    Journal articles | 2017
    Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J, 2017, 'Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study', International Journal of Drug Policy, 47, pp. 230 - 238,
    Journal articles | 2017
    Morris MD; Shiboski S; Bruneau J; Hahn JA; Hellard M; Prins M; Cox AL; Dore G; Grebely J; Kim AY; Lauer GM; Lloyd A; Rice T; Shoukry N; Maher L; Page K, 2017, 'Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: The InC3 collaboration', Clinical Infectious Diseases, 64, pp. 860 - 869,
    Journal articles | 2017
    Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I, 2017, 'Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting', International Journal of Drug Policy, 47, pp. 209 - 215,
    Journal articles | 2017
    Rodrigo C; Eltahla AA; Bull RA; Luciani F; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Morris MD; Cox AL; Osburn W; Kim AY; Shoukry NH; Lauer GM; Maher L; Schinkel J; Prins M; Hellard M; Lloyd AR, 2017, 'Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study', Journal of Viral Hepatitis, 24, pp. 43 - 52,
    Journal articles | 2017
    Rodrigo C; Walker MR; Leung P; Eltahla AA; Grebely J; Dore GJ; Applegate T; Page K; Dwivedi S; Bruneau J; Morris MD; Cox AL; Osburn W; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Luciani F; Lloyd AR; Bull RA, 2017, 'Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection', Infection, Genetics and Evolution, 49, pp. 88 - 96,
    Journal articles | 2017
    Russell DB; Fox P; Cabatingan H; Jaros A; Gorton C; Lewis R; Priscott E; Bartlett S; Dore GJ, 2017, 'O16 A regional prison cleared of hepatitis C in less than 12 months', Journal of Virus Eradication, 3, pp. 6 - 6,
    Journal articles | 2017
    Samji H; Yu A; Kuo M; Alavi M; Woods R; Alvarez M; Dore GJ; Tyndall M; Krajden M; Janjua NZ, 2017, 'Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development', Journal of Hepatology, 67, pp. 909 - 917,
    Journal articles | 2017
    Sheppard-Law S; Zablotska-Manos I; Kermeen M; Holdaway S; Lee A; Zekry A; Dore GJ; George J; Maher L, 2017, 'Factors associated with HBV virological breakthrough', Antiviral Therapy, 22, pp. 53 - 60,
    Journal articles | 2017
    Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ, 2017, 'Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014)', Hepatology Communications, 1, pp. 736 - 747,
    Journal articles | 2017
    Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ, 2017, 'Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression', Journal of Hepatology, 67, pp. 1204 - 1212,
    Journal articles | 2017
    Zeuzem S; Mizokami M; Pianko S; Mangia A; Han KH; Martin R; Svarovskaia E; Dvory-Sobol H; Doehle B; Hedskog C; Yun C; Brainard DM; Knox S; McHutchison JG; Miller MD; Mo H; Chuang WL; Jacobson I; Dore GJ; Sulkowski M, 2017, 'NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome', Journal of Hepatology, 66, pp. 910 - 918,
    Journal articles | 2016
    Alavi M; Law MG; Grebely J; Amin J; Hajarizadeh B; George J; Dore GJ; Han A, 2016, 'Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study', Journal of Hepatology, 65, pp. 879 - 887,
    Journal articles | 2016
    Asimakopoulos A; Mangia A; Dore GJ; Lloyd AR; George J; Eslam M, 2016, 'Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in europeans', Hepatology, 64, pp. 2264 - 2265,
    Journal articles | 2016
    Bartlett SR; Jacka B; Bull RA; Luciani F; Matthews GV; Lamoury FMJ; Hellard ME; Hajarizadeh B; Teutsch S; White B; Maher L; Dore GJ; Lloyd AR; Grebely J; Applegate TL, 2016, 'HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection', Infection, Genetics and Evolution, 37, pp. 252 - 258,
    Journal articles | 2016
    Bourgeois S; Grebely J; Dore GJ; Aspinall R; Rodriguez-Torres M; Fox R; Sulkowski M; Feld JJ; Carr V; Liu L; Ding X; McNally J; Osinusi A; Brainard DM; Subramanian M, 2016, 'SOF/VEL for 12 weeks is well tolerated and results in high SVR12 rates in people receiving opioid substitution therapy', HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, 18, pp. 16 - 16,
    Journal articles | 2016
    Bradshaw D; Raghwani J; Jacka B; Sacks-Davis R; Lamoury F; Down I; Prestage G; Applegate TL; Hellard M; Sasadeusz J; Dore GJ; Pybus OG; Matthews GV; Danta M, 2016, 'Venue-based networks may underpin HCV transmissions amongst HIV-infected gay and bisexual men', PLoS ONE, 11, pp. e0162002,
    Journal articles | 2016
    Chen Yi Mei SLG; Burchell J; Skinner N; Millen R; Matthews G; Hellard M; Dore GJ; Desmond PV; Sundararajan V; Thompson AJ; Visvanathan K; Sasadeusz J, 2016, 'Toll-like receptor expression and signaling in peripheral blood mononuclear cells correlate with clinical outcomes in acute hepatitis c virus infection', Journal of Infectious Diseases, 214, pp. 739 - 747,
    Journal articles | 2016
    Day CA; Shanahan M; Wand H; Topp L; Haber PS; Rodgers C; Deacon R; Walsh N; Kaldor J; van Beek I; Maher L; Lloyd A; Dore GJ; Walsh N, 2016, 'Development of immunity following financial incentives for hepatitis B vaccination among people who inject drugs: A randomized controlled trial', Journal of Clinical Virology, 74, pp. 66 - 72,
    Journal articles | 2016
    Dore GJ; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Grebely J; Howe AYM; Gendrano IN; Chen E; Huang HC; Dutko FJ; Nickle DC; Nguyen BY; Wahl J; Barr E; Robertson MN; Platt HL, 2016, 'Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy a randomized trial', Annals of Internal Medicine, 165, pp. 625 - 634,
    Journal articles | 2016
    Dore GJ; Conway B; Luo Y; Janczewska E; Knysz B; Liu Y; Streinu-Cercel A; Caruntu FA; Curescu M; Skoien R; Ghesquiere W; Mazur W; Soza A; Fuster F; Greenbloom S; Motoc A; Arama V; Shaw D; Tornai I; Sasadeusz J; Dalgard O; Sullivan D; Liu X; Kapoor M; Campbell A; Podsadecki T, 2016, 'Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials', Journal of Hepatology, 64, pp. 19 - 28,
    Journal articles | 2016
    Dore GJ, 2016, 'Hepatitis C treatment as prevention among HIV-infected men who have sex with men: Feasible?', Hepatology, 64, pp. 1834 - 1836,
    Journal articles | 2016
    Doyle JS; Grebely J; Spelman T; Alavi M; Matthews GV; Thompson AJ; Dore GJ; Hellard ME; Kaldor J; Marks P; Lloyd A; Haber P; French R; White P; Rawlinson W; Day C; Van Beek I; McCaughan G; Madden A; Dolan K; Farrell G; Crofts N; Sievert W; Baker D, 2016, 'Quality of life and social functioning during treatment of recent hepatitis C infection: A multi-centre prospective cohort', PLoS ONE, 11, pp. e0150655,
    Journal articles | 2016
    Eslam M; Hashem AM; Romero-Gomez M; Berg T; Dore GJ; Mangia A; Chan HLY; Irving WL; Sheridan D; Abate ML; Adams LA; Weltman M; Bugianesi E; Spengler U; Shaker O; Fischer J; Mollison L; Cheng W; Nattermann J; Riordan S; Miele L; Kelaeng KS; Ampuero J; Ahlenstiel G; McLeod D; Powell E; Liddle C; Douglas MW; Booth DR; George J, 2016, 'FibroGENE: A gene-based model for staging liver fibrosis', Journal of Hepatology, 64, pp. 390 - 398,
    Journal articles | 2016
    Eslam M; Mangia A; Berg T; Chan HLY; Irving WL; Dore GJ; Abate ML; Bugianesi E; Adams LA; Najim MAM; Miele L; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Romero-Gomez M; Spengler U; Nattermann J; Rahme A; Sheridan D; Booth DR; McLeod D; Powell E; Liddle C; Douglas MW; van der Poorten D; George J; White R; Rojas A; Gallego-Duran R; Bassendine M; Wong VWS; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Applegate T; Grebely J; Fragomeli V; Jonsson JR; Santaro R, 2016, 'Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes', Hepatology, 64, pp. 34 - 46,
    Journal articles | 2016
    Gastroenterology CAO; For The Study Of The Liver CA, 2016, 'Program and Abstracts from the Canadian Digestive Diseases Week鈩 2016.', Can J Gastroenterol Hepatol, 2016, pp. 4792898,
    Journal articles | 2016
    Grebely J; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Phung N; Weltman MD; Day CA; Treloar C; Bath N; Haber PS; Dore GJ, 2016, 'Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: The ETHOS Study', Addiction, 111, pp. 311 - 319,
    Journal articles | 2016
    Grebely J; Dore GJ; Aspinall R; Rodriguez-Torres M; Fox R; Liu L; Ding X; McNally J; Osinusi A; Brainard D; Subramanian M; Sulkowski M; Feld J, 2016, 'SOF/VEL for 12 Weeks Is Well Tolerated and Results in High SVR12 Rates in People Receiving Opioid Substitution Therapy', Journal of Hepatology, 64, pp. S776 - S776,
    Journal articles | 2016
    Grebely J; Dore GJ; Greenwald R; Swan T; Barua S; Taylor LE, 2016, 'Hepatitis c virus treatment and persons who inject drugs', Annals of Internal Medicine, 164, pp. 203,
    Journal articles | 2016
    Grebely J; Dore GJ; Zeuzem S; Aspinall RJ; Fox R; Han L; McNally J; Osinusi A; Brainard DM; Subramanian GM; Natha M; Foster GR; Mangia A; Sulkowski M; Feld JJ, 2016, 'Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials', Clinical Infectious Diseases, 63, pp. 1479 - 1481,
    Journal articles | 2016
    Grebely J; Flamm S; Zeuzem S; Hyland R; Chang P; Ding X; Yun C; Brainard D; McHutchison J; Forns X; Mangia A; Dore G, 2016, 'On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome during Therapy with Ledipasvir-Sofosbuvi with or without Ribavirin in the Phase 3 ION-1 Study', Journal of Hepatology, 64, pp. S776 - S777,
    Journal articles | 2016
    Grebely J; Litwin A; Dore GJ, 2016, 'Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all', Journal of Viral Hepatitis, 23, pp. 664 - 666,
    Journal articles | 2016
    Grebely J; Mauss S; Brown A; Bronowicki JP; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ, 2016, 'Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials', Clinical Infectious Diseases, 63, pp. 1405 - 1411,
    Journal articles | 2016
    Hajarizadeh B; Grebely J; Martinello M; Matthews GV; Lloyd AR; Dore GJ, 2016, 'Hepatitis C treatment as prevention: evidence, feasibility, and challenges', The Lancet Gastroenterology and Hepatology, 1, pp. 317 - 327,
    Journal articles | 2016
    Hajarizadeh B; Lamoury FMJ; Feld JJ; Amin J; Keoshkerian E; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Grebely J; Applegate TL, 2016, 'Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection', Virology Journal, 13, pp. 32,
    Journal articles | 2016
    Hezode C; Dore G; Pianko S; Pol S; Stuart K; Thompson A; Tse E; Bhore R; Jimenez-Exposito MJ, 2016, 'Daclatasvir plus Sofosbuvir plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients with HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis', Journal of Hepatology, 64, pp. S753 - S754,
    Journal articles | 2016
    Hezode C; Dore GJ; Pianko S; Pol S; Stuart K; Thompson A; Tse E; Bhore R; Jimenez-Exposito MJ, 2016, 'Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients With HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis', GASTROENTEROLOGY, 150, pp. S1096 - S1096,
    Journal articles | 2016
    Jacka B; Applegate T; Poon AF; Raghwani J; Harrigan PR; Debeck K; Milloy MJ; Krajden M; Olmstead A; Joy JB; Marshall BDL; Hayashi K; Pybus OG; Lima VD; Magiorkinis G; Montaner J; Lamoury F; Dore GJ; Wood E; Grebely J, 2016, 'Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada', Journal of Hepatology, 64, pp. 1247 - 1255,
    Journal articles | 2016
    Jacobson IM; Dore GJ; Foster GR, 2016, 'Erratum: Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial (Lancet (2014) 384 (403-13))', The Lancet, 387, pp. 1816,
    Journal articles | 2016
    Jacobson IM; Dore GJ; Foster GR, 2016, 'Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial (vol 384, pg 403, 2014)', LANCET, 387, pp. 1816 - 1816,
    Journal articles | 2016
    Keoshkerian E; Hunter M; Cameron B; Nguyen N; Sugden P; Bull R; Zekry A; Maher L; Seddiki N; Zaunders J; Kelleher A; Lloyd AR; Dolan K; Haber P; Rawlinson W; Treloar C; Dore G; Luciani F, 2016, 'Hepatitis C-specific effector and regulatory CD4 T-cell responses are associated with the outcomes of primary infection', Journal of Viral Hepatitis, 23, pp. 985 - 993,
    Journal articles | 2016
    Lamoury FMJ; Hajarizadeh B; Keoshkerian E; Feld JJ; Amin J; Teutsch S; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Applegate TL; Grebely J; Dolan K, 2016, 'HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection', BMC Infectious Diseases, 16, pp. 241,
    Journal articles | 2016
    Leroy V; Angus P; Bronowicki JP; Dore GJ; Hezode C; Pianko S; Pol S; Stuart K; Tse E; Mcphee F; Bhore R; Jimenez-Exposito MJ; Thompson AJ, 2016, 'Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)', Hepatology, 63, pp. 1430 - 1441,
    Journal articles | 2016
    MacParland SA; Fadel SM; Mihajlovic V; Fawaz A; Kim C; Nur-Ur Rahman AKM; Liu J; Kaul R; Kovacs C; Grebely J; Dore GJ; Wong DK; Ostrowski MA, 2016, 'HCV specific IL-21 producing T cells but not IL-17A producing T cells are associated with HCV viral control in HIV/HCV coinfection', PLoS ONE, 11, pp. e0154433,
    Journal articles | 2016
    Martin NK; Vickerman P; Dore GJ; Grebely J; Miners A; Cairns J; Foster GR; Hutchinson SJ; Goldberg DJ; Martin TCS; Ramsay M; Hickman M, 2016, 'Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation', Journal of Hepatology, 65, pp. 17 - 25,
    Journal articles | 2016
    Martinello M; Amin J; Matthews GV; Dore GJ, 2016, 'Prevalence and disease burden of HCV coinfection in HIV cohorts in the Asia pacific region: A systematic review and meta-analysis', AIDS Reviews, 18, pp. 69 - 80
    Journal articles | 2016
    Martinello M; Dore GJ; Skurowski J; Bopage RI; Finlayson R; Baker D; Bloch M; Matthews GV, 2016, 'Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection', Open Forum Infectious Diseases, 3, pp. ofw105,
    Journal articles | 2016
    Martinello M; Dore GJ, 2016, 'Editorial commentary: Interferon-free Hepatitis C treatment efficacy from clinical trials will translate to "Real World" outcomes', Clinical Infectious Diseases, 62, pp. 927 - 928,
    Journal articles | 2016
    Martinello M; Gane E; Hellard M; Sasadeusz J; Shaw D; Petoumenos K; Applegate T; Grebely J; Maire L; Marks P; Dore GJ; Matthews GV; Cooper D, 2016, 'Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study', Hepatology, 64, pp. 1911 - 1921,
    Journal articles | 2016
    Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies', ANTIVIRAL THERAPY, 21, pp. 425 - 434,
    Journal articles | 2016
    Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2016, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies', Antiviral therapy, 21, pp. 465,
    Journal articles | 2016
    Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2016, 'The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', ANTIVIRAL THERAPY, 21, pp. 127 - 132,
    Journal articles | 2016
    Moussalli J; Dore G; Platt H, 2016, 'COL 4-04 - C-EDGE CO-STAR : efficacit茅 de l鈥檈lbasvir et du grazopr茅vir chez les utilisateurs de drogues injectables (UDI) recevant un traitement par agoniste des r茅cepteurs opio茂des', M茅decine et Maladies Infectieuses, 46, pp. 9 - 9,
    Journal articles | 2016
    Ogrunc M; Martinez-Zamudio RI; Sadoun PB; Dore G; Schwerer H; Pasero P; Lemaitre JM; Dejean A; Bischof O, 2016, 'USP1 Regulates Cellular Senescence by Controlling Genomic Integrity', Cell Reports, 15, pp. 1401 - 1411,
    Journal articles | 2016
    Page K; Mirzazadeh A; Rice TM; Grebely J; Kim AY; Cox AL; Morris MD; Hellard M; Bruneau J; Shoukry NH; Dore GJ; Maher L; Lloyd AR; Lauer G; Prins M; McGovern BH, 2016, 'Interferon lambda 4 genotype is associated with jaundice and elevated aminotransferase levels during acute hepatitis C virus infection: Findings from the InC3 collaborative', Open Forum Infectious Diseases, 3, pp. ofw024,
    Journal articles | 2016
    Rodrigo C; Eltahla AA; Bull RA; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Morris MD; Cox AL; Osburn W; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Estes C; Razavi H; Lloyd AR; Luciani F, 2016, 'Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia', Journal of Infectious Diseases, 214, pp. 1383 - 1389,
    Journal articles | 2016
    Sheridan DA; Hajarizadeh B; Fenwick FI; Matthews GV; Applegate T; Douglas M; Neely D; Askew B; Dore GJ; Lloyd AR; George J; Bassendine MF; Grebely J, 2016, 'Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection', Liver International, 36, pp. 1774 - 1782,
    Journal articles | 2016
    Thabet K; Asimakopoulos A; Shojaei M; Romero-Gomez M; Mangia A; Irving WL; Berg T; Dore GJ; Gr酶nb忙k H; Sheridan D; Abate ML; Bugianesi E; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Spengler U; Nattermann J; Wahid A; Rojas A; White R; Douglas MW; McLeod D; Powell E; Liddle C; Van Der Poorten D; George J; Eslam M; Gallego-Duran R; Applegate T; Bassendine M; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Grebely J; Fragomeli V; Jonsson JR; Santaro R, 2016, 'MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C', Nature Communications, 7, pp. 12757,
    Journal articles | 2016
    Tsui JI; Mirzazadeh A; Hahn JA; Maher L; Bruneau J; Grebely J; Hellard M; Kim AY; Shoukry NH; Cox AL; Prins M; Dore GJ; Lauer G; Lloyd AR; Page K, 2016, 'The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males', Drug and Alcohol Dependence, 169, pp. 156 - 162,
    Journal articles | 2016
    Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ; Han A, 2016, 'Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000鈥2014)', Journal of Hepatology, 65, pp. 1086 - 1093,
    Journal articles | 2015
    Aghemo A; Dore GJ; Hatzakis A; Wedemeyer H; Razavi H, 2015, 'Estimating HCV disease burden - Volume 3 (editorial)', Journal of Viral Hepatitis, 22, pp. 1 - 3,
    Journal articles | 2015
    Alavi M; Micallef M; Fortier E; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Grebely J, 2015, 'Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: The ETHOS study', Journal of Viral Hepatitis, 22, pp. 914 - 925,
    Journal articles | 2015
    Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J; Marks P; Amin J; Doab A; Carroll T; Teutsch S; Li H; Oon A; Cameron B; Lloyd A; White P; Rawlinson W; Jacqueline Flynn ; Goy K; Nguyen O; von Bibra S; Ffrench R; McCaughan G; Madden A; Farrell G; Crofts N; Sievert W; Baker D; Jacka B; Pan Y; Shaw D; Sasadeusz J; Crawford D; Phung N; George J; Bloch M; Hughes B; Mollison L; Roberts S; Desmond P; Acraman B, 2015, 'Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C', International Journal of Drug Policy, 26, pp. 976 - 983,
    Journal articles | 2015
    Applegate TL; Gaudieri S; Plauzolles A; Chopra A; Grebely J; Lucas M; Hellard M; Luciani F; Dore GJ; Matthews GV, 2015, 'Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C', Antiviral Therapy, 20, pp. 199 - 208,
    Journal articles | 2015
    Aspinall EJ; Hutchinson SJ; Janjua NZ; Grebely J; Yu A; Alavi M; Amin J; Goldberg DJ; Innes H; Law M; Walter SR; Krajden M; Dore GJ; Han A, 2015, 'Trends in mortality after diagnosis of hepatitis C virus infection: An international comparison and implications for monitoring the population impact of treatment', Journal of Hepatology, 62, pp. 269 - 277,
    Journal articles | 2015
    Barua S; Greenwald R; Grebely J; Dore GJ; Swan T; Taylor LE, 2015, 'Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States', Annals of Internal Medicine, 163, pp. 215 - 223,
    Journal articles | 2015
    Bradshaw D; Lamoury F; Catlett B; Applegate TL; McAllister J; Dore GJ; Matthews GV; Danta M, 2015, 'A comparison of seminal hepatitis C virus (HCV) RNA levels during recent and chronic HCV infection in HIV-infected and HIV-uninfected individuals', Journal of Infectious Diseases, 211, pp. 736 - 743,
    Journal articles | 2015
    Breta帽a N; Boelen L; Bull R; Teutsch S; White P; Lloyd A; Luciani F; Bretana N; Dolan K; Rawlinson W; Dore G; Maher L, 2015, 'Transmission of Hepatitis C Virus among Prisoners, Australia, 2005鈥2012.', Emerging Infectious Diseases, 21, pp. 765 - 774,
    Journal articles | 2015
    Bull RA; Leung P; Gaudieri S; Deshpande P; Cameron B; Walker M; Chopra A; Lloyd AR; Luciani F; Dolan K; Haber P; Rawlinson W; Treloar C; Dore G; Maher L, 2015, 'Transmitted/founder viruses rapidly escape from CD8+ T cell responses in acute hepatitis C virus infection', Journal of Virology, 89, pp. 5478 - 5490,
    Journal articles | 2015
    Cunningham EB; Applegate TL; Lloyd AR; Dore GJ; Grebely J, 2015, 'Mixed HCV infection and reinfection in people who inject drugs-impact on therapy', Nature Reviews Gastroenterology and Hepatology, 12, pp. 218 - 230,
    Journal articles | 2015
    Dore GJ; Feld JJ, 2015, 'Hepatitis C virus therapeutic development: In pursuit of "perfectovir', Clinical Infectious Diseases, 60, pp. 1829 - 1836,
    Journal articles | 2015
    Dore GJ; Knysz B; Luo Y; Janczewska E; Streinu-Cercel A; Caruntu FA; Motoc A; Mazur W; Shaw DR; Tornai I; Sasadeusz J; Skoien R; Sullivan D; Liu X; Podsadecki T, 2015, 'Tu1015 MALACHITE-II: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir + Ribavirin or Telaprevir + Peginterferon/Ribavirin in Peginterferon/Ribavirin Treatment-Experienced Adults With HCV Genotype 1', Gastroenterology, 148,
    Journal articles | 2015
    Dore GJ; Lawitz E; H茅zode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; De L茅dinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA, 2015, 'Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection', Gastroenterology, 148, pp. 355 - 366.e1,
    Journal articles | 2015
    Doyle JS; Deterding K; Grebely J; Wedemeyer H; Sacks-Davis R; Spelman T; Matthews G; Rice TM; Morris MD; McGovern BH; Kim AY; Bruneau J; Lloyd AR; Page K; Manns MP; Hellard ME; Dore GJ; Maher L, 2015, 'Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort', Journal of Viral Hepatitis, 22, pp. 1020 - 1032,
    Journal articles | 2015
    Eslam M; Hashem AM; Leung R; Romero-Gomez M; Berg T; Dore GJ; Chan HLK; Irving WL; Sheridan D; Abate ML; Adams LA; Mangia A; Weltman M; Bugianesi E; Spengler U; Shaker O; Fischer J; Mollison L; Cheng W; Powell E; Nattermann J; Riordan S; McLeod D; Armstrong NJ; Douglas MW; Liddle C; Booth DR; George J; Ahlenstiel G; Ampuero J; Bassendine M; Wong VWS; Rosso C; White R; Mezzabotta L; Suppiah V; Michalk M; Malik B; Matthews G; Applegate T; Grebely J; Fragomeli V; Jonsson JR; Santaro R, 2015, 'Interferon-位 rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease', Nature Communications, 6, pp. 6422,
    Journal articles | 2015
    Eslam M; Hashem AM; Romero-Gomez M; Berg T; Dore GJ; Mangia A; Chan HLY; Irving WL; Sheridan D; Abate ML; Adams LA; Weltman M; Bugianesi E; Spengler U; Shaker O; Fischer J; Mollison L; Cheng W; Nattermann J; Riordan S; Miele L; Kelaeng KS; Ampuero J; Ahlenstiel G; McLeod D; Powell E; Liddle C; Douglas MW; Booth DR; George J, 2015, 'FibroGENE: A gene-based model for staging liver fibrosis', Journal of Hepatology, 64, pp. 390 - 398,
    Journal articles | 2015
    Fortier E; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Bruneau J; Grebely J, 2015, 'The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study', International Journal of Drug Policy, 26, pp. 1094 - 1102,
    Journal articles | 2015
    Grebely J; Bruggmann P; Treloar C; Byrne J; Rhodes T; Dore GJ, 2015, 'Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs', International Journal of Drug Policy, 26, pp. 893 - 898,
    Journal articles | 2015
    Grebely J; Bruggmann P; Treloar C; Byrne J; Rhodes T; Dore GJ, 2015, 'Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs', International Journal of Drug Policy, 26, pp. 893 - 898,
    Journal articles | 2015
    Grebely J; Bruggmann P; Treloar C; Byrne J; Rhodes T; Dore GJ, 2015, 'Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs', International Journal of Drug Policy, 26, pp. 1039 - 1040,
    Journal articles | 2015
    Grebely J; Haire B; Taylor LE; Macneill P; Litwin AH; Swan T; Byrne J; Levin J; Bruggmann P; Dore GJ, 2015, 'Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data?', Journal of Hepatology, 63, pp. 779 - 782,
    Journal articles | 2015
    Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2015, 'Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden', International Journal of Drug Policy, 111, pp. 101670,
    Journal articles | 2015
    Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2015, 'Recommendations for the management of hepatitis C virus infection among people who inject drugs', International Journal of Drug Policy, 26, pp. 1028 - 1038,
    Journal articles | 2015
    Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Dore GJ; Grebely J, 2015, 'Patterns of hepatitis C Virus RNA levels during acute infection: The InC3 study', PLoS ONE, 10, pp. e0122232,
    Journal articles | 2015
    Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J; InC , 2015, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study', Journal of Viral Hepatitis, 22, pp. 708 - 717,
    Journal articles | 2015
    Jacobson IM; Dore GJ; Wyles D; Lawitz E; Talal A; Ball G; Dumas EO; Feld JJ, 2015, 'Tu1024 Plasma Interferon-纬-Inducible Protein 10 (Ip-10) and Response to Interferon-Free Direct-Acting Antiviral Therapy in HCV Genotype 1-Infected Patients With and Without Cirrhosis', Gastroenterology, 148,
    Journal articles | 2015
    Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A; Haber P; Carolyn D; Gregory D; Tawil V; Krahn M; Loveday S; Thein HH, 2015, 'Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia', International Journal of Drug Policy, 26, pp. 999 - 1006,
    Journal articles | 2015
    Lamoury FMJ; Bartlett S; Jacka B; Hajarizadeh B; Grebely J; Matthews GV; Dore GJ; Applegate TL, 2015, 'Interferon 位 3 and 4 genotyping using high-resolution melt curve analysis suitable for multiple clinical sample types', Journal of Molecular Diagnostics, 17, pp. 583 - 589,
    Journal articles | 2015
    Lamoury FMJ; Jacka B; Bartlett S; Bull RA; Wong A; Amin J; Schinkel J; Poon AF; Matthews GV; Grebely J; Dore GJ; Applegate TL, 2015, 'The influence of hepatitis C virus genetic region on phylogenetic clustering analysis', PLoS ONE, 10, pp. e0131437,
    Journal articles | 2015
    Larney S; Grebely J; Hickman M; De Angelis D; Dore GJ; Degenhardt L, 2015, 'Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs', International Journal of Drug Policy, 26, pp. 950 - 957,
    Journal articles | 2015
    Lundgren J; Babiker A; Gordin F; Emery S; F盲tkenheuer G; Molina JM; Wood R; Neaton JD; Agan BK; Alston-Smith B; Arenas-Pinto A; Arribas JR; Baker JV; Baxter J; Belloso WH; Brekke K; Brew B; Brobst SW; Burman W; Carey C; Clark R; Cooper DA; Davey RT; De La Rosa G; Denning ET; Dolan M; Dore G; Duprez D; Emanuel E; Grady C; Grund B; Hirschel B; Hoen B; Hudson F; Johnson MA; Kambili C; Klingman K; Kunisaki KM; Landay A; Ledergerber B; Lehrman SN; Martinez A; Meger S; Misar K; Mitsuyasu RT; Mocroft A; Munroe D; Norton M; Palmer RC; Pett SL; Phillips A; Pillay D; Porter D; Price RW; Proschan M; Rappoport C; Reiss P; Renjifo B; Robertson K; Rockstroh J; Rodriguez G; Rooney JF; Ross MJ; Schechter M; Schwarze S; Seekins D; Sharma S; Snowden W; Telenti A; Tryon J; van Wyk J; Vjecha MJ; Wright E; Cooper D, 2015, 'Why START? Reflections that led to the conduct of this large long-term strategic HIV trial', HIV Medicine, 16, pp. 1 - 9,
    Journal articles | 2015
    Maher L; White B; Dore G; Lloyd A; Rawlinson W, 2015, 'Opioid substitution treatment protects against hepatitis C virus acquisition in people who inject drugs: The HITS-c study', Drug and Alcohol Dependence, 146, pp. e191 - e191,
    Journal articles | 2015
    Marshall AD; Micallef M; Erratt A; Telenta J; Treloar C; Everingham H; Jones SC; Bath N; How-Chow D; Byrne J; Harvey P; Dunlop A; Jauncey M; Read P; Collie T; Dore GJ; Grebely J, 2015, 'Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study', International Journal of Drug Policy, 26, pp. 984 - 991,
    Journal articles | 2015
    Martin NK; Vickerman P; Dore GJ; Hickman M, 2015, 'The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): The use of direct-acting antivirals as treatment for prevention', Current Opinion in HIV and AIDS, 10, pp. 374 - 380,
    Journal articles | 2015
    Muir AJ; Poordad F; Lalezari J; Everson G; Dore GJ; Herring R; Sheikh A; Kwo P; H茅zode C; Pockros PJ; Tran A; Yozviak J; Reau N; Ramji A; Stuart K; Thompson AJ; Vierling J; Freilich B; Cooper J; Ghesquiere W; Yang R; McPhee F; Hughes EA; Swenson ES; Yin PD, 2015, 'Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis', JAMA - Journal of the American Medical Association, 313, pp. 1736 - 1744,
    Journal articles | 2015
    Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CAM; Rajender Reddy K; Roberts SK, 2015, 'Sofosbuvir plus velpatasvir combination therapy for treatment- Experienced patients with genotype 1 or 3 hepatitis c virus infection', Annals of Internal Medicine, 163, pp. 809 - 817,
    Journal articles | 2015
    Sacks-Davis R; Grebely J; Dore GJ; Osburn W; Cox AL; Rice TM; Spelman T; Bruneau J; Prins M; Kim AY; Mcgovern BH; Shoukry NH; Schinkel J; Allen TM; Morris M; Hajarizadeh B; Maher L; Lloyd AR; Page K; Hellard M; Matthews G, 2015, 'Hepatitis c virus reinfection and spontaneous clearance of reinfection - The InC3 study', Journal of Infectious Diseases, 212, pp. 1407 - 1419,
    Journal articles | 2015
    Sievert W; Razavi H; Thompson A; Zekry A; Dore GJ; Roberts SK, 2015, 'HCV鈥恑nfected patients need access now to new direct鈥恆cting antiviral agents to avert liver鈥恟elated deaths', The Medical Journal of Australia, 202, pp. 479 - 479,
    Journal articles | 2015
    Spelman T; Morris MD; Zang G; Rice T; Page K; Maher L; Lloyd A; Grebely J; Dore GJ; Kim AY; Shoukry NH; Hellard M; Bruneau J; Cox AL; Lauer G; McGovern BH; Prins M; Hahn J; Shiboski S; Mirzazadeh A; Alavi M; Bouchard R; Evans J; Grady B; Aneja J; Sacks-Davis R; Teutsch S; White B; Wells B; Applegate T; Matthews G; Yeung B; Schinkel J; Prince LE; Roy E; Bates A; Enriquez J; Chow S; McCredie L; Aitken C; Doyle J, 2015, 'A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs', Journal of Epidemiology and Community Health, 69, pp. 745 - 752,
    Journal articles | 2015
    Treloar C; Rance J; Bath N; Everingham H; Micallef M; Day C; Hazelwood S; Grebely J; Dore GJ, 2015, 'Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia', International Journal of Drug Policy, 26, pp. 992 - 998,
    Journal articles | 2015
    Wedemeyer H; Dore GJ; Ward JW, 2015, 'Estimates on HCV disease burden worldwide - Filling the gaps', Journal of Viral Hepatitis, 22, pp. 1 - 5,
    Journal articles | 2014
    Alavi M; Law MG; Grebely J; Thein HH; Walter S; Amin J; Dore GJ; Han A, 2014, 'Lower life expectancy among people with an HCV notification: A population-based linkage study', Journal of Viral Hepatitis, 21, pp. e10 - e18,
    Journal articles | 2014
    Alavi M; Raffa JD; Deans GD; Lai C; Krajden M; Dore GJ; Tyndall MW; Grebely J, 2014, 'Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents', Liver International, 34, pp. 1198 - 1206,
    Journal articles | 2014
    Baker D; Alavi M; Erratt A; Hill S; Balcomb A; Hallinan R; Siriragavan S; Richmond D; Smart J; Keats J; Doong N; Marks P; Grebely J; Dore GJ, 2014, 'Delivery of treatment for hepatitis C virus infection in the primary care setting', European Journal of Gastroenterology and Hepatology, 26, pp. 1003 - 1009,
    Journal articles | 2014
    Baker D; Alavi M; Erratt A; Hill S; Balcomb A; Hallinan R; Siriragavan S; Richmond D; Smart J; Keats J; Doong N; Marks P; Grebely J; Dore GJ, 2014, 'Delivery of treatment for hepatitis C virus infection in the primary care setting', Journal of Nursing Administration, 44, pp. 1003 - 1009,
    Journal articles | 2014
    Boelen L; Teutsch S; Wilson DP; Dolan K; Dore GJ; Lloyd AR; Luciani F; Maher L, 2014, 'Per-event probability of hepatitis C infection during sharing of injecting equipment', PLoS ONE, 9, pp. e100749,
    Journal articles | 2014
    Bradshaw D; Applegate T; Dore G; Hellard M; Sasadeusz J; Matthews G; Danta M, 2014, 'The majority of acute HCV infection in HIV-positive men who have sex with men (HIV plus MSM) is transmitted permucosally in the context of HIV serosorting in Australia', HIV MEDICINE, 15, pp. 137 - 137
    Journal articles | 2014
    Bradshaw D; Lamoury F; Catlett B; Mcallister J; Applegate T; Dore G; Matthews G; Danta M, 2014, 'Seminal HCV RNA level may mirror dynamics of plasma HCV RNA in HIV-infected men with acute HCV', HIV MEDICINE, 15, pp. 8 - 8
    Journal articles | 2014
    Bruggmann P; Berg T; 脴vrehus ALH; Moreno C; Brand茫o Mello CE; Roudot-Thoraval F; Marinho RT; Sherman M; Ryder SD; Sperl J; Akarca U; Bal谋k I; Bihl F; Bilodeau M; Blasco AJ; Buti M; Calinas F; Calleja JL; Cheinquer H; Christensen PB; Clausen M; Coelho HSM; Cornberg M; Cramp ME; Dore GJ; Doss W; Duberg AS; El-Sayed MH; Erg枚r G; Esmat G; Estes C; Falconer K; F茅lix J; Ferraz MLG; Ferreira PR; Frankova S; Garc铆a-Samaniego J; Gerstoft J; Giria JA; Gon莽ales FL; Gower E; Gschwantler M; Guimar茫es Pess么a M; H茅zode C; Hofer H; Husa P; Idilman R; K氓berg M; Kaita KDE; Kautz A; Kaymakoglu S; Krajden M; Krarup H; Laleman W; Lavanchy D; L谩zaro P; Marotta P; Mauss S; Mendes Correa MC; M眉llhaupt B; Myers RP; Negro F; Nemecek V; 脰rmeci N; Parkes J; Peltekian KM; Ramji A; Razavi H; Reis N; Roberts SK; Rosenberg WM; Sarmento-Castro R; Sarrazin C; Semela D; Shiha GE; Sievert W; St盲rkel P; Stauber RE; Thompson AJ; Urbanek P; van Thiel I; Van Vlierberghe H; Vandijck D; Vogel W; Waked I; Wedemeyer H; Weis N; Wiegand J; Yosry A; Zekry A; Van Damme P; Aleman S; Hindman SJ, 2014, 'Historical epidemiology of hepatitis C virus (HCV) in selected countries', Journal of viral hepatitis, 21, pp. 5 - 33,
    Journal articles | 2014
    Crane M; Avihingsanon A; Rajasuriar R; Velayudham P; Iser D; Solomon A; Sebolao B; Tran A; Spelman T; Matthews G; Cameron P; Tangkijvanich P; Dore GJ; Ruxrungtham K; Lewin SR, 2014, 'Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy', Journal of Infectious Diseases, 210, pp. 745 - 751,
    Journal articles | 2014
    Dore GJ; Ward J; Thursz M, 2014, 'Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward)', Journal of viral hepatitis, 21, pp. 1 - 4,
    Journal articles | 2014
    Grebely J; Dore GJ; Kim AY; Lloyd A; Shoukry NH; Prins M; Page K, 2014, 'Genetics of spontaneous clearance of hepatitis C virus infection: A complex topic with much to learn', Hepatology, 60, pp. 2127 - 2128,
    Journal articles | 2014
    Grebely J; Dore GJ, 2014, 'Can hepatitis C virus infection be eradicated in people who inject drugs?', Antiviral Research, 104, pp. 62 - 72,
    Journal articles | 2014
    Grebely J; Grady B; Hajarizadeh B; Page K; Dore GJ, 2014, 'Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels?', Hepatology, 59, pp. 1650 - 1651,
    Journal articles | 2014
    Grebely J; Lima VD; Marshall BDL; Milloy MJ; DeBeck K; Montaner J; Simo A; Krajden M; Dore GJ; Kerr T; Wood E, 2014, 'Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012', PLoS ONE, 9, pp. e97726,
    Journal articles | 2014
    Grebely J; Page K; Sacks-Davis R; van der Loeff MS; Rice TM; Bruneau J; Morris MD; Hajarizadeh B; Amin J; Cox AL; Kim AY; Mcgovern BH; Schinkel J; George J; Shoukry NH; Lauer GM; Maher L; Lloyd AR; Hellard M; Dore GJ; Prins M, 2014, 'The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection', Hepatology, 59, pp. 109 - 120,
    Journal articles | 2014
    Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J; Lauer G; Shoukry NH; Hahn J; Shiboski S; Rice TM; Alavi M; Bouchard R; Aneja J; Teutsch S; White B; Wells B; Zang G; Matthews G; Marks P; Yeung B; Prince LE; Roy E; Bates A; Enriquez J; Chow S; McCredie L; Aitken C; Doyle J; Spelman T; Evans J, 2014, 'Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study', Journal of Clinical Virology, 61, pp. 430 - 434,
    Journal articles | 2014
    Hajarizadeh B; Grebely J; Applegate T; Matthews GV; Amin J; Petoumenos K; Hellard M; Rawlinson W; Lloyd A; Kaldor J; Dore GJ; Dolan K, 2014, 'Dynamics of HCV RNA Levels During Acute Hepatitis C Virus Infection', Journal of Medical Virology, 86, pp. 1722 - 1729,
    Journal articles | 2014
    Harrod ME; Couzos S; Delaney-Thiele D; Dore GJ; Hammond B; Saunders M; Belfrage M; Williams S; Kaldor JM; Ward J, 2014, 'Markers of hepatitis B infection and immunity in patients attending Aboriginal community controlled health services', Medical Journal of Australia, 201, pp. 339 - 342,
    Journal articles | 2014
    Holmes JA; Roberts SK; Ali RJ; Dore GJ; Sievert W; Mccaughan GW; Crawford DH; Cheng WS; Weltman MD; Bonanzinga S; Visvanathan K; Sundararajan V; Desmond PV; Bowden DS; Matthews GV; Thompson AJ, 2014, 'ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response', Hepatology, 59, pp. 2152 - 2160,
    Journal articles | 2014
    Iversen J; Grebely J; Topp L; Wand H; Dore G; Maher L, 2014, 'Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011', Journal of Viral Hepatitis, 21, pp. 198 - 207,
    Journal articles | 2014
    Jacka B; Applegate T; Krajden M; Olmstead A; Harrigan PR; Marshall BDL; Debeck K; Milloy MJ; Lamoury F; Pybus OG; Lima VD; Magiorkinis G; Montoya V; Montaner J; Joy J; Woods C; Dobrer S; Dore GJ; Poon AFY; Grebely J, 2014, 'Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada', Hepatology, 60, pp. 1571 - 1580,
    Journal articles | 2014
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M, 2014, 'Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial', The Lancet, 384, pp. 403 - 413,
    Journal articles | 2014
    Kitson MT; George J; Dore GJ; Leung R; Button P; Mccaughan GW; Crawford DHG; Sievert W; Weltman MD; Cheng WSC; Roberts SK, 2014, 'Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection', Journal of Gastroenterology and Hepatology (Australia), 29, pp. 1458 - 1462,
    Journal articles | 2014
    Luciani F; Breta帽a NAR; Teutsch S; Amin J; Topp L; Dore GJ; Maher L; Dolan K; Lloyd AR; Bretana N, 2014, 'A prospective study of hepatitis C incidence in Australian prisoners', Addiction (Abingdon, England), 109, pp. 1695 - 1706,
    Journal articles | 2014
    Luciani F; Breta帽a NAR; Teutsch S; Amin J; Topp L; Dore GJ; Maher L; Dolan K; Lloyd AR, 2014, 'A prospective study of hepatitis C incidence in Australian prisoners', Addiction (Abingdon, England), 109, pp. 1695 - 1706,
    Journal articles | 2014
    Martin NK; Devine A; Eaton JW; Miners A; Hallett TB; Foster GR; Dore GJ; Easterbrook PJ; Legood R; Vickerman P, 2014, 'Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa', AIDS, 28, pp. s35 - s46,
    Journal articles | 2014
    Martinello M; Chow DH; Danta M; Matthews GV; Dore GJ, 2014, 'Regression of advanced fibrosis following virological response to anti-HCV therapy', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29, pp. 85 - 85,
    Journal articles | 2014
    Martinello M; Chow DH; Danta M; Matthews GV; Dore GJ, 2014, 'Safety and efficacy of telaprevir and boceprevir in the "real world": an Australian experience', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29, pp. 85 - 86,
    Journal articles | 2014
    Muir A; Poordad F; Lalezari JP; Everson GT; Dore GJ; Kwo P; Hezode C; Pockros PJ; Tran A; Ramji A; Yang R; Hughes EA; Swenson ES; Yin PD, 2014, '2014 Hepatology referees (volumes 59 and 60)', Hepatology, 60, pp. 2236 - 2240,
    Journal articles | 2014
    Peters L; Neuhaus J; Duprez D; Neaton JD; Tracy R; Klein MB; Mocroft A; Rockstroh J; Dore G; Lundgren JD; Emery S, 2014, 'Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study', Journal of Clinical Virology, 60, pp. 295 - 300,
    Journal articles | 2014
    Razavi H; Bruggmann P; Wedemeyer H; Dore G, 2014, 'Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: A comment on the results presented in JVH Special Issue', Journal of Viral Hepatitis, 21, pp. e169 - e170,
    Journal articles | 2014
    Razavi H; Waked I; Sarrazin C; Myers RP; Idilman R; Calinas F; Vogel W; Mendes Correa MC; H茅zode C; L谩zaro P; Akarca U; Aleman S; Bal谋k I; Berg T; Bihl F; Bilodeau M; Blasco AJ; Brand茫o Mello CE; Bruggmann P; Buti M; Calleja JL; Cheinquer H; Christensen PB; Clausen M; Coelho HSM; Cramp ME; Dore GJ; Doss W; Duberg AS; El-Sayed MH; Erg枚r G; Esmat G; Falconer K; F茅lix J; Ferraz MLG; Ferreira PR; Frankova S; Garc铆a-Samaniego J; Gerstoft J; Giria JA; Gon莽ales FL; Gower E; Gschwantler M; Guimar茫es Pess么a M; Hindman SJ; Hofer H; Husa P; K氓berg M; Kaita KDE; Kautz A; Kaymakoglu S; Krajden M; Krarup H; Laleman W; Lavanchy D; Marinho RT; Marotta P; Mauss S; Moreno C; Murphy K; Negro F; Nemecek V; 脰rmeci N; 脴vrehus ALH; Parkes J; Pasini K; Peltekian KM; Ramji A; Reis N; Roberts SK; Rosenberg WM; Roudot-Thoraval F; Ryder SD; Sarmento-Castro R; Semela D; Sherman M; Shiha GE; Sievert W; Sperl J; St盲rkel P; Stauber RE; Thompson AJ; Urbanek P; Van Damme P; van Thiel I; Van Vlierberghe H; Vandijck D; Wedemeyer H; Weis N; Wiegand J; Yosry A; Zekry A; Cornberg M; M眉llhaupt B; Estes C, 2014, 'The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm', Journal of viral hepatitis, 21, pp. 34 - 59,
    Journal articles | 2014
    Roberts SK; Mitchell J; Leung R; Booth D; Bollipo S; Ostapowicz G; Sloss A; Mccaughan GW; Dore GJ; Thompson A; Crawford DH; Sievert W; Weltman M; Cheng W; George J; Angus P; Chu G; Cornwall M; Douglas M; Hallinan R; Haque M; Hawkin G; Jackson H; Johnson R; Kronborg I; Lee A; Leggett B; Mire ML; Levy M; Lubel J; MacQuillan G; Masson J; McDonald J; McGarity B; Mollison L; Nicoll A; Ombiga J; Riordan S; Strasser S; Thompson A; Watson J; Wenman J; Wigg A; Zekry A, 2014, 'Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies', Journal of Gastroenterology and Hepatology (Australia), 29, pp. 179 - 184,
    Journal articles | 2014
    Shiffman ML; Cheinquer H; Berg CP; Berg T; de Figueiredo-Mendes C; Dore GJ; Ferraz ML; Mendes-Corr锚a MC; Lima MP; Parise ER; Rios AMP; Reuter T; Sanyal AJ; Shafran SD; Hohmann M; Tatsch F; Bakalos G; Zeuzem S, 2014, 'Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial', Hepatology International, 8, pp. 517 - 526,
    Journal articles | 2014
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ, 2014, 'Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia', Journal of Gastroenterology and Hepatology (Australia), 29, pp. 1 - 9,
    Journal articles | 2014
    Treloar C; Rance J; Dore GJ; Grebely J, 2014, 'Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: Insights from the ETHOS study', Journal of Viral Hepatitis, 21, pp. 560 - 567,
    Journal articles | 2014
    Treloar C; Rance J; Grebely J; Marks P; Dore G, 2014, 'How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting', International Journal of Drug Policy, 25, pp. 865 - 870,
    Journal articles | 2014
    Wedemeyer H; Duberg AS; Buti M; Rosenberg WM; Frankova S; Esmat G; 脰rmeci N; Van Vlierberghe H; Gschwantler M; Akarca U; Aleman S; Bal谋k I; Berg T; Bihl F; Bilodeau M; Blasco AJ; Brand茫o Mello CE; Bruggmann P; Calinas F; Calleja JL; Cheinquer H; Christensen PB; Clausen M; Coelho HSM; Cornberg M; Cramp ME; Dore GJ; Doss W; El-Sayed MH; Erg枚r G; Estes C; Falconer K; F茅lix J; Ferraz MLG; Ferreira PR; Garc铆a-Samaniego J; Gerstoft J; Giria JA; Gon莽ales FL; Guimar茫es Pess么a M; H茅zode C; Hindman SJ; Hofer H; Husa P; Idilman R; K氓berg M; Kaita KDE; Kautz A; Kaymakoglu S; Krajden M; Krarup H; Laleman W; Lavanchy D; L谩zaro P; Marinho RT; Marotta P; Mauss S; Mendes Correa MC; Moreno C; M眉llhaupt B; Myers RP; Nemecek V; 脴vrehus ALH; Parkes J; Peltekian KM; Ramji A; Razavi H; Reis N; Roberts SK; Roudot-Thoraval F; Ryder SD; Sarmento-Castro R; Sarrazin C; Semela D; Sherman M; Shiha GE; Sperl J; St盲rkel P; Stauber RE; Thompson AJ; Urbanek P; Van Damme P; van Thiel I; Vandijck D; Vogel W; Waked I; Weis N; Wiegand J; Yosry A; Zekry A; Negro F; Sievert W; Gower E, 2014, 'Strategies to manage hepatitis C virus (HCV) disease burden', Journal of viral hepatitis, 21, pp. 60 - 89,
    Journal articles | 2014
    White B; Dore GJ; Lloyd AR; Rawlinson WD; Maher L, 2014, 'Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: The HITS-c study', Medical Journal of Australia, 201, pp. 326 - 329,
    Journal articles | 2014
    White B; Madden A; Prins M; Hellard M; Wand H; Dore GJ; Page K; Maher L, 2014, 'Assessing the feasibility of hepatitis C virus vaccine trials: Results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study', Vaccine, 32, pp. 5460 - 5467,
    Journal articles | 2013
    Alavi M; Grebely J; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ, 2013, 'Assessment and treatment of hepatitis c virus infection among people who inject drugs in the opioid substitution setting: ETHOS study', Clinical Infectious Diseases, 57, pp. s62 - s69,
    Journal articles | 2013
    Aspinall EJ; Corson S; Doyle JS; Grebely J; Hutchinson SJ; Dore GJ; Goldberg DJ; Hellard ME, 2013, 'Treatment of hepatitis c virus infection among people who are actively injecting drugs: A systematic review and meta-analysis', Clinical Infectious Diseases, 57, pp. s80 - s89,
    Journal articles | 2013
    Deans GD; Raffa JD; Lai C; Fischer B; Krajden M; Amin J; Walter SR; Dore GJ; Grebely J; Tyndall MW, 2013, 'Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada', CMAJ Open, 1, pp. e68 - e76,
    Journal articles | 2013
    Dore GJ; Lawitz E; Hezode C; Shafran S; Ramji A; Tatum H; Taliani G; Tran A; Brunetto M; Zaltron S; Strasser S; Weis N; Ghesquiere W; Lee S; Larrey D; Pol S; Harley H; George J; Fung S; De Ledinghen V; Hagens P; Cohen D; Cooney E; Noviello S; Hughes E, 2013, 'Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT2/3 study', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 28, pp. 155 - 156
    Journal articles | 2013
    Eslam M; Leung R; Berg T; Irving WL; Mangia A; Sheridan D; Abate ML; Weltman M; Spengler U; Mollison L; Cheng W; Dore GJ; Powell E; Riordan S; Douglas M; Suppiah V; Stewart GJ; Booth DR; George J; Ahlenstiel G, 2013, 'Association of IFNL3 polymorphisms with fibrosis progression in viral and non-viral chronic liver disease', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 28, pp. 67 - 67,
    Journal articles | 2013
    Feld JJ; Grebely J; Matthews GV; Applegate T; Hellard M; Sherker A; Cherepanov V; Petoumenos K; Yeung B; Kaldor JM; Lloyd AR; Dore GJ, 2013, 'Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection', PLoS ONE, 8, pp. e80003,
    Journal articles | 2013
    Flynn JK; Dore GJ; Hellard M; Yeung B; Rawlinson WD; White PA; Kaldor JM; Lloyd AR; Ffrench RA; Dolan K, 2013, 'Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment', Journal of Gastroenterology and Hepatology (Australia), 28, pp. 1770 - 1781,
    Journal articles | 2013
    Fried MW; Buti M; Dore GJ; Flisiak R; Ferenci P; Jacobson I; Marcellin P; Manns M; Nikitin I; Poordad F; Sherman M; Zeuzem S; Scott J; Gilles L; Lenz O; Peeters M; Sekar V; De Smedt G; Beumont-Mauviel M, 2013, 'Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-na茂ve genotype 1 hepatitis C: The randomized PILLAR study', Hepatology, 58, pp. 1918 - 1929,
    Journal articles | 2013
    Grebely J; Feld JJ; Applegate T; Matthews GV; Hellard M; Sherker A; Petoumenos K; Zang G; Shaw I; Yeung B; George J; Teutsch S; Kaldor JM; Cherepanov V; Bruneau J; Shoukry NH; Lloyd AR; Dore GJ, 2013, 'Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection', Hepatology, 57, pp. 2124 - 2134,
    Journal articles | 2013
    Grebely J; Matthews GV; Lloyd AR; Dore GJ, 2013, 'Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: Feasibility and future requirements', Clinical Infectious Diseases, 57, pp. 1014 - 1020,
    Journal articles | 2013
    Grebely J; Oser ML; Taylor L; Dore GJ, 2013, 'Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels', Journal of Infectious Diseases, 207, pp. S19 - S25,
    Journal articles | 2013
    Hajarizadeh B; Grebely J; Dore GJ, 2013, 'Epidemiology and natural history of HCV infection', Nature Reviews Gastroenterology and Hepatology, 10, pp. 553 - 562,
    Journal articles | 2013
    Hegerle N; Rayat L; Dore G; Zidane N; Bedouelle H; Guiso N, 2013, 'In-vitro and in-vivo analysis of the production of the Bordetella type three secretion system effector A in Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica', Microbes and Infection, 15, pp. 399 - 408,
    Journal articles | 2013
    Holmes JA; Roberts SK; Sievert W; Dore GJ; Mccaughan M; Crawford DJ; Cheng W; Weltman M; Bonanzinga S; Visvanathan K; Desmond PV; Bowden DS; Matthews G; Thompson AJ, 2013, 'RBV pharmacokinetics explain the relationship between on-treatment anaemia and SVR, which is independent of ITPA genotype: analysis from the CHARIOT study', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 28, pp. 171 - 172,
    Journal articles | 2013
    Jacka B; Lamoury F; Simmonds P; Dore GJ; Grebely J; Applegate T, 2013, 'Sequencing of the Hepatitis C Virus: A Systematic Review', PLoS ONE, 8, pp. e67073,
    Journal articles | 2013
    Jacobson IM; Dore GJ; Foster G; Fried MW; Radu MN; Rafalskiy VV; Moroz L; Craxi; ag A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Kalmeijer R; Beumont-Mauviel M, 2013, 'Sa2072 Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial', Gastroenterology, 144, pp. S - 374,
    Journal articles | 2013
    Kitson MT; Dore GJ; George J; Button P; McCaughan G; Crawford D; Sievert W; Weltman M; Cheng W; Robertson S, 2013, 'Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection', Journal of Hepatology, 58, pp. 467 - 472,
    Journal articles | 2013
    Macdonald GA; Roberts SK; Dore GJ; Gane EJ; Thompson AJ; Weltman MD; Weilert F; Hill A; Laeuffer J; Strasser SI, 2013, 'Treatment of hepatitis c genotype 1 patients with severe fibrosis or compensated cirrhosis: The telaprevir early access program in patients from Australia and New Zealand', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 28, pp. 169 - 169,
    Journal articles | 2013
    Martin NK; Vickerman P; Grebely J; Hellard M; Hutchinson SJ; Lima VD; Foster GR; Dillon JF; Goldberg DJ; Dore GJ; Hickman M, 2013, 'Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals', Hepatology, 58, pp. 1598 - 1609,
    Journal articles | 2013
    Matthews G; Seaberg E; Avihingsanon A; Bowden S; Dore GJ; Lewin SR; Sasadeusz JJ; Revill PA; Littlejohn M; Hoy J; Finlayson R; Ruxrungtham K; Saulynas M; Locarnini S; Thio C, 2013, 'Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus', Clinical Infectious Diseases, 56, pp. e87 - e94,
    Journal articles | 2013
    Matthews GV; Ali RJ; Avihingsanon A; Amin J; Hammond RA; Bowden S; Lewin SR; Sasadeusz JJ; Littlejohn M; Locarnini SL; Ruxrungtham K; Dore GJ, 2013, 'Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals', PLoS One, 8, pp. e61297,
    Journal articles | 2013
    Post J; Arain A; Lloyd AR; Grebely J; Dore G, 2013, 'Enhancing Assessment and Treatment Hepatitis C in the Custodial Setting', Clinical Infectious Diseases, 57, pp. S70 - S74,
    Journal articles | 2013
    Robaeys G; Grebely J; Mauss S; Bruggmann P; Moussalli J; De Gottardi A; Swan T; Arain A; Kautz A; St枚ver H; Wedemeyer H; Schaefer M; Taylor L; Backmund M; Dalgard O; Prins M; Dore GJ, 2013, 'Recommendations for the management of hepatitis C virus infection among people who inject drugs', Clinical Infectious Diseases, 57, pp. s129 - s137,
    Journal articles | 2013
    Strasser SI; Roberts SK; Gane EJ; Macdonald GA; Thompson AJ; Weltman MD; Weilert F; Hill A; Laeuffer J; Dore GJ, 2013, 'Management and outcomes of side effects with focus on anaemia in patients with hepatitis c genotype 1 infection: The telaprevir early access program in patients from Australia and New Zealand', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 28, pp. 168 - 169,
    Journal articles | 2013
    Suppiah V; Armstrong NJ; O'Connor KS; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Dore GJ; Irving WL; Powell E; Nattermann J; Mueller T; Riordan S; Stewart GJ; George J; Booth DR; Ahlenstiel G; Michalk M; Malik B; McClure P; Smith S; Sheridan D; Snape E; Fragomeli V; Norris R; How-Chow D; Jonsson JR; Barrie H; Stelzer-Braid S; Fletcher S; Applegate T; Grebely J; Matthews G; Bharadwaj M; Smedile A, 2013, 'CCR5-螖32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection', Genes and Immunity, 14, pp. 286 - 290,
    Journal articles | 2013
    Treloar C; Rance J; Grebely J; Dore GJ, 2013, 'Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia', Drug and Alcohol Dependence, 133, pp. 529 - 534,
    Journal articles | 2013
    White B; Madden A; Hellard M; Kerr T; Prins M; Page K; Dore GJ; Maher L, 2013, 'Increased hepatitis C virus vaccine clinical trial literacy following a brief intervention among people who inject drugs', Drug and Alcohol Review, 32, pp. 419 - 425,
    Journal articles | 2012
    Avihingsanon A; Matthews GV; Lewin SR; Marks P; Sasadeusz JJ; Cooper DA; Bowden S; Locarnini SA; Dore GJ; Ruxrungtham K, 2012, 'Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand', AIDS Research and Therapy, 9, pp. Article number 6,
    Journal articles | 2012
    Cowie BC; Dore GJ, 2012, 'The Perpetual Challenge of Infectious Diseases', New England Journal of Medicine, 367, pp. 89 - 89,
    Journal articles | 2012
    Crawford DHG; Dore GJ; Sievert W; Cheng WSC; Weltman M; McCaughan G; Rawlinson WD; Marks P; Yoshihara M; Rizkalla B; Roberts SK, 2012, 'Early on-treatment viral load and baseline METAVIR score: Improved prediction of sustained virological response in HCV genotype 1 patients', Antiviral Therapy, 17, pp. 849 - 854,
    Journal articles | 2012
    Dore GJ, 2012, 'The changing therapeutic landscape for hepatitis C.', Medical Journal of Australia, 196, pp. 629 - 632,
    Journal articles | 2012
    Flynn J; Dore GJ; Matthews G; Hellard M; Yeung B; Rawlinson W; White PA; Kaldor JM; Lloyd AR; Ffrench RA; Dolan K, 2012, 'Impaired hepatitis C virus (HCV)-specific interferon-responses in individuals with HIV who acquire HCV infection: Correlation with CD4 + T-cell counts', Journal of Infectious Diseases, 206, pp. 1568 - 1576,
    Journal articles | 2012
    Gidding HF; Law MG; Amin J; Ostapowicz G; Weltman MD; Macdonald GAM; Sasadeusz JJ; Haber PS; George J; Dore GJ; Han A, 2012, 'Hepatitis C treatment outcomes in Australian clinics', Medical Journal of Australia, 196, pp. 633 - 637,
    Journal articles | 2012
    Grebely J; Alavi M; Spelman T; Haber P; Day C; Matthews G; Van Beek I; Walsh N; Yeung B; Petoumenos K; Dolan K; Kaldor J; Dore G; Hellard M, 2012, 'IMPACT OF TREATMENT OF RECENTLY-ACQUIRED HEPATITIS C INFECTION ON INJECTING DRUG USE BEHAVIOURS', DRUG AND ALCOHOL REVIEW, 31, pp. 34 - 34
    Journal articles | 2012
    Grebely J; Dore GJ, 2012, 'What is killing people with hepatitis C virus infection?', Seminars in Liver Disease, 31, pp. 331 - 339,
    Journal articles | 2012
    Grebely J; Hellard M; Applegate TL; Petoumenos K; Yeung B; Feld J; Rawlinson WD; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews G; Dolan K, 2012, 'Virological responses during treatment for recent hepatitis C virus: Potential benefit for ribavirin use in HCV/HIV co-infection', AIDS, 26, pp. 1653 - 1661,
    Journal articles | 2012
    Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Beek IV; Kaldor JM; Hellard M; Dore GJ; Haber PS; Alavi M; Van Beek I; Amin J; Dolan K; Rawlinson W; Flynn J; Marks P; Acraman B; Bloch M; Li H; Madden A; George J, 2012, 'Effect of pegylated interferon-a-2a treatment on mental health during recent hepatitis C virus infection', Journal of Gastroenterology and Hepatology, 27, pp. 957 - 965,
    Journal articles | 2012
    Grebely J; Morris M; Rice T; Bruneau J; Cox AL; Kim A; McGovern B; Shoukry N; Lauer G; Maher L; Lloyd AR; Hellard M; Prins M; Dore GJ; Page K, 2012, 'Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study.', International Journal of Epidemiology, in press, pp. 1-11,
    Journal articles | 2012
    Grebely J; Pham ST; Matthews G; Petoumenos K; Bull RA; Yeung B; Rawlinson WD; Kaldor JM; Lloyd AR; Hellard M; Dore GJ; White PA; Bull ; Dolan K, 2012, 'Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection', Hepatology, 55, pp. 1058 - 1069,
    Journal articles | 2012
    Grebely J; Prins M; Hellard M; Cox AL; Osburn WO; Lauer G; Page K; Lloyd AR; Dore GJ; Maher L, 2012, 'Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine', Lancet Infectious Diseases, 12, pp. 408 - 414,
    Journal articles | 2012
    Hajarizadeh B; Grebely J; Dore GJ, 2012, 'Case definitions for acute hepatitis C virus infection: A systematic review', Journal of Hepatology, 57, pp. 1349 - 1360,
    Journal articles | 2012
    Hegerle N; Paris AS; Brun D; Dore G; Njamkepo E; Guillot S; Guiso N, 2012, 'Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: Increase of Bordetellae not expressing pertactin', Clinical Microbiology and Infection, 18,
    Journal articles | 2012
    Hellard M; Grebely J; Yeung B; Dore G; Marks P; Shaw D; Byrne M; Matthews G, 2012, 'EFFECTIVENESS OF RESPONSE-GUIDED THERAPY IN RECENT HEPATITIS C INFECTION: THE AUSTRALIAN TRIAL IN ACUTE HEPATITIS C', DRUG AND ALCOHOL REVIEW, 31, pp. 33 - 33
    Journal articles | 2012
    Holmes JA; Bonanzinga S; Roberts S; Sievert W; Dore G; Mccaughan G; Crawford DH; Cheng W; Weltman MD; Matthews G; Visvanathan K; Desmond P; Bowden DS; Thompson A, 2012, 'ITPA genotype strongly protects from ribavirin-induced haemolytic anaemia: analysis from the CHARIOT study', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 27, pp. 168 - 168,
    Journal articles | 2012
    Kwon J; Anderson JS; Kerr CC; Thein H; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP; Han A, 2012, 'Estimating the cost-effectiveness of needle-syringe programs in Australia.', AIDS, 26, pp. 2201 - 2210,
    Journal articles | 2012
    Thein H; Walter SR; Gidding HF; Amin J; Law MG; George J; Dore GJ; Han A, 2012, 'Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort', Hepatology Research, 42, pp. 1175 - 1186,
    Journal articles | 2012
    Treloar C; Hull PB; Dore GJ; Grebely J, 2012, 'Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs', Drug and Alcohol Review, 31, pp. 918 - 924,
    Journal articles | 2012
    Vickerman P; Grebely J; Dore GJ; Sacks-davis R; Page K; Thomas DL; Osburn WO; Cox AL; Aitken CL; Hickman M; Hellard M; Maher L, 2012, 'The more you look, the more you find: Effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design', Journal of Infectious Diseases, 205, pp. 1342 - 1350,
    Journal articles | 2012
    White BA; Dore GJ; Lloyd AR; Rawlinson WD; Maher L, 2012, 'Ongoing susceptibility to hepatitis B virus infection among people who inject drugs in Sydney', Australian and New Zealand Journal of Public Health, 36, pp. 351 - 356,
    Journal articles | 2011
    Audsley J; Seaberg E; Sasadcusz J; Matthews G; Avihingsanon A; Ruxrungtham K; Fairley K; Finlayson RJ; Hwang H; Littlejohn M; Locarnini S; Dore GJ; Thio C; Lewin S, 2011, 'Factors associated with elevated ALT in an international HIV/HBV Co-Infected cohort on long-term HAART', PLoS One, 6, pp. e26482,
    Journal articles | 2011
    Baleriola C; Rawlinson WD; Dore GJ; Chaverot S; Stelzer-Braid S; Yoshihara M; Crawford D; Sievert W; McCaughan G; Weltman M; Cheng W; Rizkalla B; Dubois D; Thommes J; Roberts S, 2011, 'Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients', Antiviral Therapy, 16, pp. 173 - 180,
    Journal articles | 2011
    Bouchez V; Brun D; Dore G; Njamkepo E; Guiso N, 2011, 'Bordetella parapertussis isolates not expressing pertactin circulating in France', Clinical Microbiology and Infection, 17, pp. 675 - 682,
    Journal articles | 2011
    Bull RA; Luciani F; McElroy K; Gaudieri S; Pham ST; Chopra A; Cameron B; Maher L; Dore GJ; White PA; Lloyd AR, 2011, 'Sequential Bottlenecks Drive Viral Evolution in Early Acute Hepatitis C Virus Infection', PLoS Pathog, 7, pp. e1002243,
    Journal articles | 2011
    Dore GJ; Matthews GV; Rockstroh J, 2011, 'Future of hepatitis C therapy: Development of direct-acting antivirals', Current opinion in HIV & AIDS, 6, pp. 508 - 513,
    Journal articles | 2011
    Ewer P; Mills K; Teesson M; Sannibale C; Baker A; Kay-Lambkin F; Dore G, 2011, 'A BRIEF INTERVENTION FOR ALCOHOL AND OTHER DRUG USERS WHO HAVE EXPERIENCED TRAUMA', DRUG AND ALCOHOL REVIEW, 30, pp. 29 - 29,
    Journal articles | 2011
    Flynn JK; Dore GJ; Hellard M; Yeung B; Rawlinson WD; White PA; Kaldor JM; Lloyd AR; Ffrench RA; Dolan K, 2011, 'Early IL-10 predominant responses are associated with progression from acute to chronic hepatitis C virus infection in injecting drug users', Journal of Viral Hepatitis, 18, pp. 549 - 561,
    Journal articles | 2011
    Gidding HF; Amin J; Dore GJ; Law MG, 2011, 'Hospitalization rates associated with hepatitis B and HIV co-infection, age and sex in a population-based cohort of people diagnosed with hepatitis C', Epidemiology and Infection, 139, pp. 1151 - 1158
    Journal articles | 2011
    Gidding HF; Dore GJ; Amin J; Law MG, 2011, 'Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study', BMC Public Health, 11, pp. 52
    Journal articles | 2011
    Gidding HF; Law MG; Amin J; MacDonald GJ; Sasadeusz JJ; Jones TL; Strasser SI; George J; Dore GJ, 2011, 'Predictors of deferral of treatment for hepatitis C infection in Australian clinics', The Medical Journal of Australia, 194, pp. 398 - 402
    Journal articles | 2011
    Grebely J; Bryant J; Hull PB; Hopwood MN; Lavis YM; Dore GJ; Treloar C, 2011, 'Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia.', Journal of Viral Hepatitis, 18, pp. 104 - 116,
    Journal articles | 2011
    Grebely J; Dore GJ, 2011, 'An expanding role for primary care providers in the treatment of hepatitis C virus infection in the community', Hepatology, 54, pp. 2259 - 2261
    Journal articles | 2011
    Grebely J; Dore GJ, 2011, 'Hepatitis C: Enhancing treatment for hepatitis C among drug users', Nature Reviews Gastroenterology and Hepatology, 8, pp. 11 - 13,
    Journal articles | 2011
    Grebely J; Dore GJ, 2011, 'Prevention of hepatitis C virus in injecting drug users: A narrow window of opportunity', Journal of Infectious Diseases, 203, pp. 571 - 574
    Journal articles | 2011
    Grebely J; Dore GJ, 2011, 'What is killing people with HCV infection?', Seminars in Liver Disease, 31, pp. 331 - 339
    Journal articles | 2011
    Grebely J; Matthews G; Dore GJ, 2011, 'Treatment of acute HCV infection', Nature Reviews Gastroenterology and Hepatology, 8, pp. 265 - 274,
    Journal articles | 2011
    Grebely J; Matthews G; Hellard M; Shaw D; van Beek I; Petoumenos K; Alavi M; Yeung B; Haber P; Lloyd AR; Kaldor JM; Dore GJ; Dolan K, 2011, 'Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users', Journal of Hepatology, 55, pp. 76 - 85,
    Journal articles | 2011
    Grebely J; Raffa JD; Lai C; Kerr T; Fischer B; Krajden M; Dore GJ; Tyndall MW, 2011, 'Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents', Journal of Viral Hepatitis, 18, pp. 32 - 41,
    Journal articles | 2011
    Matthews G; Pham STP; Hellard M; Grebely J; Zhang L; Oon A; Marks P; Van Beek IA; Rawlinson WD; Kaldor JM; Lloyd AR; Dore GJ; White PA, 2011, 'Patterns and characteristics of Hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian Trial in Acute Hepatitis C', Clinical Infectious Diseases, 52, pp. 803 - 811,
    Journal articles | 2011
    Matthews GV; Dore GJ, 2011, 'HIV and Hepatitis C Co-Infection', , pp. 177 - 184,
    Journal articles | 2011
    Matthews GV; Dore GJ, 2011, 'Optimal duration of treatment for acute hepatitis c in human immunodeficiency virus-positive individuals?', Hepatology, 53, pp. 1055 - 1056,
    Journal articles | 2011
    Peters L; Neuhaus J; Mocroft A; Soriano V; Rockstroh J; Dore G; Puoti M; Tedaldi E; Clotet B; Kupfer B; Lundgren JD; Klein MB, 2011, 'Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART study', Antiviral Therapy, 16, pp. 667 - 675,
    Journal articles | 2011
    Sasadeusz J; Dore GJ; Kronborg I; Barton D; Yoshihara M; Weltman M, 2011, 'Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy', Addiction, 106, pp. 977 - 984,
    Journal articles | 2011
    Sievert W; Dore GJ; McCaughan GW; Yoshihara M; Crawford D; Cheng W; Weltman M; Rawlinson W; Rizkalla B; DePamphilis JK; Roberts SK, 2011, 'Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1', Hepatology, 53, pp. 1109 - 1117,
    Journal articles | 2011
    Sievert W; Dore GJ; Roberts SK, 2011, 'Reply', Hepatology, 53, pp. 1775 - 1776,
    Journal articles | 2011
    Smith KR; Suppiah V; O''Connor K; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Matthews G; Irving W; Powell E; Riordan S; Ahlensteil G; Stewart GJ; Bahlo M; Booth DR; George J, 2011, 'Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort', Genome Medicine, 3, pp. 57
    Journal articles | 2011
    Suppiah V; Gaudieri S; Armstrong N; O''connor K; Berg T; Weltman M; Abate M; Spengler U; Bassendine M; Dore G; Irving W; Powell E; Hellard M; Riordan S; Mathews G; Sheridan D; Natterman J; Smedile A; Muller T; Hammond E; Dunn D; Negro F; Bochud Y; Mallal S; Ahlenstiel G; Stewart G; George J; Booth D, 2011, 'IL28B, HLA-C and KIR variants additively and interactively predict response to therapy in chronic hepatitis C virus infection', PLOS Medicine, 8, pp. e1001092,
    Journal articles | 2011
    Suppiah V; Gaudieri S; Armstrong NJ; O''Connor KS; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Dore GJ; Irving WL; Powell E; Hellard M; Riordan S; Matthews G; Sheridan D; Nattermann J; Smedile A; Muller T; Hammond E; Dunn ; Negro F; Bochud PY; Mallal SA; Ahlenstiel G; Stewart GJ; George J; Booth DR, 2011, 'IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: A cross-sectional study.', PLOS Medicine, 8, pp. e1001092
    Journal articles | 2011
    Thein HH; Walter SR; Gidding HF; Amin J; Law MG; George J; Dore GJ, 2011, 'Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: A population-based cohort study, 1992-2007', Journal of Viral Hepatitis, 18, pp. e232 - e241,
    Journal articles | 2011
    Walter SR; Thein H; Gidding HF; Amin J; George J; Dore GJ, 2011, 'Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C', Journal of Gastroenterology and Hepatology (JGH), 26, pp. 1757 - 1764,
    Journal articles | 2011
    Walter SR; Thein HH; Amin J; Gidding HF; Ward K; Law MG; George J; Dore GJ, 2011, 'Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006', Journal of Hepatology, 54, pp. 879 - 886,
    Journal articles | 2010
    Audsley J; Yuen L; Littlejohn M; Sasadcusz J; Ayres A; Desmond C; Spelman T; Lau GT; Matthews G; Avihingsanon A; Seaberg E; Philp F; Saulynas M; Ruxrungtham K; Dore GJ; Locarnini S; Thio C; Lewin S; Revill P, 2010, 'HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing', Virology, 405, pp. 539 - 547,
    Journal articles | 2010
    Avihingsanon A; Lewin S; Kerr SJ; Chang JJ; Piyawat K; Napissanant N; Matthews G; Dore GJ; Bowden S; Lange J; Ruxrungtham K, 2010, 'Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-na茂ve HIV-HBV coninfection in Thailand', Antiviral Therapy, 15, pp. 917 - 922
    Journal articles | 2010
    Cheng W; Roberts S; McCaughan G; Sievert W; Weltman MD; Crawford D; Rawlinson WD; Marks P; Thommes J; Rizkalla B; Yoshihara M; Dore GJ, 2010, 'Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing', Journal of Hepatology, 53, pp. 616 - 623
    Journal articles | 2010
    Crane M; Sirivichayakul S; Chang JJ; Avihingsanon A; Ubolyam S; Buranapraditkun S; Thantiworasit P; Wightman F; Locarnini S; Matthews G; Dore GJ; Ruxrungtham K; Lewin SR, 2010, 'No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy', Journal of Virology, 84, pp. 2657 - 2665
    Journal articles | 2010
    Day C; White B; Dore G; Van Beek I; Rodgers C; Cunningham P; Wodak A; Maher L, 2010, 'Hepatitis B virus among injecting drug users in Sydney, Australia: Prevalence, vaccination and knowledge of status', Drug and Alcohol Dependence, 108, pp. 134 - 137,
    Journal articles | 2010
    Dore G; Grebely J; Gillman A; Thein R; Day C; Ryan L; Treloar C; Haber P, 2010, 'PRESENTER 1: OVERVIEW OF TREATMENT OF HEPATITIS C (HCV) IN THE OPIATE PHARMACOTHERAPY SETTING AND THE ENHANCING TREATMENT OF HEPATITIS C IN THE OPIATE SUBSTITUTION SETTING (ETHOS) PARTNERSHIP INITIATIVE', DRUG AND ALCOHOL REVIEW, 29, pp. 21 - 21,
    Journal articles | 2010
    Dore GJ; Hellard M; Matthews G; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; Van Beek IA; McCaughan G; White PA; French R; Rawlinson WD; Lloyd AROLA; Kaldor JM; Dolan K, 2010, 'Effective treatment of injecting drug users with recently acquired hepatitis C virus infection', Gastroenterology, 138, pp. 123 - 135,
    Journal articles | 2010
    Dore GJ; Soriano V; Rockstroh J; Kupfer B; Tedaldi E; Peters L; Neuhaus J; Puoti M; Klein M; Mocroft A; Clotet B; Lundgren JD, 2010, 'Frequent hepatitis B virus rebound among HIV鈥揾epatitis B virus-coinfected patients following antiretroviral therapy interruption', AIDS, 24, pp. 857 - 865
    Journal articles | 2010
    Gidding HF; Amin J; Dore GJ; Ward K; Law MG, 2010, 'Hospital-related morbidity in people notified with hepatitis C: A population-based record linkage study in New South Wales, Australia', Journal of Hepatology, 53, pp. 43 - 49
    Journal articles | 2010
    Grebely J; Bryant J; Hull P; Hopwood M; Dore G; Treloar C, 2010, 'PRESENTER 2: SPECIALIST ASSESSMENT AND TREATMENT OF HEPATITIS C VIRUS INFECTION AMONG INJECTION DRUG USERS IN NEW SOUTH WALES, AUSTRALIA', DRUG AND ALCOHOL REVIEW, 29, pp. 21 - 21,
    Journal articles | 2010
    Grebely J; Knight E; Ngai T; Genoway K; Raffa J; Storms M; Gallagher L; Krajden M; Dore GJ; Duncan F; Conway B, 2010, 'Reinfection with hepatitis C virus following sustained virological response in injection drug users', Journal of Gastroenterology and Hepatology, 25, pp. 1281 - 1284,
    Journal articles | 2010
    Grebely J; Matthews GV; Petoumenos K; Dore GJ, 2010, 'Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection', Journal of Viral Hepatitis, 17, pp. 896,
    Journal articles | 2010
    Grebely J; Petoumenos K; Hellard M; Matthews G; Suppiah V; Applegate TL; Yeung B; Marks P; Rawlinson WD; Lloyd AROLA; Booth D; Kaldor JM; George J; Dore GJ; Amin J; Cameron B; Acraman B; Dolan K; Bloch M; Van Beek I; Li H; Madden A, 2010, 'Potential Role for Interleukin-28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection', Hepatology, 52, pp. 1216 - 1224,
    Journal articles | 2010
    Grebely J; Petoumenos K; Matthews G; Haber PS; Marks P; Lloyd AROLA; Kaldor JM; Dore GJ; Hellard M; Dolan K, 2010, 'Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study', Drug and Alcohol Dependence, 107, pp. 244 - 249,
    Journal articles | 2010
    Marcellin P; Reddy KR; Roberts SK; Jensen DM; Harrison SA; Hadziyannis SJ; Dore G; Diago M; Weltman MD; Solsky J; Tietz A; Rizzetto M, 2010, 'T1990 Peginterferon Alfa-2a (40KD) Has a Wide Safety Margin in Patients Infected With Hepatitis C Virus Genotype 1: Pooled Data From Four Randomized Multicenter Studies', Gastroenterology, 138, pp. S - 844,
    Journal articles | 2010
    Milner K; van der Poorten D; Trenell M; Jenkins AB; Xu A; Smythe GA; Dore GJ; Zekry A; Weltman MD; Fragomeli V; George J; Chisholm DJ, 2010, 'Chronic Hepatitis C is associated with peripheral rather than hepatic insulin resistance', Gastroenterology, 138, pp. 932 - 941
    Journal articles | 2010
    Pham STP; Bull RA; Bennett JM; Rawlinson WD; Lloyd AR; Dore GJD; White PA; Bull , 2010, 'Frequent multiple hepatitis C virus infections among injection drug users in a prison setting', Hepatology, 52, pp. 1564 - 1572,
    Journal articles | 2010
    Teutsch S; Luciani F; Scheuer N; McCredie L; Hosseiny P; Rawlinson WD; Kaldor JM; Dore GJ; Dolan K; Ffrench R; Lloyd AROLA; Haber P; Levy MH, 2010, 'Incidence of primary Hepatitis C infection and risk factors for transmission in an Australian prisoner cohort', BMC Public Health, 10, pp. 1 - 9,
    Journal articles | 2009
    Bouchez V; Brun D; Cantinelli T; Dore G; Njamkepo E; Guiso N, 2009, 'First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin', Vaccine, 27, pp. 6034 - 6041,
    Journal articles | 2009
    Chang JH; Sirivichayakul S; Avihingsanon A; Thompson A; Revill P; Iser D; Slavin J; Buranapraditkun S; Marks P; Matthews G; Cooper DA; Kent SJ; Cameron P; Sasadeusz J; Desmond PV; Locarnini S; Dore GJ; Ruxrungtham K; Lewin S, 2009, 'Impaired Quality of the Hepatitis B Virus (HBV)-Specific T-Cell Response in Human Immunodeficiency Virus Type 1-HBV Coinfection', Journal of Virology, 83, pp. 7649 - 7658
    Journal articles | 2009
    Crane M; Oliver B; Matthews G; Avihingsanon A; Ubolyam S; Markovska V; Chang JJ; Dore GJ; Price P; Visvanathan K; French MA; Ruxrungtham K; Lewin S, 2009, 'Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy', Journal of Infectious Diseases, 199, pp. 974 - 981
    Journal articles | 2009
    Doab A; Topp L; Day C; Dore G; Maher L, 2009, 'Clinical trial literacy among injecting drug users in Sydney, Australia: A pilot study', Contemporary Clinical Trials, 30, pp. 431 - 435
    Journal articles | 2009
    Gidding H; Topp L; Middleton M; Robinson K; Hellard M; McCaughan G; Maher L; Kaldor J; Dore G; Law M, 2009, 'The epidemiology of hepatitis C in Australia: Notifications, treatment uptake and liver transplantations, 1997-2006', Journal of Gastroenterology and Hepatology, 24, pp. 1648 - 1654,
    Journal articles | 2009
    Grebely J; Knight E; Ngai T; Genoway KA; Raffa JD; Storms M; Gallagher L; Krajden M; Dore GJ; Duncan F; Conway B, 2009, 'Reinfection with hepatitis C virus following sustained virological response in injection drug users', Journal of Gastroenterology and Hepatology, pp. no - no,
    Journal articles | 2009
    Grebely J; Thomas D; Dore GJ, 2009, 'HCV reinfection studies and the door to vaccine development', Journal of Hepatology, 51, pp. 628 - 631
    Journal articles | 2009
    Haber P; Hellard M; Matthews GV; Grebely J; Petoumenos K; Yeung B; Marks P; Van Beek I; Kaldor J; Dore GJ, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', DRUG AND ALCOHOL REVIEW, 28, pp. A27 - A27,
    Journal articles | 2009
    Haber P; Hellard M; Matthews GV; Grebely J; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan G; White PA; Ffrench R; Rawlinson W; Lloyd A; Kaldor J; Dore GJ, 2009, 'Treatment of recent hepatitis C virus infection in a predominantly injection drug user cohort: the ATAHC Study', The Canadian Journal of Addiction, 1, pp. 33 - 33,
    Journal articles | 2009
    Lewin S; Ribiero R; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini S; Ruxrungtham K; Perelson AS; Dore GJ, 2009, 'Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy', Hepatology, 49, pp. 1113 - 1121
    Journal articles | 2009
    Matthews G; Dore GJ, 2009, 'HIV and hepatitis C co-infection', Asian Biomedicine, 3, pp. 29 - 37
    Journal articles | 2009
    Matthews G; Hellard M; Dore GJ, 2009, 'Initial Presentation of Acute Hepatitis C Virus (HCV) Infection among HIV-Negative and HIV-Positive Individuals-Experience from 2 Large German Networks on the Study of Acute HCV Infection Reply', Clinical Infectious Diseases, 49, pp. 319 - 319,
    Journal articles | 2009
    Matthews G; Hellard M; Haber P; Yeung B; Marks PB; Baker D; McCaughan G; Sasadeusz J; White PA; Rawlinson WD; Lloyd AR; Kaldor JM; Dore GJ; Dolan K, 2009, 'Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in acute hepatitis C', Clinical Infectious Diseases, 48, pp. 650 - 658,
    Journal articles | 2009
    Matthews G; Seaberg E; Dore GJ; Bowden S; Lewin S; Sasadeusz J; Marks P; Goodman Z; Philp F; Tang Y; Locarnini S; Thio C, 2009, 'Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals', AIDS, 23, pp. 1707 - 1715,
    Journal articles | 2009
    Matthews GV; Hellard M; Dore GJ, 2009, 'Reply', Clinical Infectious Diseases, 49, pp. 319,
    Journal articles | 2009
    Nguyen VT; Amin J; Law MG; Dore GJ, 2009, 'Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales, Australia', Journal of Gastroenterology and Hepatology, 24, pp. 436 - 442,
    Journal articles | 2009
    Nguyen VT; Law MG; Dore GJ, 2009, 'Hepatitis B-related hepatocellular carcinoma: Epidemiological characteristics and disease burden', Journal of Viral Hepatitis, 16, pp. 453 - 463,
    Journal articles | 2009
    Razali K; Amin J; Dore GJ; Law MG, 2009, 'Modelling and calibration of the hepatitis C epidemic in Australia', Statistical Methods in Medical Research, 18, pp. 253 - 270
    Journal articles | 2009
    Roberts S; Weltman M; Crawford D; Mccaughan GW; Sievert W; Cheng W; Rawlinson WD; Desmond PV; Marks P; Yoshihara M; Rizkalla B; DePamphilis J; Dore GJ, 2009, 'Impact of High-Dose Peginterferon Alfa-2A on Virological Response Rates in Patients with Hepatitis C Genotype 1: a Randomized Controlled Trial', Hepatology, 50, pp. 1045 - 1055
    Journal articles | 2009
    Robotin M; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy MT; Penman A, 2009, 'Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer', Journal of Hepatology, 50, pp. 990 - 998,
    Journal articles | 2009
    Suppiah V; Moldovan M; Ahlenstiel G; Berg T; Weltman M; Abate M; Bassendine M; Spengler U; Dore GJ; Powell E; Riordan SM; Sheridan D; Smedile A; Fragomeli V; Muller T; Bahlo M; Stewart GJ; Booth D; George J, 2009, 'IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy', Nature Genetics, 41, pp. 1100 - 1104,
    Journal articles | 2009
    Thein H; Dore GJ, 2009, 'Trends in chronic viral hepatitis: Notifications, treatment uptake and advanced disease burden', Cancer Forum, 33, pp. 97 - 105
    Journal articles | 2009
    Topp L; Day C; Dore G; Maher L, 2009, 'Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: A review', Drug and Alcohol Review, 28, pp. 669 - 675,
    Journal articles | 2009
    van de Laar T; Pybus O; Bruisten S; Brown D; Nelson M; Bhagani S; Vogel M; Baumgarten A; Chaix M; Fisher M; Gotz H; Matthews G; Neifer S; White PA; Rawlinson W; Pol S; Rockstroh J; Coutinho RA; Dore GJ; Dusheiko GM; Danta M, 2009, 'Evidence of a Large, International Network of HCV Transmission in HIV-Positive Men Who Have Sex With Men', Gastroenterology, 136, pp. 1609 - 1617,
    Journal articles | 2008
    Crawford DHG; Roberts S; Weltman M; Cheng WSC; Sievert W; McCaughan G; Desmond P; Alston AW; DePamphilis J; Marks P; Dore GJ, 2008, '779 BASELINE FACTORS ASSOCIATED WITH RAPID AND EARLY VIROLOGICAL RESPONSES IN HCV GENOTYPE 1 PATIENTS TREATED WITH INDUCTION DOSING OF PEGYLATED INTERFERON: THE CHARIOT STUDY', Journal of Hepatology, 48, pp. S290 - S291,
    Journal articles | 2008
    Day C; White B; Thein H; Doab A; Dore G; Bates A; Holden J; Maher L, 2008, 'Experience of hepatitis C testing among injecting drug users in Sydney, Australia', AIDS Care - Psychological and Socio - Medical Aspects of AIDS/HIV, 20, pp. 116 - 123,
    Journal articles | 2008
    Dore GJ; Haber P, 2008, 'Tell me it ain驴t so: Patient-to-patient transmission of hepatitis C in an endoscopy clinic.', Hepatology, 48, pp. 1333 - 1335
    Journal articles | 2008
    Dor茅 G; Leclerc C; Lazarini F, 2008, 'Treatment by CpG or Flt3-ligand does not affect mouse susceptibility to BSE prions', Journal of Neuroimmunology, 197, pp. 74 - 80,
    Journal articles | 2008
    Grebely J; Raffa JD; Lai C; Kerr T; Krajden M; Kerr T; Dore GJ; Tyndall MW, 2008, 'Impact of HCV and HIV infections on mortality in a large community-based cohort of inner city residents', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 23, pp. A379 - A380,
    Journal articles | 2008
    Jin F; Prestage GP; Dore GJ; Zablotska I; Rawstorne P; Kippax SC; Kaldor JM; Grulich AE, 2008, 'PREVALENCE, INCIDENCE AND RISK FACTORS FOR HEPATITIS C IN HIV NEGATIVE AND HIV POSITIVE HOMOSEXUAL MEN', SEXUAL HEALTH, 5, pp. 389 - 389,
    Journal articles | 2008
    Matthews G; Avihingsanon A; Lewin S; Amin J; Rerknimitr R; Petcharapirat P; Marks PB; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ, 2008, 'A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand', Hepatology, 48, pp. 1062 - 1069
    Journal articles | 2008
    Matthews G; Dore GJ, 2008, 'HIV and hepatitis C coinfection', Journal of Gastroenterology and Hepatology, 23, pp. 1000 - 1008
    Journal articles | 2008
    Matthews G; Grebely J; Dore GJ, 2008, 'The role of re-infection in determining rates of spontaneous clearance after hepatitis C exposure', Journal of Hepatology, 49, pp. 305 - 307,
    Journal articles | 2008
    Nguyen VT; Law MG; Dore GJ, 2008, 'An enormous hepatitis B virus-related liver disease burden projected in Vietnam by 2025', Liver International, 28, pp. 525 - 531,
    Journal articles | 2008
    Nguyen VT; Razali K; Amin J; Law MG; Dore GJ, 2008, 'Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia-Pacific countries', Journal of Gastroenterology and Hepatology, 23, pp. 922 - 929,
    Journal articles | 2008
    Preiss S; Littlejohn M; Angus PA; Thompson A; Desmond PV; Lewin S; Sasadeusz J; Matthews G; Dore GJ; Shaw T; Sozzi V; Yuen L; Lau GT; Ayres A; Thio C; Avihingsanon A; Ruxrungtham K; Locarnini S; Revill P, 2008, 'Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance', Hepatology, 48, pp. 741 - 749
    Journal articles | 2008
    Roberts S; Cooksley G; Dore GJ; Robson RA; Shaw DW; Berns H; Hill G; Klumpp K; Najera I; Washington C, 2008, 'Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C', Hepatology, 48, pp. 398 - 406,
    Journal articles | 2008
    Tedaldi E; Peters L; Neuhaus J; Puoti M; Rockstroh J; Klein M; Dore GJ; Mocroft A; Soriano V; Clotet B; Lundgren JD, 2008, 'Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study', Clinical Infectious Diseases, 47, pp. 1468 - 1475
    Journal articles | 2008
    Thein H; Yi Q; Dore GJ; Krahn M, 2008, 'Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression', Hepatology, 48, pp. 418 - 431,
    Journal articles | 2008
    Thein H; Yi Q; Dore GJ; Krahn M, 2008, 'Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis', AIDS, 22, pp. 1979 - 1991
    Journal articles | 2007
    Amin J; Law MG; Micallef JM; Jauncey ME; Van Beek IA; Kaldor JM; Dore GJ, 2007, 'Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users', Epidemiology and Infection, 135, pp. 144 - 150
    Journal articles | 2007
    Amin J; O Connell DL; Bartlett M; Tracey E; Kaldor JM; Law MG; Dore GJ, 2007, 'Liver cancer and hepatitis B and C in New South Wales, 1990-2002: a linkage study', Australian and New Zealand Journal of Public Health, 31, pp. 475 - 482
    Journal articles | 2007
    Butler TG; Boonwaat L; Hailstone S; Falconer T; Lems P; Ginley T; Read V; Smith N; Levy MH; Dore GJ; Kaldor JM, 2007, 'The 2004 Australian prison entrants` blood-borne virus and risk behaviour survey', Australian and New Zealand Journal of Public Health, 31, pp. 44 - 50
    Journal articles | 2007
    Dore GJ; Hellard M; Matthews G; Haber PS; Shaw D; Yeung B; Petoumenos K; Van Beek IA; Mccaughan GW; Pan Y; Ffrench R; Rowlinson W; Lloyd AR; Kaldor JM, 2007, 'Treatment of recently acquired hepatitis C infection in injecting drug users: Preliminary results from the Australian trial in acute hepatitis C (ATAHC)', Hepatology, 46, pp. 358A - 358A
    Journal articles | 2007
    Dore GJ; Micallef JM, 2007, 'Low incidence of HCV reinfection: Exposure, testing frequency, or protective immunity?', Hepatology, 45, pp. 1330 - 1330
    Journal articles | 2007
    Dore GJ; Torriani F; Rodriguez-Torres M; Brau N; Sulkowski M; Sola Lamoglia R; Clumeck N; Mendes-Correa M; Nelson M; Godofsky E; Dieterich D; Yetzer E; Lissen E; Cooper DA, 2007, 'Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection', AIDS, 21, pp. 1555 - 1559
    Journal articles | 2007
    Dore GJ, 2007, 'Enhancing hepatitis C treatment uptake and outcomes for injection drug users', Hepatology, 45, pp. 3 - 5
    Journal articles | 2007
    Hallinan R; Byrne AP; Agho K; Dore GJ, 2007, 'Referral for chronic hepatitis C treatment from a drug dependency treatment setting', Drug and Alcohol Dependence, 88, pp. 49 - 53
    Journal articles | 2007
    Hallinan R; Byrne AP; Dore GJ, 2007, 'Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction', Drug and Alcohol Review, 26, pp. 437 - 443
    Journal articles | 2007
    Macdonald V; Dore GJ; Amin J; Van Beek IA, 2007, 'Predictors of completion of a hepatitis Bvaccination schedule in attendees at a primary health care centre.', Sexual Health, 4, pp. 27 - 30
    Journal articles | 2007
    Matthews G; Cooper DA; Dore GJ, 2007, 'Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir', Antiviral Therapy, 12, pp. 119 - 122
    Journal articles | 2007
    Matthews G; Dore GJ, 2007, 'Response to Schmutz et al., `Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapv of hepatitis B in HIV-coinfection`', AIDS, 21, pp. 777 - 778
    Journal articles | 2007
    Matthews G; Hellard M; Kaldor JM; Lloyd AR; Dore GJ, 2007, 'Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al', AIDS, 21, pp. 2112 - 2113,
    Journal articles | 2007
    Matthews GV; Seaberg E; Dore GJ; Lewin SR; Bowden S; Sasadeuz J; Marks P; Hoy J; Locarnini S; Thio CL, 2007, 'Combination of HBV-active antiretroviral therapy influences hbv virological suppression in an international cohort of 120 HIVHBV coinfected individuals', JOURNAL OF HEPATOLOGY, 46, pp. S194 - S194,
    Journal articles | 2007
    Micallef JM; Macdonald V; Jauncey ME; Amin J; Rawlinson WD; Van Beek IA; Kaldor JM; White PA; Dore GJ, 2007, 'High Incidence of hepatitis C virus reinfection within a cohort of injecting drug users', Journal of Viral Hepatitis, 14, pp. 413 - 418
    Journal articles | 2007
    Nguyen O; Dore GJ; Kaldor JM; Hellard M; Dolan K, 2007, 'Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: Insights from the ATAHC study', International Journal of Drug Policy, 18, pp. 447 - 451,
    Journal articles | 2007
    Nguyen VT; McLaws M; Dore GJ, 2007, 'Highly endemic hepatitis B infection in rural Vietnam', Journal of Gastroenterology and Hepatology, 22, pp. 2093 - 2100
    Journal articles | 2007
    Nguyen VT; McLaws M; Dore GJ, 2007, 'Prevalence and risk factors for hepatitis C infection in rural north Vietnam.', Hepatol Int, 1, pp. 387 - 393
    Journal articles | 2007
    Razali K; Thein H; Bell J; Cooper-Stanbury M; Dolan K; Dore G; George J; Kaldor J; Karvelas M; Li J; Maher L; McGregor S; Hellard M; Poeder F; Quaine J; Stewart K; Tyrrell H; Weltman M; Westcott O; Wodak A; Law M, 2007, 'Modelling the hepatitis C virus epidemic in Australia', Drug and Alcohol Dependence, 91, pp. 228 - 235,
    Journal articles | 2007
    Revill P; Littlejohn M; Ayres A; Yuen L; Colledge D; Bartholomeusz A; Sasaduesz J; Lewin S; Dore GJ; Matthews G; Thio C; Locarnini S, 2007, 'Identification of a novel hepatitis B virus precore/core deletion mutant in HIV-1/hepatitis B virus co-infected individuals.', AIDS, 21, pp. 1701 - 1710
    Journal articles | 2007
    Thein H; Maruff P; Krahn M; Kaldor JM; Koorey D; Brew BJ; Dore GJ, 2007, 'Cognitive function, mood and health-related quality of life in hepatitis C virus (HCV)-monoinfected and HIV/HCV-coinfected individuals commencing HCV treatment', HIV Medicine, 8, pp. 192 - 202
    Journal articles | 2007
    Thein H; Maruff P; Krahn M; Kaldor JM; Koorey D; Brew BJ; Dore GJ, 2007, 'Improved cognitive function as a consequence of hepatitis C virus treatment', HIV Medicine, 8, pp. 520 - 528
    Journal articles | 2007
    Thein H; Yi Q; Dore GJ; Krahn M, 2007, 'Natural history of hepatitis C virus infection in HIV-infected individuals in the era of HAART: Systematic review and meta-analysis', Hepatology, 46, pp. 840A - 841A
    Journal articles | 2007
    Zhou J; Dore GJ; Zhang F; Lim P; Chen Y, 2007, 'Hepatitis B and C virus coinfection in the TREAT asia HIV observational database', Journal of Gastroenterology and Hepatology, 22, pp. 1510 - 1518
    Journal articles | 2006
    Amin J; Dore GJ; O Connell DL; Bartlett M; Tracey E; Kaldor JM; Law MG, 2006, 'Cancer incidence in people with hepatitis B or C infection: A large community-based linkage study', Journal of Hepatology, 45, pp. 197 - 203
    Journal articles | 2006
    Amin J; Law MG; Bartlett M; Kaldor JM; Dore GJ, 2006, 'Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study', Lancet, 368, pp. 938 - 945
    Journal articles | 2006
    Amin J; Law MG; Dore G, 2006, 'Mortality in patients with hepatitis B or hepatitis C - Authors' reply', Lancet, 368, pp. 1767,
    Journal articles | 2006
    Dore GJ; Cooper DA, 2006, 'HAART`s first decade: success brings further challenges', Lancet, 368, pp. 427 - 428
    Journal articles | 2006
    Dore GJ; Guan R; Jafri SM; Sarin S; Keeffe E, 2006, 'Management of chronic hepatitis B in challenging patient populations.', Liver International, 26, pp. 38 - 46
    Journal articles | 2006
    Matthews G; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio C, 2006, 'Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy', AIDS, 20, pp. 863 - 870
    Journal articles | 2006
    Micallef JM; Kaldor JM; Dore GJ, 2006, 'Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies', Journal of Viral Hepatitis, 13, pp. 34 - 41
    Journal articles | 2006
    Roberts S; Cooksley G; Dore GJ; Robson RA; Shaw DW; Berns H; Brandl M; Fettner S; Hill G; Ipe D; Klumpp K; Mannino M; O Mara E; Tu Y; Washington C, 2006, 'Results of a phase 1B, multiple dose study of R1626, a novel nucleoside analog targeting HCV polymerase in chronic HCV genotype 1 patients', Hepatology, 44, pp. 692A - 692A,
    Journal articles | 2006
    Smith BJ; Bauman A; Loveday S; Costello M; Mackie B; Dore GJ; Chen J, 2006, 'Hepatitis C in Australia: impact of a mass media campaign', American Journal of Preventive Medicine, 31, pp. 492 - 498,
    Journal articles | 2006
    Thein H; Butler T; Krahn M; Rawlinson WD; Levy M; Kaldor JM; Dore GJ; Butler , 2006, 'The effect of hepatitis C virus infection on health-related quality of life in prisoners', Journal of Urban Health - Bulletin of the New York Academy of Medicine, 83, pp. 275 - 288
    Journal articles | 2005
    Amin J; Law MG; O Connell DL; Bartlett M; Tracey E; Kaldor JM; Dore GJ, 2005, 'Cancer incidence in people with hepatitis B or C infection: A population based cohort study', Journal of Hepatology, 42, pp. 88 - 88,
    Journal articles | 2005
    Doab AE; Treloar C; Dore GJ, 2005, 'Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia', Clinical Infectious Diseases, 40, pp. S313 - S320
    Journal articles | 2005
    Dore GJ; Thomas DL, 2005, 'Management and treatment of injection drug users with hepatitis C virus(HCV) infection and HCV/human immunodeficiency virus coinfection', Seminars in Liver Disease, 25, pp. 18 - 32
    Journal articles | 2005
    Duncombe CJ; Kerr SJ; Ruxrungtham K; Dore GJ; Law MG; Emery S; Lange J; Phanuphak P; Cooper DA, 2005, 'HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting', AIDS, 19, pp. 169 - 178
    Journal articles | 2005
    Hallinan R; Byrne A; Amin J; Dore GJ, 2005, 'Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy', Journal of Gastroenterology and Hepatology, 20, pp. 1082 - 1086
    Journal articles | 2005
    Jin F; Prestage G; Kippax SC; Kaldor JM; Dore GJ; Grulich AE, 2005, 'Prevalence and risk factors of hepatitis C in HIV-negative homosexual men in Sydney, Australia', Australian and New Zealand Journal of Public Health, 29, pp. 536 - 539
    Journal articles | 2005
    Matthews G; Kronborg I; Dore GJ, 2005, 'Treatment for hepatitis C virus infection among current injection drug users in Australia', Clinical Infectious Diseases, 40, pp. S325 - S329
    Journal articles | 2005
    Stoove M; Gifford S; Dore GJ, 2005, 'The impact of injecting drug use status on hepatitis C-related referral and treatment', Drug and Alcohol Dependence, 77, pp. 81 - 86,
    Journal articles | 2005
    Thein H; Krahn M; Kaldor JM; Dore GJ, 2005, 'Estimation of utilities for chronic hepatitis C from SF-36 scores', American Journal of Gastroenterology, 100, pp. 643 - 651
    Journal articles | 2004
    Amin J; Gidding HF; Gilbert GL; Backhouse J; Kaldor JM; Dore GJ; Burgess MA, 2004, 'Hepatitis C prevalence - a nationwide serosurvey', Annual report of the Australian Meningococcal Surveillance Programme, 2007--Amended, 28, pp. 517 - 521
    Journal articles | 2004
    Amin J; Kaye M; Skidmore S; Pillay D; Cooper DA; Dore GJ, 2004, 'HIV and hepatitis C coinfection within the CAESAR study', HIV Medicine, 5, pp. 174 - 179
    Journal articles | 2004
    Dore GJ; Cooper DA; Pozniak A; DeJesus E; Zhong L; Miller MD; Lu B; Cheng A, 2004, 'Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus', Journal of Infectious Diseases, 189, pp. 1185 - 1192
    Journal articles | 2004
    Dore GJ, 2004, 'Editorial comment: Triple infection with HIV and hepatitis B and C viruses - Lesson in combination therapy', AIDS Reader, 14, pp. 392
    Journal articles | 2004
    Hallinan R; Amin J; Dore GJ, 2004, 'Hepatitis C virus incidence among injecting drug users on opioid replacement therapy', Australian and New Zealand Journal of Public Health, 28, pp. 576 - 578
    Journal articles | 2004
    Hutin Y; Kitler M; Dore GJ; Perz J; Armstrong G; Dusheiko G; Ishibashi H; Grob P; Kew M; Marcellin P; Seeff L; Beutels P; Nelson CJ; Stein C; Zurn P; Clifford G; Vranckx R; Alberti A; Hallaj Z; Hadler S; Lavanchy D, 2004, 'Global burden of disease (GBD) for hepatitis C', Journal of Clinical Pharmacology, 44, pp. 20 - 29
    Journal articles | 2004
    Jauncey ME; Micallef JM; Gilmour S; Amin J; White PA; Rawlinson WD; Kaldor JM; Van Beek IA; Dore GJ, 2004, 'Clearance of hepatitis C virus after newly acquired infection ininjection drug users', Journal of Infectious Diseases, 190, pp. 1270 - 1274
    Journal articles | 2004
    Law WP; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA; Dore GJ, 2004, 'Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort', AIDS, 18, pp. 1169 - 1177
    Journal articles | 2004
    O Sullivan BG; Gidding H; Law MG; Kaldor JM; Gilbert GL; Dore GJ, 2004, 'Estimates of chronic hepatitis B virus infection in Australia, 2000', Australian and New Zealand Journal of Public Health, 28, pp. 212 - 216
    Journal articles | 2004
    O'Sullivan BG; Gidding HF; Law M; Kaldor JM; Gilbert GL; Dore GJ, 2004, 'Estimates of chronic hepatitis B virus infection in Australia, 2000', Australian and New Zealand Journal of Public Health, 28, pp. 212 - 216,
    Journal articles | 2004
    Qasabian R; Meagher AP; Lee RW; Dore GJ; Keogh AM, 2004, 'Severe diverticulitis after heart, lung, and heart-lung transplantation', Journal of Heart and Lung Transplantation, 23, pp. 845 - 849
    Journal articles | 2004
    Rerksuppaphol S; Hardikar W; Dore GJ, 2004, 'Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children', Journal of Gastroenterology and Hepatology, 19, pp. 1357 - 1362
    Journal articles | 2004
    Robotin M; Copland J; Tallis G; Coleman D; Giele C; Carter L; Spencer J; Kaldor JM; Dore GJ, 2004, 'Surveillance for newly acquired hepatitis C in Australia', Journal of Gastroenterology and Hepatology, 19, pp. 283 - 288
    Journal articles | 2003
    Bernstein D; Dore GJ; Thein HH; Salomon JA; Goldie SJ, 2003, 'Cost-effectiveness of Treatment for Chronic Hepatitis C Infection [2] (multiple letters)', JAMA, 290, pp. 1993 - 1994,
    Journal articles | 2003
    Dore G, 2003, 'Antiretroviral therapy-related hepatotoxicity: predictors and clinical management.', Journal of HIV therapy, 8, pp. 96 - 100
    Journal articles | 2003
    Dore GJ; Freeman A; Law MG; Kaldor JM, 2003, 'Natural history models for hepatitis C-related liver disease: different disease progression parameters for different settings', Antiviral Therapy, 8, pp. 365 - 372
    Journal articles | 2003
    Dore GJ; Law MG; MacDonald MA; Kaldor JM, 2003, 'Epidemiology of hepatitis C virus infection in Australia', Journal of Clinical Virology, 26, pp. 171 - 184
    Journal articles | 2003
    Dore GJ; MacDonald M; Law MG; Kaldor JM, 2003, 'Epidemiology of hepatitis C virus infection in Australia.', Australian family physician, 32, pp. 796 - 798
    Journal articles | 2003
    Dore GJ; McDonald AM; Li Y; Kaldor JM; Brew BJ, 2003, 'Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy', AIDS, 17, pp. 1539 - 1545
    Journal articles | 2003
    Dore GJ; Thein HH, 2003, 'Cost-effectiveness of treatment for chronic hepatitis C infection', JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 290, pp. 1993 - 1993,
    Journal articles | 2003
    Dore GJ, 2003, 'Clinical management of HIV/viral Hepatitis coinfection', Journal of Clinical Virology, 28, pp. S43 - S43,
    Journal articles | 2003
    Dore GJ, 2003, 'Cost-effectiveness of treatment for chronic hepatitis C infection', Journal of the American Medical Association, 290, pp. 1933 - 1934
    Journal articles | 2003
    Freeman A; Law MG; Kaldor JM; Dore GJ, 2003, 'Predicting progression to cirrhosis in chronic hepatitis C virus infection', Journal of Viral Hepatitis, 10, pp. 285 - 293
    Journal articles | 2003
    Hellard M; Hocking J; Willis JE; Dore GJ; Fairley CK, 2003, 'Risk factors leading to Cryptosporidium infection in men who have sex with men', Sexually Transmitted Infections, 79, pp. 412 - 414
    Journal articles | 2003
    Hiransuthikul N; Hanvanich M; Dore GJ; Mokkhawes T; Li Y; Perriens J; Kaldor JM, 2003, 'Factors associated with tuberculin skin test reactivity among HIV-infected people in Bangkok', Southeast Asian Journal of Tropical Medicine and Public Health, 34, pp. 804 - 809
    Journal articles | 2003
    Law MG; Dore GJ; Bath N; Thompson S; Crofts N; Dolan K; Giles W; Gow P; Kaldor JM; Loveday S; Powell E; Spencer J; Wodak AD, 2003, 'Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001', International Journal of Epidemiology, 32, pp. 717 - 724
    Journal articles | 2003
    Law WP; Dore GJ; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA, 2003, 'Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001', AIDS, 17, pp. 2191 - 2199
    Journal articles | 2003
    Lincoln DW; Petoumenos K; Dore GJ, 2003, 'HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy', HIV Medicine, 4, pp. 241 - 249
    Journal articles | 2003
    MICALLEF J; JAUNCEY M; AMIN J; RAWLINSON W; GILMOUR S; VANBEEK I; KALDOR J; WHITE P; DORE G, 2003, '229 Hepatitis C virus reinfection within a cohort of injecting drug users', Hepatology, 38, pp. 266 - 266,
    Journal articles | 2003
    MacDonald MA; Law MG; Kaldor JM; Hales J; Dore GJ, 2003, 'Effectiveness of needle and syringe programmes for preventing HIV transmission', International Journal of Drug Policy, 14, pp. 353 - 357
    Journal articles | 2003
    Matthews G; Dore G, 2003, 'Response to Soriano et al., 'Treatment of chronic hepatitis C virus infection: We must target the virus or liver fibrosis?' [3]', AIDS, 17, pp. 2675 - 2676
    Journal articles | 2003
    Matthews G; Dore GJ, 2003, 'Treatment of chronic hepatitis c virus infection: we must target the virus or liver fibrosis (letter)?', AIDS, 17, pp. 2675 - 2676
    Journal articles | 2003
    McDonald AM; Li Y; Dore GJ; Ree H; Kaldor JM, 2003, 'Late HIV presentation among AIDS cases in Australia, 1992-2001', Australian and New Zealand Journal of Public Health, 27, pp. 608 - 613
    Journal articles | 2003
    Spencer J; Tibbits D; Tippet C; Mead C; Kaldor JM; Dore GJ, 2003, 'Review of antenatal testing policies and pratice for HIV and hepatitis C infection', Australian and New Zealand Journal of Public Health, 27, pp. 614 - 619
    Journal articles | 2003
    Thein H; Denoe M; Van Beek IA; Dore GJ; MacDonald MA, 2003, 'Injecting behaviour of injecting drug users at needle and syringe programs and pharmacies in Australia', International Journal of Drug Policy, 14, pp. 425 - 430
    Journal articles | 2003
    Thein H; Haber P; Dore GJ, 2003, 'Quality of life among women with hepatitis C (editorial)', Journal of Gastroenterology and Hepatology, 18, pp. 1329 - 1331
    Journal articles | 2003
    Thein HH; Haber PS; Dore GJ, 2003, 'Quality of life of women living with hepatitis C', Journal of Gastroenterology and Hepatology (Australia), 18, pp. 1329 - 1331,
    Journal articles | 2003
    Thompson S; Boughton CR; Dore GJ, 2003, 'Blood-borne viruses and their survival in the environment: is publicconcern about community needlestick exposures justified?', Australian and New Zealand Journal of Public Health, 27, pp. 602 - 607
    Journal articles | 2003
    Thompson S; Boughton CR; Dore GJ, 2003, 'The Viral Hepatitis Prevention Board (Australia). Blood-borne viruses and their survival in the environment: Is public concern about community needlestick exposures justified?', Australian and New Zealand Journal of Public Health, 27, pp. 602 - 607
    Journal articles | 2002
    Danta M; Dore GJ; Hennessy L; Li Y; Vickers CR; Harley H; Ngu M; Reed W; Desmond PV; Sievert W; Farrell G; Kaldor JM; Batey RG, 2002, 'Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection', Medical Journal of Australia, 177, pp. 240 - 245
    Journal articles | 2002
    Dore GJ; Freeman A; Kaldor JM, 2002, '. Immunity against hepatitis C virus infection', Lancet, 360, pp. 1019 - 1020
    Journal articles | 2002
    Dore GJ; Freeman A; Law MG; Kaldor JM, 2002, 'Is severe liver disease a common outcome for people with chronic hepatitis C?', Journal of Gastroenterology and Hepatology, 17, pp. 423 - 430
    Journal articles | 2002
    Dore GJ; Freeman AJ; Kaldor JM; Post JJ; Harvey CE; Ffrench RA; Lloyd AR; Mehta SH; Cox AL; Strathdee SA; Vlahov D; Thomas DL, 2002, 'Immunity against hepatitis C virus infection [2] (multiple letters)', Lancet, 360, pp. 1019 - 1020,
    Journal articles | 2002
    Dore GJ; Li Y; McDonald AM; Ree H; Kaldor JM, 2002, 'Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 29, pp. 388 - 395
    Journal articles | 2002
    McDonald AM; Dore GJ; Grulich AE; Law MG; Prestage G; Smith DE, 2002, 'Epidemiological and social research finds at the 14th International AIDS Conference', Australian HIV Surveillance Report, 18, pp. 1 - 8
    Journal articles | 2002
    Pett SL; Dore GJ; Fielden R; Cooper DA, 2002, 'Cyclical hepatitis and early liver cirrhosis after hepatitis C seroconversion during pulsed antiretroviral therapy for primary HIV-1', AIDS, 16, pp. 2364 - 2365
    Journal articles | 2002
    Spencer J; Dore GJ; Robotin M; Correll PK; Kaldor JM, 2002, 'Outcomes from the first two years of the Australian Hepatitis surveillance strategy', Annual report of the Australian Meningococcal Surveillance Programme, 2007--Amended, 26, pp. 14 - 22
    Journal articles | 2002
    Talawat S; Dore GJ; Le Coeur S; Lallemant M, 2002, 'Infant feeding practices and attitudes among women with HIV infection in northern Thailand', AIDS Care - Psychological and Socio - Medical Aspects of AIDS/HIV, 14, pp. 625 - 631
    Journal articles | 2001
    Dore GJ; Cooper DA, 2001, 'Bridging the divide: Global inequities in access to HIV/AIDS therapy', Medical Journal of Australia, 175, pp. 570 - 572,
    Journal articles | 2001
    Dore GJ; Cooper DA, 2001, 'The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses', Current Opinion in Infectious Diseases, 14, pp. 749 - 755
    Journal articles | 2001
    Dore GJ; Li Y; McDonald AM; Kaldor JM, 2001, 'Spectrum of AIDS-defining illnesses in Australia, 1992 to 1998: Influence of country/region of birth', JAIDS: Journal of Acquired Immune Deficiency Syndromes, pp. 283 - 290
    Journal articles | 2001
    Freeman A; Dore GJ; Law MG; Thorpe M; Von Overbeck J; Lloyd AR; Marinos G; Kaldor JM, 2001, 'Estimating progression to cirrhosis in chronic hepatitis C virus infection.', Hepatology, pp. 809 - 816
    Journal articles | 2001
    Law MG; Dore GJ; Kaldor JM, 2001, 'Projecting severe sequelae of injection-related hepatitis C virus epidemic in UK by SM Bird, DJ Goldberg and SJ Hutchinson', Journal of Epidemiology and Biostatistics, 6, pp. 279 - 281,
    Journal articles | 2000
    Brew BJ; Dore GJ, 2000, 'Decreasing incidence of CNS AIDS defining events associated with antiretroviral therapy (letter)', Neurology, 55, pp. 1424 - 1424,
    Journal articles | 2000
    Dore GJ; Brew BJ, 2000, 'Response to Eberly et al., Kaposi驴s sarcoma and central nervous system disease: a real association or an artifact of the control group? (letter)', AIDS, 14, pp. 2631 - 2632
    Journal articles | 2000
    Dore GJ; Grulich AE; Prestage G, 2000, 'Epidemiological and social research findings reported at the 13th World AIDS Conference', Australian HIV Surveillance Report, 16, pp. 1 - 6
    Journal articles | 2000
    Dore GJ; Kaldor JM; Leruez-Ville M; Rouzioux C; Chaix ML, 2000, 'Detection of HCV RNA in semen [1] (multiple letters)', Lancet, 356, pp. 1520,
    Journal articles | 2000
    Dore GJ; Kaldor JM, 2000, 'Detection of HCV RNA in semen (letter)', Lancet, pp. 1520 - 1520
    Journal articles | 2000
    Dore GJ; Kaldor JM, 2000, 'Detection of HCV RNA in semen', LANCET, 356, pp. 1520 - 1520,
    Journal articles | 2000
    Dore GJ, 2000, 'Infectious diseases in the 21st century: are we entering the hot-zone?', Australian Family Physician, pp. 627 - 630
    Journal articles | 2000
    Dore GJ, 2000, 'Sexual transmission of hepatitis C: what is the evidence?', Australian Hepatitis Chronicle, pp. 2 - 5
    Journal articles | 2000
    Freeman AJ; Dore GJ; Law MG; Thorpe M; Von Overbeck J; Lloyd AR; Marinos G; Kaldor JM, 2000, 'The natural history of chronic hepatitis C: A systematic review', HEPATOLOGY, 32, pp. 422A - 422A,
    Journal articles | 2000
    Grulich AE; Dore GJ; Brew BJ, 2000, 'Human herpesvirus 8 and protection from AIDS dementia complex', Herpes, pp. 38 - 40
    Journal articles | 2000
    Guthrie J; Dore GJ; McDonald AM; Kaldor JM; For TNHS, 2000, 'HIV and AIDS in Aboriginal and Torres Strait Islander Australians:1992-1998', Medical Journal of Australia, 172, pp. 266 - 269
    Journal articles | 2000
    Guthrie JA; Dore GJ; McDonald AM; Kaldor JM, 2000, 'HIV and AIDS in aboriginal and Torres Strait Islander Australians: 1992-1998. The National HIV Surveillance Committee.', Med J Aust, 172, pp. 266 - 269,
    Journal articles | 2000
    Kaldor JM; Dore GJ; Correll PK, 2000, 'Towards control of hepatitis C in the Asia-Pacific region 驴 Public health challenges in hepatitis C virus infection', Journal of Gastroenterology and Hepatology, 15, pp. E83 - E90
    Journal articles | 2000
    Kaldor JM; Dore GJ; Correll PKL, 2000, 'Public health challenges in hepatitis C virus infection', Journal of Gastroenterology and Hepatology (Australia), 15,
    Journal articles | 2000
    Law MG; Roberts S; Dore GJ; Kaldor JM, 2000, 'Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality', Medical Journal of Australia, 173, pp. 403 - 405
    Journal articles | 2000
    Li Y; McDonald AM; Dore GJ; Kaldor JM; For TNHS, 2000, 'Improving survival following AIDS in Australia, 1991-1996', AIDS, 14, pp. 2349 - 2354
    Journal articles | 2000
    Li Y; McDonald AM; Dore GJ; Kaldor JM, 2000, 'Improving survival following AIDS in Australia, 1991-1996. National HIV Surveillance Committee.', AIDS, 14, pp. 2349 - 2354,
    Journal articles | 2000
    Wilkinson DL; Dore GJ, 2000, 'An unbridgeable gap? Comparing the HIV/AIDS epidemics in Australia and sub-Saharan Africa', Australian and New Zealand Journal of Public Health, pp. 276 - 280
    Journal articles | 1999
    Dore GJ; Cooper DA; Barrett C; Goh L; Thakrar B; Atkins M, 1999, 'Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR)', Journal of Infectious Diseases, 180, pp. 607 - 613
    Journal articles | 1999
    Dore GJ; Correll PK; Li Y; Kaldor JM; Cooper DA; Brew BJ, 1999, 'Changes to AIDS dementia complex in the era of highly active antiretroviral therapy', AIDS, 13, pp. 1249 - 1253
    Journal articles | 1999
    Dore GJ; Law MG; Kaldor JM, 1999, 'Prevalence of hepatitis C virus infection in the United States', New England Journal of Medicine, 341, pp. 2093 - 2094 (lett
    Journal articles | 1999
    Dore GJ; Pritchard-Jones J; Fisher D; Law MG, 1999, 'Who's at risk: risk factors for HCV infection in Australia', Australian Family Physician, pp. 8 - 13
    Journal articles | 1999
    Lurie P; Wolfe SM; McNeill PM; Dore GJ, 1999, 'Should research ethics change at the border? (multiple letters) [6]', Medical Journal of Australia, 171, pp. 167 - 168,
    Journal articles | 1999
    Mcneil PM; Dore GJ, 1999, 'Should research ethics change at the border?', Medical Journal of Australia, 171, pp. 168 - (letter),
    Journal articles | 1998
    Collignon P; Dore GJ; Li Y; Plant AJ; Kaldor JM, 1998, 'Trends in infectious disease mortality rates (multiple letters) [3]', Medical Journal of Australia, 169,
    Journal articles | 1998
    Crofts JN; Dore GJ; Kaldor JM; Law MG; Wodak AD; Et A, 1998, 'Estimates and projections of the hepatitis C virus epidemic in Australia', ION Meeting Proceedings
    Journal articles | 1998
    Dore GJ; Brown TA; Tarantola D; Kaldor JM, 1998, 'HIV and AIDS in the Asia-Pacific region: an epidemiological overview', AIDS, 12, pp. S1 - S10
    Journal articles | 1998
    Dore GJ; Grulich AE; Law MG; Brew BJ; Kaldor JM, 1998, 'Kaposi驴s sarcoma and protection from AIDS dementia complex', AIDS, 12, pp. 2354 - 2355
    Journal articles | 1998
    Dore GJ; Kaldor JM; McCaughan GW, 1998, 'Polymerase chain reaction as marker of infectivity in people with hepatitis C - Summary vertical transmission rates may be misleading - Reply', BRITISH MEDICAL JOURNAL, 316, pp. 554 - 554,
    Journal articles | 1998
    Dore GJ; Kaldor JM; Mccaughan GW, 1998, 'Polymerase chain reaction as marker of infectivity in people with hepatitis C', British Medical Journal: International, pp. 553 - 554
    Journal articles | 1998
    Dore GJ; Kaldor JM, 1998, 'Sexually transmissible diseases surveillance in Australia: towards a coordinated national system', Annual report of the Australian Meningococcal Surveillance Programme, 2007--Amended, 22, pp. 49 - 52
    Journal articles | 1998
    Dore GJ; Li YW; Plant AJ; Kaldor JM, 1998, 'Trends in infectious disease mortality in Australia, 1979-1994', Medical Journal of Australia, 168, pp. 601 - 604
    Journal articles | 1998
    Dore GJ; Li YW; Plant AJ; Kaldor JM, 1998, 'Trends in infectious disease mortality rates', Medical Journal of Australia, 169, pp. 444 - 445,
    Journal articles | 1998
    Dore GJ, 1998, 'Chronic hepatitis C infection: a disease ideally suited to management in the primary care setting', Australian Family Physician, 27, pp. 791 - 793
    Journal articles | 1998
    Dore GJ, 1998, 'Report from the 4th International Conference on AIDS in Asia and the Pacific', Noah's Arc
    Journal articles | 1998
    Hira SK; Dore GJ; Sirisanthana T, 1998, 'Clinical spectrum of HIV/AIDS in the Asia-Pacific region.', AIDS (London, England), 12 Suppl B
    Journal articles | 1998
    McDonald AM; French R; Dore GJ; Hamernik E; Kippax SC; Ashton LJ, 1998, 'Epidemiological and social research findings reported at the 12th World AIDS Conference, Geneva 1998', Australian HIV Surveillance Report, 14, pp. 1 - 9
    Journal articles | 1998
    McNeill PM, 1998, 'Should research ethics change at the border?', Medical Journal of Australia, 169, pp. 509 - 510,
    Journal articles | 1998
    Thomas S; Hall A; Newell ML; Dore GJ; Kaldor JM; McCaughan GW, 1998, 'Polymerase chain reaction as marker of infectivity in people with hepatitis C (multiple letters) [5]', British Medical Journal, 316, pp. 553 - 554
    Journal articles | 1998
    Van Beek IA; Dwyer RG; Dore GJ; Luo K; Kaldor JM, 1998, 'Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study', British Medical Journal: International, pp. 433 - 437
    Journal articles | 1998
    Wettstein AR; Dore G; Murphy C; Edwards PD, 1998, 'HIV related cholangiopathy (HIVRC): Is endoscopic biliary sphincterotomy (EBS) an effective therapy?', Gastrointestinal Endoscopy, 47
    Journal articles | 1997
    Aguado JM; Pulido F; Dore GJ; Law MG; Kaldor JM; Gordin F; Matts J, 1997, 'Isoniazid prophylaxis for high-risk patients with anergy and HIV infection [4] (multiple letters)', New England Journal of Medicine, 337, pp. 1696 - 1697,
    Journal articles | 1997
    Dore GJ; Hoy JF; Mallal SS; Li YW; Mijch AM; French MA; Cooper DA; Kaldor JM, 1997, 'Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS Cohort', Journal of acquired immune deficiency syndrome and human retrovirology, 16, pp. 39 - 43
    Journal articles | 1997
    Dore GJ; Kaldor JM; Mccaughan GW, 1997, 'Systematic review of role of polymerase chain reaction in defining infectiousness among people with hepatitis C virus', British Medical Journal: Clinical Research, pp. 333 - 337
    Journal articles | 1997
    Dore GJ; Law MG; Brew BJ, 1997, 'Prospective analysis of seizures occurring in human immunodeficiency virus type-1 infection', Journal of Neuro-AIDS, 1, pp. 59 - 69,
    Journal articles | 1997
    Dore GJ; Law MG; Kaldor JM, 1997, 'A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis', New England Journal of Medicine, pp. 315 - 320
    Journal articles | 1997
    Dore GJ; Law MG; Kaldor JM, 1997, 'Isoniazid prophylaxis for high-risk patients with anergy and HIV infection.', The New England journal of medicine, 337, pp. 1697
    Journal articles | 1997
    Gray JA; Dore GJ; Li Y; Supawitkul S; Effler P; Kaldor JM, 1997, '"HIV-1 Infection among Female Commercial Sex Workers in Rural Thailand."', Studies in Family Planning, 28, pp. 168 - 168,
    Journal articles | 1997
    Gray JA; Dore GJ; Li Y; Supawitkul S; Effler P; Kaldor JM, 1997, 'HIV-1 infection among female commercial sex workers in rural Thailand', AIDS, 11, pp. 89 - 94
    Journal articles | 1996
    Couldwell D; Dore GJ; Harkness JL; Marriott D; Cooper DA; Edwards RJ; Li YW; Kaldor JM, 1996, 'Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room', AIDS, 10, pp. 521 - 525
    Journal articles | 1996
    Dore GJ; Kaldor JM; Ungchusak K; Mertens TE, 1996, 'Epidemiology of HIV and AIDS in the Asia-Pacific region', Medical Journal of Australia, 165, pp. 494 - 498,
    Journal articles | 1996
    Dore GJ; Kaldor JM; Ungchusak K; Mertens TE, 1996, 'Managing HIV .9. HIV in Asia and the Pacific - Epidemiology of HIV and AIDS in the Asia-Pacific region', MEDICAL JOURNAL OF AUSTRALIA, 165, pp. 494 - 498,
    Journal articles | 1996
    Dore GJ; Li YW; Mallal SA; Hoy JF; Mijch AM; French MA; Cooper DA; Kaldor JM; Grulich AE, 1996, 'Declining incidence and later occurrence of Kaposi`s sarcoma among people with AIDS in Australia: the Australian AIDS cohort', AIDS, 10, pp. 1401 - 1406
    Journal articles | 1996
    Law MG; Dore GJ; McDonald AM; Kaldor JM, 1996, 'The use of back-projection to estimate HIV prevalence in pregnant women', Paediatric AIDS and HIV Infection, pp. 331 - 336
    Journal articles | 1995
    Dore GJ; Marriot DJ; Duflou J, 1995, 'Clinico-pathological study of cytomegalovirus infection (CMV) is AIDS autopsies: under-recognition of CMV pneumonitis and CMV adrenalitis', Australian and New Zealand Journal of Medicine, pp. 503 - 506
    Journal articles | 1995
    Dore GJ; Marriott D; Hing MC; Harkness JL; Field AS, 1995, 'Disseminated microsporidiosis due to Septata intestinalis in nine patients infected with Human Immunodeficiency virus: Response to therapy with Albendazole', Clinical Infectious Diseases, pp. 70 - 76
  • Preprints | 2024
    Young C; Singh M; Jackson KJL; Field MA; Peters TJ; Angioletti-Uberti S; Frenkel D; Ravishankar S; Gupta M; Wang JJ; Agapiou D; Faulks ML; Al-Eryani G; Luciani F; Gordon TP; Reed JH; Danta M; Carr A; Kelleher AD; Dore GJ; Matthews G; Brink R; Bull RA; Suan D; Goodnow CC, 2024, Self-reactive B cells traverse a perfect storm of somatic mutagenesis to cause a virus-induced autoimmune disease,
    Reports | 2023
    Hajarizadeh B; Carson J; Dore G, 2023, Monitoring hepatitis C treatment uptake in Australia: Issue #13, July 2023, The Kirby Institute, 91探花, Sydney, Australia, ,
    Preprints | 2023
    Joseph Yeoh YK; Dore GJ; Lockart I; Danta M; Flynn C; Blackmore C; Levy MT; George J; Alavi M; Hajarizadeh B, 2023, Temporal change in etiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients with hepatocellular carcinoma in New South Wales, Australia,
    Preprints | 2023
    Phetsouphanh C; Jacka B; Ballouz S; Jackson KJL; Wilson D; Manandhar B; Klemm V; Tan H-X; Wheatley A; Aggarwal A; Akerman A; Milogiannakis V; Starr M; Cunningham P; Turville S; Kent S; Byrne A; Brew B; Darley D; Dore G; Kelleher A; Matthews G, 2023, Improvement of immune dysregulation and health-related quality of life in individuals with long COVID at 24-months following SARS-CoV-2 infection,
    Reports | 2023
    Wilkinson A; Griffin S; Hellard M; Stoov茅 M; Dore G; Grebely J; Pedrana A; Doyle J; Thompson A; Hajarizadeh B; Aitken C; Broady T; Combo T, 2023, Australia鈥檚 progress towards hepatitis C elimination: Annual Report 2023,
    Conference Abstracts | 2022
    Alavi M; Valerio H; Law M; Lockart I; Danta M; Grebely J; Amin J; Hajarizadeh B; George J; Dore G, 2022, 'Incidence and risk factors of hepatitis C liver morbidity and mortality in the era of direct-acting antiviral therapies: a population-based linkage study', in JOURNAL OF HEPATOLOGY, ELSEVIER, ENGLAND, London, Vol. 77, pp. S568 - S569, presented at International Liver Congress, ENGLAND, London, 22 June 2022 - 26 June 2022,
    Conference Abstracts | 2022
    Carson J; Dore G; Lloyd A; Grebely J; Byrne M; Cunningham EB; Amin J; Vickerman P; Martin N; Treloar C; Matthews G; Hajarizadeh B, 2022, 'Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study', in Journal of Hepatology, Elsevier BV, Vol. 77, pp. S565 - S565,
    Preprints | 2022
    Cysique L; Jakabek D; Bracken S; Allen-Davidian Y; Heng B; Chow S; Dehhaghi M; Pires AS; Darley D; Byrne A; Phetsouphanh C; Kelleher A; Dore G; Matthews G; Guillemin G; Brew B, 2022, Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study,
    Theses / Dissertations | 2022
    Hosseini Hooshyar S; Matthews G; Dore G; Martinello M, 2022, Hepatitis C elimination among people living with HIV,
    Conference Abstracts | 2022
    Lockart I; Hin Yeo MG; Hajarizadeh B; Dore G; Danta M, 2022, 'Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis', in Journal of Hepatology, Elsevier BV, Vol. 77, pp. S561 - S562,
    Preprints | 2022
    Phetsouphanh C; Khoo WH; Jackson K; Klemm V; Howe A; Aggarwal A; Akerman A; Milogiannakis V; Stella AO; Rouet R; Schofield P; Faulks M; Law H; Danwilai T; Starr M; Munier ML; Christ D; Singh M; Croucher P; Brilot-Turville F; Turville S; Phan TG; Dore G; Darley D; Cunningham P; Matthews G; Kelleher A; Zaunders J, 2022, High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells,
    Conference Abstracts | 2022
    Price O; Dietze PM; Maher L; Dore GJ; Crawford S; Sutherland R; Salom C; Bruno R; Lenton S; Degenhardt L; Peacock A, 2022, 'COVID-19 pandemic experiences of people in Australia who inject drugs: Analysis of illicit drug reporting system interview data 2020-2022', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 41, pp. S115 - S115
    Conference Abstracts | 2022
    Shah SHBU; Alavi M; Hajarizadeh B; Matthews G; Martinello M; Danta M; Amin J; Law M; George J; Dore G, 2022, 'Trends in decompensated cirrhosis and hepatocellular carcinoma diagnosis among people with a hepatitis B notification in New South Wales: a population-based data linkage study', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 77, pp. S302 - S302,
    Conference Abstracts | 2022
    Shah SHBU; Alavi M; Hajarizadeh B; Matthews G; Martinello M; Danta M; Amin J; Law M; George J; Innes H; Dore G, 2022, 'Liver-related mortality among people with hepatitis B and C: a validation study using linked healthcare administrative datasets', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 77, pp. S560 - S560,
    Conference Papers | 2022
    Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J, 2022, 'Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study', in International Journal of Drug Policy,
    Reports | 2022
    Wilkinson A; Hayes M; Hellard M; Stoov茅 M; Dore G; Grebely J; Pedrana A; Doyle J; Thompson A; Hajarizadeh B; Alavi M; Aitken C; Broady T; Combo T, 2022, Australia's progress towards hepatitis C elimination: annual report 2022,
    Reports | 2021
    Bajis S; Dore G; Alavi M; McGregor S; Kwon A; Monaghan R; Iversen J; Martinello M; Buckland G; Guy R; Kaldor J; Grebely J, 2021, Progress towards hepatitis C elimination among Aboriginal and Torres Strait Islander people in Australia: monitoring and evaluation report, The Kirby Institute, 91探花 Sydney, Sydney, Australia,
    Conference Papers | 2021
    Conway A; Treloar C; Crawford S; Degenhardt L; Dore GJ; Farrell M; Grebely J; Marshall AD, 2021, '"WE'VE HAD A CIRCUIT BREAKER FOR AN OLD DOGMA OF MORE THAN 20 YEARS": CHANGES TO OPIOID AGONIST TREATMENT SERVICES DURING COVID-19, THE CHOICE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S59 - S59,
    Conference Papers | 2021
    Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Amin J; Christmass M; Dunlop AJ; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Dore GJ; Treloar C; Grebely J, 2021, 'OPIOID OVERDOSE AND NALOXONE ACCESS AMONG PEOPLE WHO RECENTLY USED OPIOIDS OR RECEIVED OPIOID AGONIST TREATMENT IN AUSTRALIA: THE ETHOS ENGAGE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S59 - S60,
    Conference Abstracts | 2021
    Farrell M; Shahbazi J; Byrne M; Larance B; Lintzeris N; Nielsen S; Grebely J; Shanahan M; Lancaster K; Dore GJ; Ali R; Dunlop AJ; Rodgers C; Degenhardt L, 2021, 'AN OPEN-LABEL, MULTICENTRE, SINGLE-ARM TRIAL OF MONTHLY INJECTIONS OF EXTENDED RELEASE BUPRENORPHINE IN PEOPLE WITH OPIOID USE DISORDER: THE COLAB STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 40, pp. S71 - S72,
    Conference Abstracts | 2021
    Farrell M; Shahbazi J; Byrne M; Larance B; Lintzeris N; Nielsen S; Grebely J; Shanahan M; Lancaster K; Dore GJ; Ali R; Dunlop AJ; Rodgers C; Degenhardt L, 2021, 'OVERVIEW AND FINDINGS OF THE COLAB STUDY: AN OPEN-LABEL IMPLEMENTATION STUDY OF SUBLOCADE TREATMENT IN SPECIALIST AND PRIMARY CARE SETTINGS IN AUSTRALIA', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 40, pp. S25 - S25,
    Conference Abstracts | 2021
    He S; Alavi M; Hajarizadeh B; Grebely J; Law M; Amin J; George J; Danta M; Dore G, 2021, 'comparison of hbv-related hcc incidence between entecavir and tenofovir treated cohorts: a population-based study', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 75, pp. S515 - S516,
    Conference Abstracts | 2021
    Hosseini-Hooshyar S; Alavi M; Martinello M; Matthews G; Dore G, 2021, 'Evaluation of the HCV cascade of care among people with HIV/hepatitis C co-infection in New South Wales, Australia: a data linkage study', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, Vol. 24, pp. 19 - 19,
    Conference Abstracts | 2021
    Lazarus J; Picchio C; Byrne C; Crespo J; Colombo M; Cooke G; Dore G; Grebely J; Ward J; White T; Dillon J, 2021, 'A global systematic review of efforts to accelerate the elimination of hepatitis C virus (HCV) through micro-elimination', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 75, pp. S661 - S662,
    Conference Abstracts | 2021
    Lockart I; Yeo M; Hajarizadeh B; Dore GJ; Danta M, 2021, 'Hepatocellular carcinoma occurrence after hepatitis C virus cure among patients with advanced fibrosis or cirrhosis: A systematic review, meta-analysis, and meta-regression', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 36, pp. 40 - 41,
    Conference Posters | 2021
    Price O; Dietze P; Maher L; Dore G; Trent M; Sutherland R; Karlsson A; Uporova J; Chandrasena K; Gibbs D; Swanton R; Salom C; Lenton S; Bruno R; Degenhardt L; Farrell M; Peacock A, 2021, 'Barriers and facilitators to COVID-19 vaccination among Australians who inject drugs: how can we maximise uptake?', Sydney, presented at NDARC Annual Research Symposium, Sydney, 20 October 2021
    Conference Presentations | 2021
    Price O; Dietze P; Maher L; Dore G; Trent M; Sutherland R; Karlsson A; Uporova J; Chandrasena K; Gibbs D; Swanton R; Salom C; Lenton S; Bruno R; Degenhardt L; Farrell M; Peacock A, 2021, 'COVID-19 vaccine hesitancy among Australians who use drugs', presented at APSAD conference, Virtual, 07 November 2021
    Conference Abstracts | 2021
    Price O; Dietze PM; Maher L; Dore GJ; Trent M; Sutherland R; Karlsson A; Uporova J; Chandrasena U; Gibbs D; Swanton R; Salom C; Lenton S; Bruno R; Degenhardt L; Farrell M; Peacock A, 2021, 'COVID-19 VACCINE HESITANCY AMONG AUSTRALIANS WHO USE DRUGS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 40, pp. S120 - S120
    Conference Papers | 2020
    Casey J; MacParland S; Zahoor A; Janssen HLA; Matthews G; Marks P; Grebely J; Dore G; Hansen BE; Kaul R; Chua C; Gehring AJ; Feld JJ, 2020, 'RESTORATION OF HCV-SPECIFIC T CELLS FOLLOWING DAA THERAPY IN ACUTE HCV INFECTION-SUPPORT FOR TREATMENT OF ACUTE INFECTION.', in HEPATOLOGY, WILEY, ELECTR NETWORK, pp. 613A - 614A, presented at Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 November 2020 - 16 November 2020,
    Conference Abstracts | 2020
    Kwon JA; Dore G; Hajarizadeh B; Guy R; Gray RT, 2020, 'Evidence of declining HCV transmission in Australia following scale-up of direct acting antiviral therapy', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 73, pp. S606 - S606,
    Conference Abstracts | 2020
    Lockart I; Hajarizadeh B; Alavi M; Davison S; Prakoso E; Levy MT; George J; Dore GJ; Danta M, 2020, 'Sustained virological response before hepatitis C-related hepatocellular carcinoma diagnosis is associated with improved survival', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 35, pp. 53 - 54
    Conference Papers | 2020
    Papaluca T; Roberts S; Strasser S; Stuart K; New K; Farrell G; Dore G; Wigg A; Woodward A; Wade A; George J; Sinclair M; McGarity B; Fisher AL; Sawhney R; Wilson M; Valiozis I; Levy M; Tse E; Ahlenstiel G; Haque M; Prewett E; Sievert W; Sood S; O'Beirne J; Thomas J; Hazeldine S; Valaydon Z; Douglas M; Bowden S; O'Keefe J; Holmes J; Thompson A, 2020, 'Final challenges: real-world experience with sofosbuvir, velpatasvir and voxilaprevir in patients with advanced cirrhosis', in JOURNAL OF HEPATOLOGY, ELSEVIER, pp. S363 - S363,
    Reports | 2019
    Alavi M; Valerio H; Selvey C; Dore G, 2019, Hepatitis C Elimination in NSW: Monitoring Evaluation Report 2019,
    Conference Abstracts | 2019
    Grebely J; Conway B; Litwin AH; Dalgard O; Shibolet O; Nahass RG; Altice F; Gane EJ; Luetkemeyer A; Peng C-Y; Iser D; Gendrano IN; Kelly M; Hwang P; Asante-Appiah E; Barr E; Robertson MN; Platt H; Dore G, 2019, 'DRUG USE AND REINFECTION DURING AND FOLLOWING HCV TREATMENT WITH ELBASVIR/GRAZOPREVIR AMONG PATIENTS RECEIVING OPIOID AGONIST THERAPY: FINAL RESULTS FROM THE CO-STAR STUDY', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 955A - 956A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019,
    Conference Abstracts | 2019
    Grebely J; Cunningham EB; Dalgard O; Hajarizadeh B; Conway B; Powis J; Bruneau J; Feld J; Read P; Cooper C; Amin J; Bruggmann P; Lacombe K; Stedman C; Hellard M; Marks P; Dunlop A; Moriggia A; Applegate T; Litwin A; Matthews G; Dore G, 2019, 'Reinfection following successful HCV DAA therapy among people with recent injecting drug use', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E732 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019,
    Conference Abstracts | 2019
    Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Reid H; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J, 2019, 'HEPATITIS C VIRUS REINFECTION FOLLOWING ANTIVIRAL TREATMENT AMONG PEOPLE WHO USE OR INJECT DRUGS: A SYSTEMATIC REVIEW AND META-ANALYSIS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S50 - S51,
    Conference Abstracts | 2019
    Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Reid H; Law M; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore G; Grebely J, 2019, 'Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E733 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019,
    Conference Abstracts | 2019
    Hajarizadeh B; Marshall AD; Grebely J; Dore GJ; Treloar C; Corry A; Hayllar J; Byrne J, 2019, 'SYMPOSIUM: ENHANCING HEPATITIS C CARE AMONG PEOPLE WHO INJECT DRUGS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S8 - S9,
    Conference Abstracts | 2019
    He S; Dore G; Law M; Heahter V; Grebely J; Amin J; Hajarizadeh B; George J; Danta M; Alavi M, 2019, 'IMPROVED SURVIVAL FOLLOWING HEPATITIS C-RELATED HEPATOCELLULAR CARCINOMA DIAGNOSIS IN THE DIRECT-ACTING ANTIVIRAL THERAPY ERA IN NEW SOUTH WALES, AUSTRALIA', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 906A - 906A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019,
    Conference Abstracts | 2019
    He S; Dore G; Law M; Valerio H; Grebely J; Amin J; Hajarizadeh B; George J; Danta M; Alavi M, 2019, 'Improved survival after hepatitis C-related hepatocellular carcinoma diagnosis in the direct-acting antiviral therapy era in New South Wales, Australia', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 34, pp. 82 - 82,
    Conference Abstracts | 2019
    He S; Hajarizadeh B; Lockart I; Alavi M; Danta M; Dore G, 2019, 'Effectiveness of direct-acting antiviral therapy for hepatitis C among people with hepatocellular carcinoma: A systematic review and meta-analysis', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 34, pp. 71 - 72,
    Conference Abstracts | 2019
    Hooshyar SH; Martinello M; Yee J; Bartlett S; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Marks P; Applegate T; Dore G; Matthew G, 2019, 'Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E734 - E734, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019
    Conference Abstracts | 2019
    Kearley J; Gilliver R; Lothian R; Cunningham EB; Dore GJ; Read P, 2019, 'MAXIMISING ADHERENCE TO DIRECT-ACTING ANTI-VIRALS FOR HEPATITIS C AMONG STREET-BASED AND MARGINALISED CLIENTS USING AN OPIOID AGONIST TREATMENT PROGRAM: THE RESULTS OF DAILY DOSING', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S59 - S60,
    Conference Abstracts | 2019
    Kearley J; Gilliver R; Lothian R; Dore GJ; Read P, 2019, 'WHEN TREATMENT ACCESS DOES NOT EQUAL TREATMENT INITIATION: AN ANALYSIS OF CLIENTS WHO DO NOT INITIATE DIRECT ACTING ANTIVIRALS FOR HEPATITIS C', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S60 - S60,
    Conference Papers | 2019
    Marshall AD; Grebely J; Dore GJ; Treloar C, 2019, 'BARRIERS AND FACILITATORS TO ENGAGING IN HEPATITIS C MANAGEMENT AND DIRECT-ACTING ANTIVIRAL THERAPY AMONG GENERAL PRACTITIONERS AND DRUG AND ALCOHOL SPECIALISTS: THE PRACTITIONER EXPERIENCE', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S9 - S9,
    Conference Abstracts | 2019
    Matthews G; Bhagani S; Van der Valk M; Rockstroh JK; Kim AY; Thurnheer C; Feld JJ; Bruneau J; Gane EJ; Hellard M; Grebely J; Applegate T; Marks P; Martinello M; Petoumenos K; Dore G, 2019, 'SHORT COURSE DURATION SOFOSBUVIR/VELPATASVIR IS INFERIOR TO STANDARD DURATION THERAPY IN THE TREATMENT OF RECENTLY ACQUIRED HCV INFECTION: RESULTS FROM REACT STUDY', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 1487A - 1488A, presented at 70th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019,
    Conference Papers | 2019
    Papaluca T; New K; Strasser S; Stuart K; Dore G; Farrell G; George J; Jeffrey G; O'Beirne J; Sinclair M; Wade A; Ahlenstiel G; Hazeldine S; Wigg A; Sheikh K; Woodward A; Weltman M; Valiozis I; Mcgarity B; Fisher L; Levy M; Tse E; Wilson M; Thomas J; Lee A; Sawhney R; Sievert W; Sood S; Cheng W; Roberts S; Thompson A, 2019, 'Efficacy and safety of sofosbuvir, velpatasvir, and voxilaprevir in NS5A-experienced patients with advanced liver disease or prior liver transplantation: The first Australian real-world experience', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 72 - 73,
    Conference Abstracts | 2019
    Valerio H; Alavi M; Silk D; Treloar C; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Degenhardt L; Dore G; Grebely J, 2019, 'Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage study', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E42 - E42, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019,
    Conference Papers | 2018
    Artenie AA; Cunningham E; Conway B; Dalgard O; Powis J; Bruggmann P; Hellard M; Cooper C; Read P; Feld JJ; Hajarizadeh B; Amin J; Applegate TL; Dillon JF; Fraser C; Gane E; Litwin AH; Marks P; Matthews GV; Quiene S; Thurnheer MC; Weltman M; Dore G; Bruneau J; Grebely J, 2018, 'Drug and alcohol use patterns during and following treatment with sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use: Insights from trajectory analyses', in JOURNAL OF VIRAL HEPATITIS, WILEY, CANADA, Toronto, pp. 31 - 32, presented at 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), CANADA, Toronto, 14 June 2018 - 17 June 2018,
    Conference Posters | 2018
    Cunningham EB; Hajarizadeh B; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Bretana NA; Dolan K; Lloyd AR; Grebely J, 2018, 'Ongoing incident hepatitic c virus infection among people with a history of injecting drug use in an Australian prison setting', Vol. 1, pp. 278 - 280,
    Conference Abstracts | 2018
    Dalgard O; Grebely J; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2018, 'Sofosbuvir and Velpatasvir for Hepatitis C Virus Infection in People with Recent Injecting Drug Use (Simplify): An Open-Label, Single-Arm, Phase 4, Multicentre Trial', in HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, PACINI EDITORE, Vol. 20, pp. 14 - 14,
    Conference Abstracts | 2018
    Dalgard O; Grebely J; Feld JJ; Wyles D; Sulkowski M; Ni L; Llewellyn J; Soyemi T; Sajed N; Stamm LM; Hyland RH; McNally J; Brainard DM; Jacobson I; Zeuzem S; Bourliere M; Foster G; Afdhal N; Dore GJ, 2018, 'Sofosbuvir-Based Direct-Acting Antiviral Therapies for Hcv in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies', in HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, PACINI EDITORE, Vol. 20, pp. 13 - 14,
    Conference Abstracts | 2018
    Dore G; Hezode C; Kwo P; Sperl J; Hwang P; Long J; Talwani R; Robertson M; Haber B, 2018, 'Efficacy and safety of elbasvir/ grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy', in JOURNAL OF VIRAL HEPATITIS, WILEY, CANADA, Toronto, Vol. 25, pp. 56 - 57, presented at 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), CANADA, Toronto, 14 June 2018 - 17 June 2018,
    Conference Abstracts | 2018
    Grebely J; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Conway B; Nahass R; Altice F; Luetkemeyer A; Peng C-Y; Iser D; Gendrano IN; Huang H-C; Kelly MM; Hwang P; Barr E; Robertson MN; Platt H; Dore G, 2018, 'HCV Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Patients on Opioid Agonist Therapy: Co-STAR Part B', in HEPATOLOGY, WILEY, CA, San Francisco, Vol. 68, pp. 35A - 35A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, CA, San Francisco, 09 November 2018 - 13 November 2018,
    Conference Papers | 2018
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin N; Mchutchison JG; Brainard D; Treloar C; Lloyd A; Dore G, 2018, 'Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S187 - S188, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018,
    Conference Abstracts | 2018
    Hezode C; Kwo P; Sperl J; Dore G; Hwang P; Long J; Talwani R; Robertson M; Haber B, 2018, 'Efficacy and safety of Elbasvir/Grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, Vol. 68, pp. S264 - S265, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018,
    Conference Posters | 2018
    Kwon A; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham E; Estes C; Razavi H; Gray RT, 2018, 'Australia on track to achieve WHO elimination targets following rapid initial DAA treatment uptake', presented at International Liver Congress (European Association for the Study of the Liver (EASL 2018)), 11 April 2018 - 15 April 2018
    Conference Presentations | 2018
    Kwon A; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Homie R; Gray RT, 2018, 'Ongoing Burden of Advanced Liver Disease Complications Despite Rapid HCV Treatment Scale-Up', presented at Australasian Viral Hepatitis Conference, 13 August 2018 - 15 August 2018
    Conference Papers | 2018
    Lamoury F; Bajis S; Hajarizadeh B; Marshall A; Martinello M; Ivanova E; Catlett B; Mowat Y; Marks P; Amin J; Smith J; Ezard N; Cock V; Hayllar J; Persing D; Kleman M; Cunningham P; Dore G; Applegate T; Grebely J, 2018, 'Evaluation of the Xpert fingerstick HCV viral load assay', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S167 - S167, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018,
    Conference Papers | 2018
    Lamoury F; Bajis S; Martinez D; Mowat Y; Jayasinghe I; Martinez M; Cunningham P; Catlett B; Jacka B; Marks P; Grebely J; Cloherty G; Dore G; Applegate T, 2018, 'Evaluation of a hepatitis C virus core antigen assay in dried-blood spots: a cohort study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S317 - S318, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018,
    Conference Abstracts | 2018
    Martinello M; Bartlett S; Dore G; Bopage R; Finlayson R; Baker D; Bloch M; Doyle J; Shaw D; Hajkowicz K; Read P; Filep E; Lin L; Yee J; Applegate T; Hellard M; Matthews G, 2018, 'Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia', in Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia, Paris, France, presented at THE INTERNATIONAL LIVER CONGRESS 2018, Paris, France, 11 April 2018 - 15 April 2018
    Conference Abstracts | 2018
    Martinello M; Cerrone M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Schoolmeesters A; Grebely J; Nelson M; Matthews GV, 2018, 'TARGET3D: high efficacy of 8 weeks paritaprevir/ritonavir/ombitasvir and dasabuvir among people with recent genotype 1 HCV infection', in HIV MEDICINE, WILEY, Vol. 19, pp. S151 - S152,
    Conference Abstracts | 2018
    Salazar-Vizcaya L; Boettiger DC; Dore GJ; Gray R; Law M; Rauch A; Lea T; Matthews G, 2018, 'Will hepatitis C transmission be eliminated by 2025 among HIV-positive men who have sex with men in Australia?', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, Vol. 21, pp. 66 - 66,
    Conference Abstracts | 2018
    Yee J; Dore GJ; Hanson J; Iser D; Danta M; Shaw D; Read P; Balcomb A; Post J; Faros J; Montebello M; Collie P; Hallinan R; Cooper L; Marks P; Hajarizadeh B; Matthews GV, 2018, 'High efficacy of HCV therapy following universal DAA access in Australia: the REACH-C cohort', in JOURNAL OF VIRAL HEPATITIS, WILEY, CANADA, Toronto, Vol. 25, pp. 54 - 54, presented at 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), CANADA, Toronto, 14 June 2018 - 17 June 2018,
    Conference Abstracts | 2017
    Bartlett SR; Grebely J; Eltahla AA; Reeves JD; Howe A; Miller V; Bull RA; Ceccherini-Silberstein F; Douglas MW; Dore GJ; Harrington P; Lloyd AR; Jacka B; Matthews GV; Wang GP; Pawlotsky J-M; Feld JJ; Schinkel J; Garcia F; Lennerstrand J; Applegate TL, 2017, 'Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S323 - S323, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017,
    Theses / Dissertations | 2017
    Bartlett SR, 2017, Molecular epidemiology of recently acquired hepatitis C virus infection in Australia
    Conference Presentations | 2017
    Byrne M; Hajarizadeh B; Dore GJ; Treloar C; Marks P; Milat A; Bowman J; McGrath C; Bath N; Calder I; Lagios K; Grebely J; Lloyd A, 2017, 'A framework for hepatitis C virus treatment as prevention in the prison setting: the SToP-C implementation toolkit', presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017,
    Conference Papers | 2017
    Cunningham EB; Hajarizadeh B; Amin J; Bretana NA; Luciani F; Degenhardt L; Larney S; Dore GJ; Lloyd AR; Grebely J, 2017, 'Injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S488 - S488, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017,
    Conference Papers | 2017
    Dore GJ; Grebely J; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Conway B; Nahass R; Luetkemeyer A; Peng C-Y; Iser DM; Gendrano IN; Kelly MM; Huang H-C; Hwang P; Barr E; Robertson M; Platt H, 2017, 'Hepatitis C Virus (HCV) Reinfection and Injecting Risk Behavior Following Elbasvir (EBR)/Grazoprevir (GZR) Treatment in Participants on Opiate Agonist Therapy (OAT): Co-STAR Part B', in HEPATOLOGY, WILEY, DC, Washington, pp. 112A - 113A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017,
    Other | 2017
    Dore GJ; Grebely J, 2017, Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030, Elsevier,
    Conference Abstracts | 2017
    Foster GR; Gane E; Asatryan A; Asselah T; Ruane PJ; Pol S; Poordad F; Stedman CA; Dore G; Roberts SK; Kaita K; Vierling J; Vargas HE; Kort J; Lin C-W; Liu R; Ng T; Mensa F, 2017, 'ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naive HCV genotype 3-infected patients without cirrhosis', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S33 - S33, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017,
    Conference Abstracts | 2017
    Foster GR; Grebely J; Sherman KE; Wang S; Dore GJ; Baumgarten A; Conway B; Jackson DF; Asselah T; Gschwantler M; Tomasiewicz K; Aguilar HI; Alami NN; Dumas EO; Hu Y; Mensa FJ, 2017, 'Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1-6 and Recent Drug Use', in HEPATOLOGY, WILEY, DC, Washington, Vol. 66, pp. 636A - 637A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017,
    Conference Abstracts | 2017
    Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop AJ; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer CM; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2017, 'Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S513 - S513, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017
    Conference Abstracts | 2017
    Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop AJ; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin AH; Dillon JF; Read P; Gane ED; Dore GJ, 2017, 'EFFICACY AND SAFETY OF SOFOSBUVIR/VELPATASVIR IN PEOPLE WITH CHRONIC HEPATITIS C VIRUS INFECTION AND RECENT INJECTING DRUG USE: THE SIMPLIFY STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 36, pp. 34 - 34,
    Conference Papers | 2017
    Grebely J; Feld JJ; Wyles D; Sulkowski MS; Ni L; Llewellyn J; Mir H; Sajed N; Stamm LM; Hyland R; McNally J; Brainard D; Jacobson I; Zeuzem S; Bourliere M; Foster G; Afdhal N; Dore GJ, 2017, 'EFFICACY AND SAFETY OF SOFOSBUVIR-BASED DIRECT-ACTING ANTIVIRAL THERAPIES FOR HEPATITIS C VIRUS INFECTION IN PATIENTS RECEIVING OPIOID SUBSTITUTION THERAPY', in DRUG AND ALCOHOL REVIEW, WILEY, pp. 34 - 35,
    Conference Abstracts | 2017
    Grebely J; Jacobson IM; Kayali Z; Verna EC; Shiffman ML; Hyland RH; Stamm LM; Huang KC; Brainard DM; McHutchison JG; Pol S; Chung RT; Bernstein DE; Dore G, 2017, 'SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S513 - S514, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017,
    Conference Papers | 2017
    Grebely J; Lamoury F; Hajarizadeh B; Mowat Y; Marshall A; Bajis S; Marks P; Amin J; Smith J; Edwards M; Gorton C; Ezard N; Persing D; Kleman M; Cunningham P; Catlett B; Dore G; Applegate TL, 2017, 'Field evaluation of Xpert (R) HCV Viral Load point-of-care test for detection of hepatitis C virus infection by venipuncture-collected and finger-stick capillary whole-blood samples', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S709 - S709, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017,
    Other | 2017
    Grebely J; Swan T; Hickman M; Bruneau J; Bruggmann P; Dalgard O; Litwin A; Backmund M; Dore GJ, 2017, Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C, Elsevier,
    Conference Papers | 2017
    Grebley J; Puoti M; Wedemeyer H; Cooper C; Sulkowski MS; Foster G; Berg T; Villa E; Rodriguez-Perez F; Wyles DL; Alami NN; Zhang Z; Dumas E; Dore GJ, 2017, 'Safety and efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S514 - S514, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017,
    Conference Papers | 2017
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin NK; Mchutchison JG; Brainard DM; Treloar C; Lloyd AR; Dore GJ, 2017, 'Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the SToP-C study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S274 - S274, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017,
    Conference Presentations | 2017
    Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2017, 'The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments', presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017,
    Conference Presentations | 2017
    Kwon A; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Razavi H; Gray RT, 2017, 'Australia Could Meet the WHO HCV Elimination Targets If the Current Rollout of DAA Treatment Is Continued', presented at Australasian Viral Hepatitis Conference (AVHC), 10 August 2017 - 11 August 2017
    Conference Abstracts | 2017
    Kwon AJ; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Razavi H; Gray RT, 2017, 'O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued', in Journal of Virus Eradication, Elsevier BV, Vol. 3, pp. 5 - 5,
    Reports | 2017
    Kwon J; Gray R; Dore G; Grebely J; Guy R; Hajarizadeh B; Cunningham E, 2017, 2017 Estimates and Projections of the Hepatitis C Virus Epidemic in NSW: Summary Report, Sydney: Kirby Institute, 91探花 Sydney
    Conference Abstracts | 2017
    Lamoury FM; Hajarizadeh B; Soker A; Martinez D; Quek C; Cunningham P; Catlett B; Cloherty GA; Marks P; Amin J; Grebely J; Dore GJ; Applegate TL, 2017, 'Hepatitis C virus core antigen and dried blood spots as simplified hepatitis C virus diagnostic tools', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S710 - S710, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017,
    Conference Papers | 2017
    Lubel JS; Pianko S; Thompson A; Strasser S; Dore G; Stuart K; MacQuillan G; Iser D; Mitchell J; Gazzola A; Chivers S; Mishra G; Gow P; George J; Gough J; Tse E; Zekry A; Levy M; Fragomeli V; Morales B; Sasadeusz J; Nazareth S; Bollipo S; Jones T; Wade A; Cheng W; Wigg A; Roberts S, 2017, 'Very high real-world efficacy of ritonavir boosted paritaprevir with ombitasvir and dasabuvir plus /- ribavirin in hepatitis C genotype 1 in patients with advanced fibrosis -Final results of the REV1TAL study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S521 - S521, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017,
    Conference Abstracts | 2017
    Marshall AD; Nielsen S; Cunningham EB; Aghemo A; Alho H; Backmund M; Bruggmann P; Dalgard O; Flisiak R; Foster G; Gheorghe L; Goldberg D; Goulis I; Hickman M; Hoffmann P; Jancoriene L; Jarcuska P; Kaberg M; Makara M; Maimets M; Marinho R; Maticic M; Norris S; Olafsson S; Ovrehus A; Pawlotsky J-M; Pocock J; Robaeys G; Roncero C; Simonova M; Sperl J; Tait M; Tolmane I; Tomaselli S; van der Valk M; Vince A; Dore GJ; Lazarus JV; Grebely J, 2017, 'Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe', in JOURNAL OF HEPATOLOGY, ELSEVIER, NETHERLANDS, Amsterdam, Vol. 66, pp. S95 - S96, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver-Disease, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017,
    Conference Abstracts | 2017
    Martinello M; Bhagani S; Gane EJ; Orkin C; Cooke G; Kulasegaram R; Shaw D; Hellard M; Tu E; Filep E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews G, 2017, 'Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study', in HEPATOLOGY, WILEY, DC, Washington, Vol. 66, pp. 574A - 575A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017
    Conference Abstracts | 2017
    Martinello M; Dore GJ; Bopage RI; Finlayson R; Baker D; Bloch M; Wilcox A; Filep E; Hellard M; Matthews GV, 2017, 'DAA treatment scale-up in HIV/HCV co-infection: characterisinga population at risk for reinfection', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S495 - S496, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017,
    Conference Papers | 2017
    Morley KC; Baillie AJ; Dore GJ; Phung N; Fraser I; Furneaux-Bate A; Haber PS, 2017, 'A RANDOMISED CLINICAL TRIAL OF BACLOFEN FOR THE TREATMENT OF ALCOHOL DEPENDENCE', in DRUG AND ALCOHOL REVIEW, WILEY, pp. 53 - 53,
    Conference Presentations | 2017
    Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ, 2017, 'No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression', presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 April 2017 - 23 April 2017,
    Conference Abstracts | 2016
    Alavi M; Janjua N; Yu A; Grebely J; Aspinall E; Innes H; Valerio H; Hayes P; Krajden M; Amin J; Law M; George J; Goldberg D; Hutchinson S; Dore G, 2016, 'DOES ALCOHOL DEPENDENCY EXPLAIN DIFFERENCES IN RATES OF DECOMPENSATED CIRRHOSIS AMONG PEOPLE WITH A HEPATITIS C NOTIFICATION? AN INTERNATIONAL COMPARISON', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S462 - S463, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016,
    Conference Papers | 2016
    Arduino JM; Shibolet O; Litwin AH; Grebeley J; Altice F; Nwankwo C; Mast TC; Jiang Z; Gendrano IN; Platt HL; Dore GJ, 2016, 'C-EDGE CO-STAR: FAVORABLE IMPACT OF ELBASVIR AND GRAZOPREVIR ON HEALTH-RELATED QUALITY OF LIFE IN TREATMENT-NAIVE HCV-INFECTED PERSONS WHO INJECT DRUGS RECEIVING OPIOID AGONIST THERAPY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S403 - S404, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016,
    Conference Papers | 2016
    Cunningham EB; Luciani F; Hajarizadeh B; Betz-Stablein B; Bretana NA; Teutsch S; Dore GJ; Grebely J; Lloyd AR, 2016, 'STABLE INCIDENCE OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WITH A HISTORY OF INJECTING DRUG USE IN AN AUSTRALIAN PRISON SETTING, 2005-2014: THE HITS-P STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S614 - S614, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016,
    Conference Papers | 2016
    Dore G; Altice F; Litwin AH; Grebely J; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng C-Y; Conway B; Gendrano IN; Huang H-C; Chen E; Nguyen B-Y; Wahl J; Barr E; Robertson M; Platt HL, 2016, 'C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR AND GRAZOPREVIR IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOID AGONIST THERAPY (OAT)', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S771 - S771, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016,
    Conference Abstracts | 2016
    Dore G; Grebely J; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng C-Y; Conway B; Iser DM; Huang H-C; Gendrano IN; Kelly MM; Hwang P; Robertson M; Wahl J; Barr E; Platt HL, 2016, 'HCV reinfection and injecting risk behavior following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR Three Year Follow-up Study', in HEPATOLOGY, WILEY, MA, Boston, Vol. 64, pp. 431A - 431A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016
    Conference Papers | 2016
    Dore GJ; Altice F; Litwin AH; Grebely J; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Gendrano IN; Huang HC; Chen E; Nguyen BY; Wahl J; Barr E; Robertson R; Platt HL, 2016, 'C-EDGE CO-STAR: Risk of reinfection following successful therapy with elbasvir and grazoprevir in persons who inject drugs (PWID) receiving opioid agonist therapy (OAT)', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 70 - 71,
    Conference Papers | 2016
    Dore GJ, 2016, 'INTERFERON-FREE HCV THERAPY FOR PEOPLE WHO INJECT DRUGS', in DRUG AND ALCOHOL REVIEW, WILEY, pp. 15 - 15,
    Conference Papers | 2016
    Foster GR; Thompson AJ; Ruane PJ; Borgia SM; Dore G; Workowski K; Hyland RH; Wang J; Svarovskaia ES; Stamm LM; Brainard DM; Subramanian M; McHutchison JG; Berg T; Agarwal K; Conway B; Feld JJ; Willems BE; Roberts SK, 2016, 'A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study', in HEPATOLOGY, WILEY, MA, Boston, pp. 135A - 136A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016,
    Conference Papers | 2016
    Grebely J; Dore GJ; Aspinall R; Rodriguez-Torres M; Fox R; Liu L; Ding X; McNally J; Osinusi A; Brainard D; Subramanian M; Sulkowski M; Feld J, 2016, 'SOF/VEL FOR 12 WEEKS IS WELL TOLERATED AND RESULTS IN HIGH SVR12 RATES IN PEOPLE RECEIVING OPIOID SUBSTITUTION THERAPY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S776 - S776, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016,
    Conference Papers | 2016
    Grebely J; Flamm S; Zeuzem S; Hyland R; Chang P; Ding X; Yun C; Brainard D; McHutchison J; Forns X; Mangia A; Dore G, 2016, 'ON-TREATMENT ILLICIT DRUG USE DID NOT IMPACT TREATMENT OUTCOME DURING THERAPY WITH LEDIPASVIR-SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN THE PHASE 3 ION-1 STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S776 - S777, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016,
    Conference Abstracts | 2016
    Grebely J; Marshall AD; Krahe M; Erratt A; Telenta J; Treloar C; Jones SC; Adey S; Bath N; How-Chow D; Byrne J; Harvey P; Dunlop AJ; Applegate TL; Lamoury F; Mowat Y; Jauncey M; Read P; Gilliver R; Smith J; Collie T; Dore GJ, 2016, 'A LIVER HEALTH PROMOTION INTERVENTION INTEGRATING NON-INVASIVE LIVER DISEASE SCREENING IN DRUG AND ALCOHOL SETTINGS: THE LIVERLIFE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 40 - 40
    Conference Abstracts | 2016
    Grebely J; Mauss S; Brown A; Bronowicki J-P; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ, 2016, 'SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION RECEIVING OPIOID SUBSTITUTION THERAPY: PHASE 3 ION TRAILS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 40 - 41
    Conference Papers | 2016
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Butler T; Amin J; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Lloyd AR; Dore G, 2016, 'Hepatitis C virus exposure, infection and associated risk behaviours in two maximum-security prisons in New South Wales, Australia', in HEPATOLOGY, WILEY, MA, Boston, pp. 385A - 386A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016
    Conference Presentations | 2016
    Hajarizadeh B; Grebely J; Matthews G; Martinello M; Dore G, 2016, 'Treatment uptake for chronic hepatitis C in Australia following universal access to interferon-free treatments', presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016
    Conference Papers | 2016
    Hezode C; Dore G; Pianko S; Pol S; Stuart K; Thompson A; Tse E; Bhore R; Jimenez-Exposito MJ, 2016, 'DACLATASVIR PLUS SOFOSBUVIR PLUS RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT-EXPERIENCED PATIENTS WITH HCV GENOTYPE 3 INFECTION AND ADVANCED FIBROSIS OR CIRRHOSIS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S753 - S754, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016,
    Conference Papers | 2016
    Lamoury F; Hajarizadeh B; Martinello M; Soker A; Martinez D; Cunningham P; Cloherty GA; Marks P; Matthews G; Amin J; Grebely J; Dore G; Applegate TL, 2016, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool among those with recent Hepatitis C virus infection, including for post-treatment relapse', in HEPATOLOGY, WILEY, MA, Boston, pp. 415A - 415A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016,
    Conference Presentations | 2016
    Lamoury F; Soker A; Martinez D; Hajarizadeh B; Cunningham E; Bruggmann P; Foster G; Dalgard O; Conway B; Robaeys G; Swan T; Backmund M; Marks P; Grebely J; Dore GJ; Applegate TL, 2016, 'HEPATITIS C VIRUS CORE ANTIGEN: A SIMPLIFIED TREATMENT MONITORING TOOL, INCLUDING FOR POST-TREATMENT RELAPSE', presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016,
    Conference Abstracts | 2016
    Larney S; Grebely J; Degenhardt L; Amin J; Law M; Alavi M; Dore GJ, 2016, 'EXPOSURE TO OPIOID SUBSTITUTION THERAPY FOLLOWING HEPATITIS C NOTIFICATION: IMPLICATIONS FOR PROVISION OF ANTIVIRAL THERAPIES IN DRUG TREATMENT SETTINGS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 48 - 48,
    Conference Papers | 2016
    Lubel J; Mitchell J; Pianko S; Thompson A; Iser D; Gazzola A; Chivers S; Mishra G; Gough J; Strasser S; Dore G; Stuart K; George J; Tse E; Zekry A; Levy M; Macquillan G; Fragomeli V; Gow P; Morales B; Sasadeusz J; Nazareth S; Bollipo S; Jones T; Wade A; Roberts SK, 2016, 'Excellent SVR12 rates with Viekira Pak in a real-world cohort of HCV genotype 1 patients predominantly with cirrhosis - the Australian REV1TAL study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 77 - 78,
    Conference Papers | 2016
    Lubel J; Mitchell J; Pianko S; Thompson A; Iser D; Gazzola A; Chivers S; Mishra G; Gough J; Strasser S; Dore G; Stuart K; George J; Tse E; Zekry A; Levy M; Macquillan G; Fragomeli V; Gow P; Morales B; Sasadeusz J; Nazareth S; Bollipo S; Jones T; Wade A; Roberts SK, 2016, 'Frequency and severity of hyperbilirubinaemia with Viekira Pak in a real-world cohort of HCV genotype 1 patients - Predictors and clinical significance', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 78 - 79,
    Conference Papers | 2016
    Lubel J; Mitchell J; Pianko S; Thompson AJ; Iser DM; Gazzola A; Chivers S; Mishra G; Gough J; Strasser SI; Dore G; Stuart KA; George J; Tse E; Zekry A; Levy M; MacQuillan GC; Fragomeli V; Gow P; Morales B; Sasadeusz J; Nazareth S; Bollipo SJ; Jones TL; Wade AJ; Roberts SK, 2016, 'Excellent SVR12 rates with Viekira Pak in a real-world cohort of HCV Genotype 1 patients predominantly with cirrhosis - the Australian REV1TAL Study', in HEPATOLOGY, WILEY, MA, Boston, pp. 483A - 484A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016,
    Conference Papers | 2016
    Lubel J; Mitchell J; Pianko S; Thompson AJ; Iser DM; Gazzola A; Chivers S; Mishra G; Gough J; Strasser SI; Dore G; Stuart KA; George J; Tse E; Zekry A; Levy M; MacQuillan GC; Fragomeli V; Gow P; Morales B; Sasadeusz J; Nazareth S; Bollipo SJ; Jones TL; Wade AJ; Roberts SK, 2016, 'Frequency and severity of biochemical abnormalities with paritaprevir/ritonavir/ombitasvir +/- ribavirin in a real-world cohort of HCV Genotype 1 patients - predictors and clinical significance', in HEPATOLOGY, WILEY, MA, Boston, pp. 442A - 442A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016,
    Conference Papers | 2016
    Martin NK; Vickerman P; Dore GJ; Grebely J; Miners A; Cairns J; Foster GR; Hutchinson SJ; Goldberg DJ; Martin TCS; Ramsay M; Hickman M, 2016, 'COMPARING INDIVIDUAL AND POPULATION PREVENTION BENEFITS OF EARLY DIRECT-ACTING ANTIVIRAL TREATMENT FOR HCV', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, pp. S464 - S464, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016,
    Conference Abstracts | 2016
    Martinello M; Petoumenos K; Grebely J; Gane E; Hellard M; Shaw D; Sasdeusz J; Applegate T; Lamoury F; Yeung B; Maire L; Dore G; Matthews G, 2016, 'INCIDENCE OF HCV REINFECTION AMONG TREATED INDIVIDUALS WITH RECENTLY ACQUIRED INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, SPAIN, Barcelona, Vol. 64, pp. S620 - S621, presented at EASL International Liver Congress, SPAIN, Barcelona, 13 April 2016 - 17 April 2016,
    Conference Presentations | 2016
    Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews G; Law M; Dore G; Law M, 2016, 'Survival following hepatocellular carcinoma among people with HBV or HCV in New South Wales, Australia between 2000 and 2014', presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016
    Conference Abstracts | 2015
    Alavi M; Grebely J; Micallef M; Dunlop A; Balcomb A; Day C; Treloar C; Bath N; Haber P; Dore G, 2015, 'P0883 : Treatment for hepatitis C virus infection among people who inject drugs in the opioid substitution setting: The ethos study', in Journal of Hepatology, Elsevier, AUSTRIA, Vienna, Vol. 62, pp. s673, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 22 April 2015 - 26 April 2015,
    Conference Abstracts | 2015
    Conway B; Luo Y; Arama V; Ghesquiere W; Sasadeusz J; Skoien R; Soza A; Inglot M; Sullivan D; Podsadecki T; Dore G, 2015, 'Ombitasvir/Paritaprevir/r and Dasabuvir plus /- Ribavirin is Better Tolerated Than Telaprevir plus Peginterferon/Ribavirin With Less Frequent and Less Severe Anemia in the MALACHITE-I and MALACHITE-II Trials', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, Vol. 62, pp. 782A - 783A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015
    Conference Papers | 2015
    Dore G; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng C-Y; Conway B; Grebely J; Howe AY; Nguyen B-YT; Wahl J; Barr E; Robertson M; Platt HL, 2015, 'C-EDGE CO-STAR: Efficacy of Grazoprevir and Elbasvir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 227A - 228A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015,
    Conference Papers | 2015
    Dore G; Knysz B; Luo Y; Janczewska E; Streinu-Cercel A; Caruntu FA; Motoc A; Mazur W; Shaw D; Tornai I; Sasadeusz J; Skoien R; Sullivan D; Liu X; Podsadecki T, 2015, 'P0847 : Malachite-II: Phase 3b trial of ombitasvir/paritaprevir/r and dasabuvir + ribavirin or telaprevir + peginterferon/ribavirin in peginterferon/ribavirin treatment-experienced adults with HCV genotype 1', in Journal of Hepatology, Elsevier, AUSTRIA, Vienna, pp. s656 - s657, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 22 April 2015 - 26 April 2015,
    Conference Papers | 2015
    Dore GJ; Knysz B; Luo Y; Janczewska E; Streinu-Cercel A; Caruntu FA; Motoc A; Mazur W; Shaw DR; Tornai I; Sasadeusz J; Skoien R; Sullivan D; Liu X; Podsadecki T, 2015, 'MALACHITE-II: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir plus Ribavirin or Telaprevir plus Peginterferon/Ribavirin in Peginterferon/Ribavirin Treatment-Experienced Adults With HCV Genotype 1', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, DC, Washington, pp. S1084 - S1085, presented at 46th Annual Digestive Disease Week (DDW), DC, Washington, 16 May 2015 - 19 May 2015,
    Conference Presentations | 2015
    Grebely J; Dalgard O; Conway B; Foster G; Bruggmann P; Backmund M; Robaeys G; Swan T; Hajarizadeh B; Amin J; Marks P; Quiene S; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Bourgeois S; Thurnheer C; Dore GJ; Group OBOTACTIVATES, 2015, 'P0848 : Efficacy of response-guided pegylated interferon and ribavirin therapy for people who inject drugs with HCV genotype 2/3 infection: The activate study', presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 22 April 2015 - 26 April 2015,
    Conference Papers | 2015
    Hickman M; Martin N; Vickerman P; David G; Hutchinson S; Martin T; Dore G; Grebeley J; Miners A; Foster G, 2015, 'P1271 : How should scale up of HCV antiviral treatment be prioritized? A cost-effectiveness analysis including individual and population prevention benefits', in Journal of Hepatology, Elsevier, AUSTRIA, Vienna, pp. s835, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 22 April 2015 - 26 April 2015,
    Conference Papers | 2015
    Jacobson IM; Dore GJ; Wyles D; Lawitz E; Talal A; Ball G; Dumas EO; Feld JJ, 2015, 'Plasma Interferon-gamma-Inducible Protein 10 (Ip-10) and Response to Interferon-Free Direct-Acting Antiviral Therapy in HCV Genotype 1-Infected Patients With and Without Cirrhosis', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, DC, Washington, pp. S1087 - S1088, presented at 46th Annual Digestive Disease Week (DDW), DC, Washington, 16 May 2015 - 19 May 2015,
    Conference Abstracts | 2015
    Janjua NZ; Yu A; Kuo ME; Alavi M; Woods R; Alvarez M; Dore G; Tyndall M; Krajden M, 2015, 'Timing of Hepatitis B and C Diagnosis Relative to Hepatocellular Carcinoma Diagnosis in the BC Hepatitis Testers Cohort (BC-HTC)', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, Vol. 62, pp. 480A - 480A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015,
    Conference Papers | 2015
    Leroy V; Angus PW; Bronowicki J-P; Dore G; Hezode C; Pianko S; Pol S; Stuart KA; Tse E; McPhee F; Bhore R; Exposito MJJ; Thompson AJ, 2015, 'All-Oral Treatment With Daclatasvir (DCV) Plus Sofosbuvir (SOF) Plus Ribavirin (RBV) for 12 or 16 Weeks in HCV Genotype (GT) 3-Infected Patients With Advanced Fibrosis or Cirrhosis: The ALLY-3+Phase 3 Study', in HEPATOLOGY, WILEY-BLACKWELL, pp. 1380A - 1381A,
    Conference Papers | 2015
    Waziry RK; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews G; Law M; Dore G; Law M, 2015, 'Trends in end-stage liver disease among people notified with HBV or HCV in New South Wales, Australia: 2000-2014', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 1121A - 1121A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015
    Conference Abstracts | 2015
    Zeuzem S; Mizokami M; Pianko S; Mangia A; Han K-H; Martin R; Svarovskaia ES; Dvory-Sobol H; Doehle B; Pang PS; Knox SJ; McHutchison JG; Brainard DM; Miller MD; Mo H; Chuang W-L; Jacobson IM; Dore G; Sulkowski MS, 2015, 'Prevalence of Pre-Treatment NS5A Resistance Associated Variants in Genotype 1 Patients Across Different Regions Using Deep Sequencing and Effect on Treatment Outcome with LDV/SOF', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, Vol. 62, pp. 254A - 255A, presented at 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 13 November 2015 - 17 November 2015
    Conference Papers | 2014
    Alavi M; Law M; Grebely J; Thein H-H; Amin J; Dore GJ, 2014, 'Time to hepatocellular carcinoma after notification of hepatitis B or C infection: a population-based cohort study, 1992-2007', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 921A - 922A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014,
    Conference Papers | 2014
    Bradshaw D; Jacka B; Sacks-Davis R; Lamoury F; Applegate T; Dore G; Down I; Luciani F; Hellard M; Sasadeusz J; Danta M; Matthews G, 2014, 'A novel method comparing sexual networks with the HCV phylogeny in HIV-positive MSM with acute HCV infection identifies two potential intervention targets for permucosally transmitted HCV in Australia', in HIV MEDICINE, WILEY-BLACKWELL, pp. 136 - 136
    Conference Papers | 2014
    Dore GJ; Razavi H; Estes C; Thompson A; Zekry A; Roberts S; Sievert W, 2014, 'P427 POTENTIAL IMPACT OF IMPROVED TREATMENT ON DISEASE BURDEN OF CHRONIC HEPATITIS C IN AUSTRALIA', in Journal of Hepatology, Elsevier, ENGLAND, London, pp. s210, presented at 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver, ENGLAND, London, 09 April 2014 - 13 April 2014,
    Conference Papers | 2014
    Doyle JS; Dore GJ; Shaw D; Grebely J; Erratt A; Hellard M; Matthews G, 2014, 'HCV re-infection rates are low after long-term follow up of acute HCV infection: The Australian Trial of Acute Hepatitis C Recall study', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 915A - 915A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014,
    Conference Papers | 2014
    Foster GR; Jacobson IM; Dore GJ; Fried M; Manns M; Marcellin P; Poordad F; de Araujo ESA; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M, 2014, 'P1127 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION IN TREATMENT-NAIVE EUROPEAN PATIENTS IN THE QUEST-1 AND QUEST-2 PHASE III TRIALS', in Journal of Hepatology, Elsevier, ENGLAND, London, pp. s456, presented at 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver, ENGLAND, London, 09 April 2014 - 13 April 2014,
    Conference Papers | 2014
    Hajarizadeh B; Grady B; Page K; Kim AY; Mcgovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J, 2014, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: The InC3 study', in Journal of Viral Hepatitis, Blackwell Publishing Ltd, MA, Boston, pp. 708 - 717, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014,
    Conference Papers | 2014
    Hajarizadeh B; Grady BP; Page K; Kim AY; McGovern BH; Cox A; Rice TM; Sacks-Davis R; Bruneau J; Morris MD; Amin J; Schinkel J; Applegate TL; Maher L; Hellard M; Lloyd AR; Prins M; Dore GJ; Grebely J, 2014, 'Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 898A - 899A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014
    Conference Papers | 2014
    Jacka B; Applegate T; Poon AF; Harrigan R; Dore GJ; Olmstead A; DeBeck K; Milloy M-J; Lamoury F; Woods C; Brumme Z; Dobrer S; Lima VD; Montaner J; Joy J; Marshall BD; Kerr T; Wood E; Krajden M; Grebely J, 2014, 'P762 TEMPORAL CHANGES IN HEPATITIS C VIRUS GENOTYPE 3A DISTRIBUTION AMONG PEOPLE WHO INJECT DRUGS IN VANCOUVER, CANADA', in Journal of Hepatology, Elsevier, ENGLAND, London, pp. s324 - s325, presented at 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver, ENGLAND, London, 09 April 2014 - 13 April 2014,
    Conference Papers | 2014
    Jacka B; Poon A; Applegate TL; Krajden M; Olmstead A; Harrigan R; Marshall BD; DeBeck K; Milloy M-J; Lamoury F; Pybus O; Lima V; Magiorkinis G; Montoya V; Montaner J; Joy J; Dore GJ; Kerr T; Wood E; Grebely J, 2014, 'Hepatitis C virus network dynamics among people who inject drugs in Vancouver, Canada', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 907A - 908A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014
    Conference Papers | 2014
    Martin NK; Devine A; Eaton JW; Hallett TB; Foster GR; Dore GJ; Easterbrook PJ; Legood R; Vickerman P, 2014, 'P1190 MODELING THE IMPACT OF EARLY ANTIRETROVIRAL THERAPY FOR ADULTS COINFECTED WITH HIV AND HEPATITIS B OR C IN SOUTH AFRICA', in Journal of Hepatology, Elsevier, ENGLAND, London, pp. s483, presented at 49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver, ENGLAND, London, 09 April 2014 - 13 April 2014,
    Conference Papers | 2014
    Martin NK; Vickerman P; Dore GJ; Grebely J; Foster GR; Miners A; Hutchinson S; Goldberg DJ; Martin TC, 2014, 'Who should be prioritized for HCV antiviral treatment? A cost-effectiveness analysis including individual and population prevention benefits', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 1042A - 1042A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014,
    Conference Papers | 2014
    Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV, 2014, 'Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studies', in Antiviral Therapy, SAGE Publications, MA, Boston, pp. 425 - 434, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014,
    Conference Papers | 2014
    Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2014, 'The impact of ribavirin plasma concentration on the eficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', in Antiviral Therapy, SAGE Publications, MA, Boston, pp. 127 - 132, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014,
    Conference Papers | 2014
    Morris MD; Rice TM; Shiboski S; Bruneau J; Cox A; Dore GJ; Grebely J; Hahn JA; Kim AY; Lloyd AR; Hellard M; Maher L; McGovern BH; Prins M; Page K, 2014, 'Historical and geographical trends in hepatitis C virus (HCV) incident infection among people who inject drugs: The International Collaboration on Incident HCV and HIV Infection among PWID (InC3 Study)', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 894A - 895A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014,
    Conference Papers | 2014
    Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Reddy KR; Roberts SK, 2014, 'High Efficacy of Treatment with Sofosbuvir+GS-5816 +/- Ribavirin for 12 Weeks in Treatment Experienced Patients with Genotype 1 or 3 HCV Infection', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 297A - 298A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014,
    Conference Papers | 2014
    Sheridan DA; Hajarizadeh B; Matthews G; Applegate TL; Douglas MW; Askew B; Neely D; Bassendine MF; Dore GJ; Lloyd AR; George J; Grebely J, 2014, 'Hepatitis C lipoviral particle levels are associated with spontaneous clearance of acute infection', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 929A - 929A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 07 November 2014 - 11 November 2014
    Conference Papers | 2013
    Alavi M; Raffa JD; Deans GD; Lai C; Krajden M; Dore GJ; Tyndall MW; Grebely J, 2013, '785 CONTINUED LOW UPTAKE OF TREATMENT FOR HCV IN A LARGE COMMUNITY-BASED COHORT OF INNER CITY RESIDENTS', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s319 - s320, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013,
    Conference Papers | 2013
    Aspinall E; Grebely J; Hutchinson S; Innes H; Walter S; Amin J; Yu A; Goldberg D; Krajden M; Law M; Dore G; Law M, 2013, '965 TRENDS IN MORTALITY AFTER DIAGNOSIS OF HEPATITIS C INFECTION 鈥 AN INTERNATIONAL COMPARISON', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s397 - s398, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013,
    Conference Papers | 2013
    Berg T; Shiffman ML; Zeuzem S; Berg CP; de Figueiredo- Mendes C; Dore GJ; Ferraz ML; Mendes-Corr锚a MC; Lima MP; Parise E; Rios AMP; Reuter T; Sanyal AJ; Shafran SD; Hohmann M; Tatsch F; Cheinquer H; Group OBOTN-CORES, 2013, '792 48 WEEKS OF PEGINTERFERON alfa-2a/RIBAVIRIN IMPROVES SVR24 AND DECREASES RELAPSE ACROSS HCV GENOTYPE 2/3 PATIENT SUBGROUPS NOT ACHIEVING A RAPID VIROLOGICAL RESPONSE: N-CORE STUDY', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s323, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013,
    Conference Papers | 2013
    Bradshaw D; Jacka B; Sacks-Davis R; Lamoury F; Applegate TL; Dore GJ; Down I; Luciani F; Hellard M; Sasadeusz J; Danta M; Matthews G, 2013, 'A novel method comparing sexual networks with the HCV phylogeny in HIV-positive men who have sex with men (MSM) with acute HCV infection identifies two potential intervention targets for permucosally-transmitted HCV', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 1307A - 1307A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013
    Conference Papers | 2013
    Bradshaw D; Lamoury F; Catlett B; Applegate TL; Mcallister J; Dore GJ; Matthews G; Danta M, 2013, 'Seminal HCV RNA level may mirror dynamics of plasma HCV RNA in HIV-positive men with acute HCV infection', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 913A - 913A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013
    Conference Papers | 2013
    Danta M; How-Chow D; McInnes E; Matthews G; Dore GJ, 2013, 'Growing burden of HCV-related advanced liver disease related to enhanced Fibroscan-based screening', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 956A - 957A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013,
    Conference Papers | 2013
    Dore GJ; Lawitz E; H'ezode C; Shafran S; Ramji A; Tatum H; Taliani G; Tran A; Brunetto M; Zaltron S; Strasser S; Weis N; Ghesquiere W; Lee S; Larrey D; Pol S; Harley H; George J; Fung S; de L'edinghen V; Hagens P; Cohen D; Cooney E; Noviello S; Hughes E, 2013, '1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s570 - s571, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013,
    Conference Abstracts | 2013
    Dore GJ, 2013, 'MOVING THE AGENDA FORWARD: ENHANCING HCV TREATMENT UPTAKE AND OUTCOMES FOR PEOPLE WITH DRUG DEPENDENCY', in DRUG AND ALCOHOL REVIEW, WILEY-BLACKWELL, Vol. 32, pp. 2 - 3,
    Conference Papers | 2013
    Doyle JS; Deterding K; Grebely J; Wedemeyer H; Sacks-Davis R; Matthews G; Rice T; Morris M; McGovern BH; Kim AY; Bruneau J; Lloyd AR; Page K; Manns M; Hellard ME; Dore GJ, 2013, 'RESPONSE TO TREATMENT FOLLOWING RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S332 - S332, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013,
    Conference Abstracts | 2013
    Eslam M; Leung R; Berg T; Irving WL; Mangia A; Sheridan D; Abate ML; Weltman M; Spengler U; Mollison L; Cheng W; Dore GJ; Powell E; Riordan S; Douglas M; Suppiah V; Stewart GJ; Booth DR; George J; Ahlenstiel G, 2013, 'Association of IFNL3 polymorphisms with fibrosis progression in viral and non-viral chronic liver disease', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, Vol. 28, pp. 67 - 67
    Conference Papers | 2013
    Grebely J; Page K; Sacks-Davis R; van der Loeff MS; Rice TM; Bruneau J; Morris MD; Hajarizadeh B; Amin J; Cox AL; Kim AY; McGovern BH; George J; Shoukry N; Lauer G; Maher L; Lloyd AR; Hellard M; Dore GJ; Prins M; Group OBOTIS, 2013, '461 SPONTANEOUS CLEARANCE OF ACUTE HCV INFECTION IS ASSOCIATED WITH FEMALE SEX, IL28B GENOTYPE AND HCV GENOTYPE 1 INFECTION', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s189, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013,
    Conference Papers | 2013
    Hajarizadeh B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Grady B; Schinkel J; Maher L; Hellard M; Lloyd AR; Prins M; Grebely J; Dore GJ; Group OBOTIS, 2013, '1157 EARLY HCVRNA DYNAMICS AND FACTORS ASSOCIATED WITH HIGH EARLY HCVRNA LEVEL DURING ACUTE HCV INFECTION', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s470 - s471, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013,
    Conference Papers | 2013
    Holmes JA; Bonanzinga S; Roberts SK; Sievert W; Dore GJ; McCaughan G; Crawford DH; Cheng WS; Weltman MD; Matthews G; Visvanathan K; Sundararajan V; Desmond PV; Bowden DS; Thompson AJ, 2013, '462 THE ASSOCIATION BETWEEN HAEMOGLOBIN DECLINE AND SVR IS INDEPENDENT OF ITPA GENOTYPE DURING PEG-INTERFERON PLUS RIBAVIRIN THERAPY FOR HCV-1: ANALYSIS FROM THE CHARIOT STUDY', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s189 - s190, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013,
    Conference Papers | 2013
    Jacka B; Lamoury F; Simmonds P; Dore GJ; Grebely J; Applegate T, 2013, 'SEQUENCING THE HEPATITIS C VIRUS: A SYSTEMATIC REVIEW', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S471 - S472, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013,
    Conference Papers | 2013
    Jacobson I; Dore GJ; Foster GR; Fried MW; Radu M; Rafalskiy VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Kalmeijer R; Beumont-Mauviel M, 2013, '1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NA脧VE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s574, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013,
    Conference Papers | 2013
    Jacobson IM; Dore GJ; Foster G; Fried MW; Radu MN; Rafalskiy VV; Moroz L; Craxiag A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Kalmeijer R; Beumont-Mauviel M, 2013, 'Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, FL, Orlando, pp. S374 - S374, presented at Digestive Disease Week / 28th Annual Residents and Fellows Research Conference of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT), FL, Orlando, 18 May 2013 - 21 May 2013,
    Conference Papers | 2013
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Manns MP; Marcellin P; Poordad F; Araujo ES; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M, 2013, 'Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: efficacy in difficult-to-treat patient sub-populations in the QUEST 1 and 2 phase III trials', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 756A - 757A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013,
    Conference Papers | 2013
    Kitson MT; Dore GJ; George J; Button P; McCaughan GW; Crawford DH; Sievert W; Weltman MD; Cheng WS; Roberts SK; Group CHARIOTS, 2013, '466 INTERLEUKIN-28B rs12979860 C ALLELE IS PROTECTIVE AGAINST ADVANCED FIBROSIS IN CHRONIC HEPATITIS C GENOTYPE 1 INFECTION: ANALYSIS OF THE AUSTRALASIAN CHARIOT STUDY COHORT', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s191, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013,
    Conference Papers | 2013
    Page K; McGovern BH; Grebely J; Kim AY; Evans J; Morris MD; Cox A; Rice TM; Sacks-Davis R; Hellard M; Bruneau J; Shoukry N; Maher L; Lloyd AR; Prins M; Dore GJ, 2013, 'IL28B Genotype is Associated with Jaundice and Elevated Aminotransferase Levels During Acute HCV Infection', in HEPATOLOGY, WILEY-BLACKWELL, DC, Washington, pp. 1188A - 1188A, presented at 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, DC, Washington, 01 November 2013 - 05 November 2013
    Conference Papers | 2013
    Thompson AJ; Roberts S; Strasser S; Bollipo S; Sloss A; Wenman J; Cheng W; Angus P; Levy M; Mitchell J; Sievert W; Leggett B; Dore G; George J, 2013, 'IL28B genotype frequency in Australian patients with genotype 2/3 HCV differs from that observed in genotype 1 HCV: Interim analysis of the GUIDE study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 173 - 173,
    Conference Papers | 2012
    Cheinquer H; Shiffman ML; Zeuzem S; Berg CP; Berg T; Figueiredo-Mendes CG; Dore GJ; Ferraz ML; Mendes-Correa MC; Lima MP; Parise ER; Perez AM; Reuter T; Sanyal AJ; Shafran SD; Hohmann M; Tatsch F, 2012, 'The outcome of 24 vs. 48 weeks of peginterferon alfa-2a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N-CORE study', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 271A - 272A, presented at 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 09 November 2012 - 13 November 2012,
    Conference Papers | 2012
    Dore GJ; Lawitz E; Hezode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Albert T; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey DG; Pol S; Harley H; George J; Fung S; de Ledinghen V; Hagens P; Cohen DS; Hughes EA; Cooney EL, 2012, 'Twelve- or 16-Week Treatment With Daclatasvir Combined With Peginterferon Alfa and Ribavirin for Hepatitis C Virus Genotype 2 or 3 Infection: Command GT2/3 Study', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 558A - 559A, presented at 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 09 November 2012 - 13 November 2012
    Conference Papers | 2012
    Grebely J; Dore GJ; van der Loeff MS; Rice T; Cox AL; Bruneau J; Kim AY; George J; Maher L; Lloyd AR; Hellard M; Page K; Prins M, 2012, '894 FEMALE SEX AND VARIATIONS IN IL28B ARE INDEPENDENTLY ASSOCIATED WITH SPONTANEOUS CLEARANCE OF ACUTE HCV INFECTION', in Journal of Hepatology, Elsevier, SPAIN, Barcelona, pp. s348, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), SPAIN, Barcelona, 18 April 2012 - 22 April 2012,
    Conference Papers | 2012
    Grebely J; Feld JJ; Applegate T; Matthews G; Hellard M; Sherker A; Petoumenos K; Shaw I; Yeung B; Kaldor JM; Cherepanov V; Bruneau J; Lloyd A; Shoukry N; Dore G, 2012, '889 PLASMA IP10 LEVEL PREDICTS SPONTANEOUS CLEARANCE IN ACUTE HCV INFECTION', in Journal of Hepatology, Elsevier, SPAIN, Barcelona, pp. s346, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), SPAIN, Barcelona, 18 April 2012 - 22 April 2012,
    Conference Papers | 2012
    Kitson MT; Dore GJ; Button P; McCaughan G; Crawford D; Sievert W; Weltman M; Cheng W; Roberts SK, 2012, '1126 VITAMIN D STATUS IS ASSOCIATED WITH COMPLETE EVR BUT NOT SVR IN CHRONIC HEPATITIS C GENOTYPE 1 INFECTION: ANALYSIS OF THE AUSTRALASIAN CHARIOT STUDY COHORT', in Journal of Hepatology, Elsevier, SPAIN, Barcelona, pp. s443 - s444, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), SPAIN, Barcelona, 18 April 2012 - 22 April 2012,
    Conference Papers | 2012
    Kitson MT; Dore GJ; Button P; McCaughan G; Crawford D; Sievert W; Weltman M; Cheng W; Roberts SK, 2012, '901 VITAMIN D STATUS AND LIVER HISTOLOGY IN CHRONIC HEPATITIS C GENOTYPE 1 INFECTION: ANALYSIS OF THE AUSTRALASIAN CHARIOT STUDY COHORT', in Journal of Hepatology, Elsevier, SPAIN, Barcelona, pp. s350 - s351, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), SPAIN, Barcelona, 18 April 2012 - 22 April 2012,
    Conference Papers | 2012
    Roberts S; Mitchell J; Leung RC; Booth D; Mccaughan G; Crawford DH; Thompson A; Sievert W; Dore G; George J, 2012, 'The distribution of polymorphisms in the IL28B gene in previously untreated Australian patients with genotype 1 CHC: the predict study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 178 - 178,
    Conference Papers | 2011
    Ali RJ; Bowden S; Avihingsanon A; Lewin SR; Ruxrungtham K; Locarnini S; Sasadeusz J; Dore GJ; Matthews G, 2011, 'CHANGES IN QUANTITATIVE HBSAG AND HBEAG PREDICT HBV TREATMENT RESPONSE IN HBV/HIV COINFECTED INDIVIDUALS ON TENOFOVIR BASED HAART IN THAILAND', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 1081A - 1081A, presented at 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 04 November 2011 - 08 November 2011,
    Conference Papers | 2011
    Ali RJ; Roberts SK; Ray J; Sievert W; McCaughan G; Weltman M; Crawford D; Cheng W; Rawlinson W; Thommes J; Rizkalla B; Yoshihara M; Dore GJ; Matthews GV, 2011, 'EARLY ON-TREATMENT PLASMA RIBAVIRIN CONCENTRATIONS ARE ASSOCIATED WITH ON-TREATMENT ANAEMIA AND TREATMENT OUTCOME IN CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S161 - S161, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011,
    Conference Papers | 2011
    Applegate T; Gaudieri S; Pham S; White P; Grebely J; Hellard M; Suppiah V; George J; Lloyd A; Dore G; Matthews GV, 2011, 'Impact of host and viral characteristics on treatment outcome within hepatitis C transmission clusters in HIV-positive individuals with recently acquired HCV', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, pp. A87 - A87,
    Conference Papers | 2011
    Applegate T; Gaudieri S; Pham S; White P; Grebely J; Hellard M; Suppiah V; George J; Lloyd A; Dore G; Matthews GV, 2011, 'Impact of host and viral characteristics on treatment outcome within hepatitis C transmission clusters in HIV-positive individuals with recently acquired HCV', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Los Cabos, MEXICO, pp. A87 - A87, presented at International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Los Cabos, MEXICO, 07 June 2011 - 11 June 2011,
    Conference Papers | 2011
    Feld JJ; Grebely J; Applegate T; Matthews GV; Hellard M; Suppiah V; Sherker A; Petoumenos K; Shaw I; Yeung B; Rawlinson W; Booth D; Kaldor JM; Lloyd AR; Dore GJ, 2011, 'IP-10 IS ASSOCIATED WITH EARLY VIRAL KINETICS, BUT NOT SUSTAINED VIROLOGICAL RESPONSE DURING TREATMENT FOR RECENT HEPATITIS C VIRUS INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S455 - S455, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011,
    Conference Papers | 2011
    Fried M; Buti M; Dore GJ; Flisiak R; Ferenci P; Jacobson IM; Marcellin P; Manns MP; Nikitin I; Poordad FF; Sherman M; Zeuzem S; Lenz O; Peeters M; Sekar V; De Smedt G, 2011, 'TMC435 IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1 PATIENTS: FINAL ANALYSIS OF THE PILLAR PHASE IIB STUDY', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 1429A - 1429A, presented at 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 04 November 2011 - 08 November 2011,
    Conference Papers | 2011
    Gaudieri S; Applegate T; Tschochner M; Plauzolles A; Pfafferott K; Lucas M; Diepolder H; Ulsenheimer A; Mallal S; Grebely J; Hellard M; Lloyd A; Kaldor J; Dore G; Matthews GV, 2011, 'Signature resistance mutations to directly acting antiviral agents occur at low prevalence in treatment-naive subjects with recently acquired hepatitis C infection', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, pp. A86 - A86,
    Conference Papers | 2011
    Gaudieri S; Applegate T; Tschochner M; Plauzolles A; Pfafferott K; Lucas M; Diepolder H; Ulsenheimer A; Mallal S; Grebely J; Hellard M; Lloyd A; Kaldor J; Dore G; Matthews GV, 2011, 'Signature resistance mutations to directly acting antiviral agents occur at low prevalence in treatment-naive subjects with recently acquired hepatitis C infection', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Los Cabos, MEXICO, pp. A86 - A86, presented at International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Los Cabos, MEXICO, 07 June 2011 - 11 June 2011,
    Conference Papers | 2011
    Gaudieri S; Applegate T; Tshochner M; Plauzolles A; Pfafferott K; Lucas M; Diepolder H; Ulsenheimer A; Mallal S; Grebely J; Hellard M; Lloyd A; Kaldor J; Dore G; Matthews G, 2011, 'SIGNATURE RESISTANCE MUTATIONS TO DIRECTLY ACTING ANTIVIRAL AGENTS OCCUR AT LOW PREVALENCE IN TREATMENT NAIVE SUBJECTS WITH RECENTLY ACQUIRED HEPATITIS C INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S184 - S185, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011,
    Conference Papers | 2011
    Grebely J; Alavi M; Haber P; Day C; Matthews GV; van Beek I; Walsh N; Yeung B; Petoumenos K; Dolan K; Spelman T; Kaldor JM; Dore GJ; Hellard M, 2011, 'IMPACT OF TREATMENT ON INJECTING DRUG USE BEHAVIORS DURING RECENT HCV INFECTION: THE ATAHC STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S174 - S174, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011,
    Conference Papers | 2011
    Grebely J; Matthews GV; Hellard M; Suppiah V; Petoumenos K; Applegate T; Yeung B; Rawlinson W; Feld J; Lloyd AR; Booth D; Kaldor JM; George J; Dore GJ, 2011, 'IL28B GENOTYPE HAS VARIABLE INFLUENCE ON EARLY VIRAL KINETICS, BUT NO INFLUENCE ON SUSTAINED VIROLOGICAL RESPONSE DURING TREATMENT FOR RECENT HEPATITIS C VIRUS INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S524 - S524, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011,
    Conference Papers | 2011
    Matthews G; Applegate TL; Tschochner M; Plauzolles A; Mallal SA; Grebely J; Hellard M; Lloyd AR; Kaldor JM; Dore GJ; Gaudieri S, 2011, 'ULTRA DEEP SEQUENCING ANALYSIS OF TREATMENT NAIVE INDIVIDUALS WITH RECENTLY ACQUIRED HEPATITIS C INFECTION DEMONSTRATES WIDESPREAD AMINO ACID VARIATION AT KEY PROTEASE AND POLYMERASE SITES OCCURRING AT LOW FREQUENCY', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 1343A - 1344A, presented at 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 04 November 2011 - 08 November 2011,
    Conference Papers | 2010
    Audsley J; Seaberg E; Sasadeusz J; Matthews GV; Avihingsanon A; Ruxrungtham K; Fairley K; Finlayson R; Hwang HS; Littlejohn M; Dore GJ; Locarnini S; Thio CL; Lewin SR, 2010, 'Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A53 - A53, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010,
    Conference Papers | 2010
    Audsley J; Seaberg E; Sasadeusz J; Matthews GV; Avihingsanon A; Ruxrungtham K; Fairley K; Finlayson R; Hwang HS; Littlejohn M; Dore GJ; Locarnini S; Thio CL; Lewin SR, 2010, 'Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A53 - A53, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010,
    Conference Papers | 2010
    Fried MW; Buti M; Dore GJ; Ferenci P; Jacobson I; Marcellin P; Zeuzem S; Lenz O; Peeters M; Sekar VJ; De Smedt G, 2010, 'EFFICACY AND SAFETY OF TMC435 IN COMBINATION WITH PEGINTERFERON alpha-2A AND RIBAVIRIN IN TREATMENT-NAiVE GENOTYPE-1 HCV PATIENTS: 24-WEEK INTERIM RESULTS FROM THE PILLAR STUDY', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 403A - 404A, presented at 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 29 October 2010 - 02 November 2010,
    Conference Papers | 2010
    Grebely J; Dore GJ; van der Loeff MS; Cox AL; Bruneau J; Kim AY; Lloyd AR; Hellard M; Page K; Prins M, 2010, 'FACTORS ASSOCIATED WITH SPONTANEOUS CLEARANCE DURING ACUTE HEPATITIS C VIRUS INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, AUSTRIA, Vienna, pp. S411 - S411, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 14 April 2010 - 18 April 2010,
    Conference Papers | 2010
    Marcellin P; Reddy KR; Roberts SK; Jensen DM; Harrison SA; Hadziyannis SJ; Dore G; Diago M; Weltman MD; Solsky J; Tietz A; Rizzetto M, 2010, 'Peginterferon Alfa-2a (40KD) Has a Wide Safety Margin in Patients Infected With Hepatitis C Virus Genotype 1: Pooled Data From Four Randomized Multicenter Studies', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, pp. S844 - S844,
    Conference Papers | 2010
    Matthews GV; Alavi M; Grebely J; Petoumenos K; Yeung B; Hellard M; Lloyd A; van Beek I; Kaldor J; Haber P; Dore GJ, 2010, 'Depression prior to and during treatment for recent hepatitis C virus (HCV) infection among HCV and HCV/HIV participants in the ATAHC study', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A21 - A21, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010,
    Conference Papers | 2010
    Matthews GV; Alavi M; Grebely J; Petoumenos K; Yeung B; Hellard M; Lloyd A; van Beek I; Kaldor J; Haber P; Dore GJ, 2010, 'Depression prior to and during treatment for recent hepatitis C virus (HCV) infection among HCV and HCV/HIV participants in the ATAHC study', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A21 - A21, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010,
    Conference Papers | 2010
    Matthews GV; Grebely J; Hellard M; Yeung B; Marks P; Rawlinson W; Kaldor J; Dore G, 2010, 'DIFFERENCES IN EARLY VIROLOGICAL DECLINE IN INDIVIDUALS TREATED WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV SUGGEST A POTENTIAL BENEFIT FOR THE USE OF RIBAVIRIN', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Vienna, AUSTRIA, pp. S28 - S28, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, AUSTRIA, 14 April 2010 - 18 April 2010,
    Conference Papers | 2010
    Matthews GV; Grebely J; Hellard M; Yeung B; Marks P; Rawlinson W; Kaldor J; Dore GJ, 2010, 'WEEK 4 HCV RNA IS THE OPTIMAL PREDICTOR OF SVR IN BOTH HIV POSITIVE AND NEGATIVE SUBJECTS WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, AUSTRIA, Vienna, pp. S116 - S116, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 14 April 2010 - 18 April 2010,
    Conference Papers | 2010
    Roberts SK; Ferenci P; Yoshihara M; Crawford DH; Sieverf W; McCaughan GW; Cheng W; Weltman M; Rawlinson WD; McCloud PI; Rizkalla B; Dore GJ, 2010, 'NON-SVR TO PEGINTERFERON ALFA-2A THERAPY AND RIBAVIRIN IS SRONGLY PREDICTED BY BASELINE FACTORS AND WEEK 8 ON-TREATMENT VIRAL LOAD IN HCV GENOTYPE (GT) 1 PATIENTS: NEW INSIGHTS FROM CART ANALYSIS OF THE CHARIOT STUDY', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 801A - 802A, presented at 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 29 October 2010 - 02 November 2010,
    Conference Papers | 2009
    Baleriola C; Rawlinson W; Chaverot S; Stelzer-Braid S; Yoshihara M; Rizkalla B; Dubois D; Sievert W; McCaughan G; Crawford DHG; Weltman M; Cheng WSC; Dore GJ; Roberts S, 2009, 'IMPACT OF LOW-LEVEL HEPATITIS C VIRAEMIA AT WEEK 24 ON HCV TREATMENT RESPONSE IN GENOTYPE 1 PATIENTS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, DENMARK, Copenhagen, pp. S220 - S220, presented at 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, DENMARK, Copenhagen, 22 April 2009 - 26 April 2009,
    Conference Papers | 2009
    Cheng WSC; Roberts S; Weltman M; Crawford DHG; Sievert W; McCaughan G; Rawlinson W; Desmond P; Yoshihara M; Rizkalla B; DePamphilis J; Marks P; Dore GJ, 2009, 'EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A 360 mu G/WEEK IN COMBINATION WITH RIBAVIRIN IN HEPATITIS C GENOTYPE I PATIENTS WITH CIRRHOSIS: ANALYSIS FROM THE CHARIOT STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, DENMARK, Copenhagen, pp. S221 - S221, presented at 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, DENMARK, Copenhagen, 22 April 2009 - 26 April 2009,
    Conference Papers | 2009
    Dalgard O; Grebely J; Dore GJ, 2009, 'Hepatitis C virus reinfection following sustained virological response in injection drug users', in Suchtmedizin in Forschung und Praxis, pp. 231 - 234
    Conference Papers | 2009
    Dore GJ; Hellard M; Matthews G; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan GW; White PA; Ffrench RA; Rawlinson W; Lloyd AR; Kaldor J, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 723A - 723A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009,
    Conference Papers | 2009
    Grebely J; Raffa J; Lai C; Krajde M; Fischer B; Kerr T; Dore G; Tyndall M, 2009, 'IMPACT OF HEPATITIS C VIRUS INFECTION ON LIVER-RELATED MORTALITY IN A LARGE COMMUNITY-BASED COHORT OF INNER CITY RESIDENTS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, DENMARK, Copenhagen, pp. S152 - S152, presented at 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, DENMARK, Copenhagen, 22 April 2009 - 26 April 2009,
    Conference Papers | 2009
    Iser DM; Boyd A; Avihingsanon A; Thompson AJ; Nguyen T; Matthews GV; Bowden S; Locarnini SA; Slavin J; Desmond PV; Dore GJ; Ruxrungtham K; Lewin SR, 2009, 'No increase in intrahepatic mononuclear or stellate cell activation in HIV-HBV co-infected individuals', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A292 - A292,
    Conference Papers | 2009
    Iser DM; Boyd AJ; Avihingsanon A; Thompson AL; Nguyen T; Matthews G; Bowden S; Locarnini S; Slavin J; Desmond PV; Dore GJ; Ruxrungtham K; Lewin SR, 2009, 'NO INCREASE IN INTRAHEPATIC MONONUCLEAR CELL OR STELLATE CELL ACTIVATION IN HIV-HBV CO-INFECTED INDIVIDUALS WITH ADVANCED HIV AND MILD LIVER DISEASE', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 993A - 994A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009,
    Conference Papers | 2009
    Marcellin P; Jensen DM; Roberts SK; Hadziyannis SJ; Dore GJ; Diago M; Weltman M; McCaughan GW; Cheng W; Crawford DH; Sievert W; Rawlinson W; Solsky J; Tietz A; Rizzetto M, 2009, 'PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha 2A) HAS A WIDE SAFETY MARGIN IN COMBINATION WITH RIBAVIRIN (RBV) 1000/1200 MG/DAY IN PATIENTS INFECTED WITH HCV GENOTYPE 1: POOLED ANALYSIS OF DATA FROM FOUR RANDOMIZED MULTICENTER STUDIES', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1030A - 1031A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009,
    Conference Papers | 2009
    Matthews G; Grebely J; Pham ST; Hellard M; Marks P; Rawlinson W; Kaldor J; Lloyd AR; White PA; Dore GJ, 2009, 'EPIDEMIOLOGY OF RECENTLY ACQUIRED HEPATITIS C VIRUS (HCV) INFECTION IN HCV AND HCV/HIV INFECTED PARTICIPANTS IN THE ATAHC STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 668A - 668A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009,
    Conference Papers | 2009
    McCaughan GW; Roberts SK; Weltman M; Crawford DH; Sievert W; Cheng W; Rawlinson W; Yoshihara M; McCloud PI; Rizkalla B; Dore GJ, 2009, 'ADVANCED FIBROSIS IN GENOTYPE 1 HCV INFECTED PATIENTS RECEIVING ANTIVIRAL THERAPY IS ASSOCIATED WITH VIROLOGIC RELAPSE INDEPENDENT OF RAPID (RVR) AND EARLY (EVR) VIROLOGIC RESPONSE', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1027A - 1028A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009,
    Conference Papers | 2009
    Roberts S; Weltman M; Crawford DHG; Cheng WSC; Sievert W; McCaughan G; Desmond P; Rawlinson W; Marks P; Yoshihara M; Rizkalla B; DePamphilis J; Dore GJ, 2009, 'HIGH-DOSE PEGINTERFERON ALFA-2A (40KD) INDUCTION THERAPY AND STANDARD RIBAVIRIN ENHANCES EARLY BUT NOT SUSTAINED VIROLOGICAL RESPONSES IN HCV GENOTYPE 1 PATIENTS: FINAL CHARIOT STUDY RESULTS', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, DENMARK, Copenhagen, pp. S50 - S51, presented at 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, DENMARK, Copenhagen, 22 April 2009 - 26 April 2009,
    Conference Papers | 2009
    Roberts SK; Ngu MC; Strasser SI; George J; Dore GJ; Locarnini S; Sasadeusz J; Sievert W; Peschell KJ; Mitchell K; Elsome AM, 2009, 'PREVALENCE AND NATURE OF VIRAL MUTATIONS IN CHRONIC HEPATITIS B (CHB) PATIENTS ON ORAL ANTIVIRAL THERAPY (AVT): THE CHARM STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 488A - 489A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009,
    Conference Papers | 2009
    Roberts SK; Ngu MC; Strasser SI; George J; Dore GJ; Locarnini SA; Sasadeusz JJ; Sievert W; Peschell K; Mitchell K, 2009, 'Prevalence and characteristics of hepatitis B virus (HBV) mutations in chronic hepatitis B (CHB) patients on oral antiviral therapy (AVT): the charm study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A296 - A296,
    Conference Papers | 2009
    Sievert W; Dore GJ; McCaughan GW; Yoshihara M; Crawford DH; Cheng W; Weltman M; Rawlinson W; Rizkalla B; McCloud PI; Roberts SK, 2009, 'SIGNIFICANT HEMOGLOBIN (HB) DECLINE DURING PEGYLATED INTERFERON AND RIBAVIRIN THERAPY IN HCV GENOTYPE 1 IS ASSOCIATED WITH SUSTAINED VIROLOGIC RESPONSE (SVR): AN ANALYSIS FROM THE CHARIOT STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1020A - 1021A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009,
    Conference Papers | 2009
    Weltman M; Dore GJ; Sievert W; McCaughan GW; Crawford DH; Cheng W; Rawlinson W; Yashihara M; McCloud PI; Rizkalla B; Roberts SK, 2009, 'BASELINE AND ONTREATMENT PREDICTORS OF SVR TO PEGINTERFERON ALFA-2A THERAPY AND RIBAVIRIN IN HCV GENOTYPE (GT) 1 TREATMENT NAIVE PATIENTS: NEW INSIGHTS FROM THE CHARIOT STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1033A - 1034A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009,
    Reports | 2009
    Wilson D; Kwon A; Anderson J; Thein H; Law M; Maher L; Dore G; Kaldor J, 2009, Return on investment 2: evaluating the cost-effectiveness of needle and syringe programs among injecting drug users in Australia, Publications Production Unit (Public Affairs, Parliamentary and Access Branch) Commonwealth Department of Health and Ageing, Canberra, Australia, 3123,
    Conference Papers | 2008
    Audsley J; Littlejohn M; Yuen L; Desmond C; Dore GJ; Ruxrungtham K; Locarnini S; Thio C; Lewin S; Revill P, 2008, 'Virological characteristics of a longitudinal HIV/HBV co-infected cohort prior to initiation of HBV-active HAART', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A336 - A337,
    Conference Papers | 2008
    Crawford D; Robertson SL; Weltman MD; Cheng W; Sievert W; McCaughan G; Desmond PV; Alston A; DePamphilis J; Marks PB; Dore GJ, 2008, 'Baseline factors associated with rapid and early virological responses in HCV genotype 1 patients treated with induction dosing of pegylated interferon: The CHARIOT study', in Journal of Hepatology, Elsevier Science BV, Amsterdam, Netherlands, pp. S290 - S291, presented at Journal of Hepatology
    Conference Papers | 2008
    Flynn J; White PA; Grebely J; Kaldor JM; Hellard M; Dore GJ; Lloyd AR; Ffrench R, 2008, 'Immunity to acute hepatitis C and the influence of early therapy', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A356 - A356,
    Conference Papers | 2008
    Gidding H; Topp L; Middleton M; Dore G; Robinson K; Maher L; Kaldor J; Law M, 2008, 'The epidemiology of hepatitis C in Australia-a review of notifications, treatment uptake, and associated liver transplantations 1997-2006', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A379 - A379,
    Conference Papers | 2008
    Grebely J; Matthews G; White PA; Renkin M; Flynn J; Ffrench R; Kaldor JM; Hellard M; Lloyd AR; Dore GJ, 2008, 'Incidence and risk factors for HCV reinfection and superinfection in individuals treated for acute/early chronic HCV infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A343 - A344,
    Conference Papers | 2008
    Grebely J; Ngai T; Knight E; Duncan F; Raffa J; Genoway K; Showler G; Krajden M; Dore GJ; Conway B, 2008, 'Low rate of hepatitis C virus re-infection following sustained virological response among injection drug users having received treatment for HCV infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A338 - A338,
    Conference Papers | 2008
    Grebely J; Raffa J; Krajde M; Fischer B; Kerr TH; Dore GJ; Tyndall M, 2008, 'IMPACT OF HEPATITIS C VIRUS INFECTION ON LIVER-RELATED MORTALITY IN A LARGE COMMUNITY-BASED COHORT OF INNER CITY RESIDENTS', in Journal of Hepatology, Elsevier Science BV, Amsterdam, Netherlands, pp. 401 - 402, presented at Journal of Hepatology
    Conference Papers | 2008
    Hellard M; Grebely J; Matthews G; Haber PS; Petoumenos K; Yeung B; Van Beek IA; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Impact of illicit drug use on response to therapy during treatment for acute and early chronic HCV infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A337 - A338
    Conference Papers | 2008
    Hellard M; Matthews G; Petoumenos K; Grebely J; Haber PS; Van Beek IA; Marks P; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Factors associated with uptake of treatment for acute and early chronic hepatitis C virus infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A344 - A344
    Conference Papers | 2008
    Jin F; Prestage G; Dore GJ; Zablotska I; Rawstorne PR; Kippax SC; Kaldor JM; Grulich AE, 2008, 'Prevalence, Incidence and Risk Factors for Hepatitis C in HIV Negative and HIV Positive Homosexual Men', in Sexual Health, CSIRO Publishing, Australia, pp. 20 - 21, presented at Sexual Health, Perth, 17 September 2008 - 20 September 2008
    Conference Papers | 2008
    Jones T; Marks P; Connelly C; Warner S; Fragomeli V; Walker PJ; Ferguson CM; Dore GJ, 2008, 'Predictors of HCV treatment uptake and clinical trial participation among patients newly referred for HCV infection: the HCV clinical audit study', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A241 - A241, presented at Journal of Gastroenterology and Hepatology,
    Conference Papers | 2008
    Maher L; Dore G; Treloar C; Rawlinson W; White P; Dolan K; Zekry A; Madden A; Loveday S; Kaldor J; Lloyd A, 2008, 'Preparedness for candidate hepatitis C vaccine trials in people who inject drugs: challenges and opportunities', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A358 - A358
    Conference Papers | 2008
    Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Marks P; Revill PA; Ayres A; Bow-den S; Locarnini S; Thio CL; Ruxrungtham K; Dore GJ, 2008, 'TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS', in HEPATOLOGY, JOHN WILEY & SONS INC, CA, San Francisco, pp. 712A - 713A, presented at 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, CA, San Francisco, 31 October 2008 - 04 November 2008,
    Conference Papers | 2008
    Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Marks PB; Revill P; Ayres A; Bow-den S; Locarnini S; Thio C; Ruxrungtham K; Dore GJ, 2008, 'TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 906 - 907, presented at Hepatology
    Conference Papers | 2008
    Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Thio C; Bowden SJ; Ayres A; Locarnini S; Ruxrungtham K; Dore GJ, 2008, 'Tenofovir based HAART is associated with high rates of HBV DNA suppression and HBEAG seroconversion in thai HIV-HBV coinfected patients', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A336 - A336,
    Conference Papers | 2008
    Matthews G; Grebely J; White PA; Renkin M; Marks PB; Ffrench R; Rawlinson WD; Kaldor JM; Hellard M; Lloyd AR; Dore GJ, 2008, 'INCIDENCE AND RISK FACTORS FOR HCV SUPERINFECTION AND REINFECTION IN INDIVIDUALS TREATED FOR ACUTE/EARLY CHRONIC HCV INFECTION', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1844 - 1845, presented at Hepatology
    Conference Papers | 2008
    Matthews G; Hellard M; Haber PS; Yeung B; Marks P; Rawlinson WD; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Frequency of rapid virological response and its utility as a predictor of treatment outcome in individuals treated within the Australian trial in acute hepatitis C (ATAHC)', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A337 - A337
    Conference Papers | 2008
    Matthews G; Hellard M; Haber PS; Yeung B; Marks PB; Sasadcusz J; Baker DA; McCaughan G; White PA; Rawlinson WD; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Frequency of RVR and its utility as a predictor of treatment outcome in individuals treated within the Australian Trial in Acute Hepatitis c (ATAHC)', in Journal of Hepatology, Elsevier Science BV, Amsterdam, Netherlands, pp. S303 - S303, presented at Journal of Hepatology
    Conference Papers | 2008
    Matthews G; White PA; Hellard M; Grebely J; Marks P; Yeung B; Kaldor JM; Lloyd AR; Danta M; Dore GJ, 2008, 'Evidence of sexual transmission of hepatitis C virus infection among HIV-positive men who have sex with men in the Australian trial in acute hepatitis C (ATAHC) study', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A365 - A366,
    Conference Papers | 2008
    Nguyen VT; Amin J; Law MG; Dore GJ, 2008, 'Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A343 - A343,
    Conference Papers | 2008
    Roberts SK; Ngu MC; Strasser SI; George J; Dore GJ; Locarnini SA; Sasadeusz JJ; Sievert W; Elsome AM, 2008, 'Prevalence and nature of viral mutations in chronic hepatitis B patients on antiviral therapy: the charm study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL PUBLISHING, INC, pp. A264 - A264,
    Conference Papers | 2008
    Robotin M; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy MT, 2008, 'Modeling population-based chronic hepatitis B screening and treatment to prevent cirrhosis and liver cancer among high risk populations in Australia', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A358 - A359
    Conference Papers | 2008
    Sasadeusz J; Dore GJ; Kronborg I; Barton D; Yoshihara M; Weltman M, 2008, 'PEGYLATED INTERFERON ALFA-2A (PEG-2A) PLUS RIBAVIRIN (RBV) FOR PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) ON OPIOID PHARMACOTHERAPY: VIROLOGICAL OUTCOMES, PSYCHOLOGICAL IMPACT AND SAFETY', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1310 - 1311, presented at Hepatology
    Conference Papers | 2008
    Sasadeusz J; Dore GJ; Kronborg I; Barton DA; Yoshihara M; Weltman M, 2008, 'PEGYLATED INTERFERON ALFA-2A (PEG-2A) PLUS RIBAVIRIN (RBV) FOR PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) ON OPIOID PHARMACOTHERAPY: VIROLOGICAL OUTCOMES, PSYCHOLOGICAL IMPACT AND SAFETY', in HEPATOLOGY, JOHN WILEY & SONS INC, CA, San Francisco, pp. 894A - 894A, presented at 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, CA, San Francisco, 31 October 2008 - 04 November 2008,
    Conference Papers | 2008
    White PA; Grebely J; Flynn J; Matthews G; Renkin M; Yeung B; Rawlinson WD; Kaldor JM; Hellard M; Lloyd AR; Ffrench R; Dore GJ, 2008, 'NATURAL HISTORY OF HCV SUPERINFECTION AND REINFECTION', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1056 - 1057, presented at Hepatology
    Conference Papers | 2008
    White PA; Grebely J; Matthews G; Flynn J; Renkin M; Kaldor JM; Lloyd AR; Hellard M; Ffrench R; Dore GJ, 2008, 'Natural history of HCV reinfection and superinfection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A355 - A355,
    Conference Papers | 2007
    Klumpp K; Smith D; Brandl M; Alfredson T; Sarma K; Smith M; Najera I; Jiang W-R; Le Pogam S; Leveque V; Ma H; Tu Y; Chan R; Chen C-W; Wu X; Birudaraj R; Swallow S; Martin JA; Cammack N; Berns H; Fettner S; Ipe D; Mannino M; O'Mara E; Washington C; Roberts S; Cooksley G; Dore G; Shaw D; Blue DR; Zahm F; Hill G, 2007, 'Design and characterization of R1626, a prodrug of the HCV replication inhibitor R1479 (4'-azidocytidine) with enhanced oral bioavailability', in ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV, CA, Palm Spring, pp. A35 - A35, presented at 20th International Conference on Antiviral Research, CA, Palm Spring, 29 April 2007 - 03 May 2007,
    Conference Papers | 2007
    McCaughan GW; Omata M; Amarapurkar D; Bowden S; Chow WC; Chutaputti A; Dore G; Gane E; Guan R; Hamid SS; Hardikar W; Hui CK; Jafri W; Jia JD; Lai MY; Wei L; Leung N; Piratvisuth T; Sarin S; Sollano J; Tateishi R, 2007, 'Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection', in Journal of Gastroenterology and Hepatology (Australia), pp. 615 - 633,
    Conference Papers | 2007
    Roberts S; Cooksley G; Dore G; Robson R; Shaw D; Berns H; Brandt M; Fenner S; Hill G; Ipe D; Klumpp K; Mannino M; O'mara E; Najera I; Tu Y; Washington C, 2007, 'Viral load and ALT reductions associated with R1626 monotherapy, a novel nucleoside analog, in chronic hepatitis C genotype 1 patients', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, DC, Washington, pp. A779 - A779, presented at Digestive Disease Weeking Meeting/ASGE Postgraduate Course Meeting, DC, Washington, 19 May 2007 - 24 May 2007,
    Conference Papers | 2007
    Roberts S; Weltman M; Crawford D; Cheng W; Sievert W; McCaughan GW; Desmond PV; Yoshihara M; Miller JE; Depamphilis J; Marks P; Dore GJ, 2007, 'Rapid and early virological response rates are increased with 12 week 360 mu g/wk peginterferon alfa-2A (40KD) and standard ribavirin in HCV genotype 1 treatment naive patients: Efficacy and safety analysis of the induction phase of the CHARIOT study', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 257A - 258A, presented at 58th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 02 November 2007 - 06 November 2007,
    Conference Papers | 2006
    Campbell S; Norris S; Mernagh P; Batey R; Dore GJ, 2006, 'Economic modelling to determine the cost-effectiveness of treatment of patients with histologically mild chronic hepatitis C with pegylated interferon alpha-2b plus ribavirin', in VALUE IN HEALTH, ELSEVIER SCIENCE INC, pp. A307 - A307,
    Conference Papers | 2006
    Ffrench RA; Flynn J; Goy K; Hosseiny P; Pan Y; Rawlinson WD; White PA; Nguyen O; Hellard M; Kaldor JM; Dore GJ; Lloyd AR, 2006, 'Comprehensive analysis of IFN-gamma and IL-2 production by T cells in acute and chronic HCV infection', in Journal of Clinical Virology, Elsevier Science BV, Amsterdam, Netherlands, pp. S123 - S123, presented at Journal of Clinical Virology, Melbourne
    Conference Papers | 2006
    Hellard M; Dore G; Haber P; Marks P; Matthews G; Yeung B; Nguyen O; Pan Y; Ffrench R; McCaughan G; Van Beek I; White P; Dolan K; Rawlinson W; Lloyd A; Kaldor J, 2006, 'Australian trial in acute hepatitis C: preliminary findings', in JOURNAL OF CLINICAL VIROLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, pp. S139 - S139, presented at 12th International Symposium on Viral Hepatitis and Liver Disease, FRANCE, Paris, 01 July 2006 - 05 July 2006,
    Conference Papers | 2006
    Nguyen VT; McLaws M; Dore GJ, 2006, 'Highly endemic hepatitis B infection in rural Vietnam', in Hepatitis 5th Australian Conference, Hepatitis 5th Australian Conference, Sydney, pp. 20 - 22, presented at Hepatitis 5th Australian Conference, Sydney, 20 February 2006 - 22 February 2006
    Conference Papers | 2006
    Nguyen VT; McLaws M; Dore GJ, 2006, 'Highly endemic hepatitis B infection in rural Vietnam', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A98 - A98,
    Conference Papers | 2006
    Nguyen VT; Razali K; Amin J; Law MG; Dore GJ, 2006, 'Estimates of Hepatitis B-Realted Liver Cancer Among Vietnam Born Population in Australia', in 18th Annual ASHM Conference, 18th Annual ASHM Conference, Melbourne, pp. 152 - 153, presented at 18th Annual ASHM Conference, Melbourne, 11 October 2006 - 14 October 2006
    Conference Papers | 2006
    Nguyen VT, 2006, 'Highly endemic Hepatitis B infection in Rural Vietnam', in Shanghai - Hong Kong International Liver Congress 2006, Shanghai, presented at Shanghai - Hong Kong International Liver Congress 2006, Shanghai, 25 March 2006 - 28 March 2006
    Conference Papers | 2005
    Amin J; Law MG; Bartlett M; Kaldor JM; Dore GJ, 2005, 'Causes of death in people with hepatitis B or C infection: A population based cohort study', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 214A - 214A, presented at 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, CA, San Francisco, 11 November 2005 - 15 November 2005,
    Conference Papers | 2004
    Hardikar W; Polis S; Kesson A; Mews C; Jones C; Elliott E; Dore G; Kaldor J, 2004, 'National surveillance of hepatitis C virus infection in Australian children.', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 415A - 415A, presented at 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 29 October 2004 - 02 November 2004,
    Conference Abstracts | 2003
    Micallef JM; Jauncey M; Amin J; Rawlinson W; Gilmour S; van Beek I; Kaldor JM; White PA; Dore GJ, 2003, 'Hepatitis C virus reinfection within a cohort of injecting drug users.', in HEPATOLOGY, W B SAUNDERS CO, MASSACHUSETTS, BOSTON, Vol. 38, pp. 266A - 266A, presented at 54th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease, MASSACHUSETTS, BOSTON, 24 October 2003 - 28 October 2003,
    Conference Papers | 2002
    Freeman AJ; Law MG; Kaldor JM; Dore GJ, 2002, 'Hepatitis C: The Australian experience.', in HEPATOLOGY, W B SAUNDERS CO, MASSACHUSETTS, BOSTON, pp. 554A - 554A, presented at 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD), MASSACHUSETTS, BOSTON, 01 November 2002 - 05 November 2002,
    Conference Papers | 1999
    Wettstein AR; Maddocks S; Dore G; Edwards P, 1999, 'Association of cryptosporidiosis to HIV-related cholangiopathy and the role of protease inhibitors', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, pp. A39 - A39,
    Conference Papers | 1997
    Wettstein A; Dore G; Murphy C; Hing M; Edwards P, 1997, 'HIV-related cholangiopathy in Australia', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, pp. A1117 - A1117,
    Preprints |
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ; Group S-CS, Reduced Hepatitis C Incidence Associated with Rapid Treatment Scale-Up in Australian Prisons: Treatment-as-Prevention in the SToP-C Study,
    Preprints |
    Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua N; fierer D; Chromy D; Rockstroh JK; Martin T; Ingiliz P; Hung C-C; Dore GJ; Martinello M; Matthews G, Hepatitis C Reinfection Risk Following Successful Therapy Among People Living with HIV: A Global Systematic Review, Meta-Analysis, and Meta-Regression,
    Preprints |
    Joseph S; Dore GJ, Vaccine Apartheid: A Human Rights Analysis of COVID-19 Vaccine Inequity,
    Preprints |
    Koopsen J; Matthews G; Rockstroh JK; Applegate TL; Bhagani SR; Grebely J; Rauch A; Sacks-Davis R; Ingiliz P; Boesecke C; Rebers S; Feld J; Bruneau J; Martinello M; Hellard ME; Dore GJ; Schinkel J; van der Valk M; Study Group REACT, Hepatitis C Virus Transmission Dynamics in a Global Cohort of Men Who Have Sex with Men with Recently Acquired Infection,
    Preprints |
    Kwon J; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT, Australia on Track to Achieve Who HCV Elimination Targets Following Rapid Initial DAA Treatment Uptake: A Modelling Study,
    Preprints |
    Lockhart I; Yeo MGH; Hajarizadeh B; Dore GJ; Danta M, Hepatocellular Carcinoma Incidence After Hepatitis C Cure Among Patients With Advanced Fibrosis or Cirrhosis: A Systematic Review and Meta-Analysis,
    Preprints |
    Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Rowling D; Doong N; Jackson E; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV, Moving Towards HCV Elimination Among People Living with HIV in Australia: Analysis of the CEASE Prospective Cohort Study,
    Preprints |
    Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon J; Lloyd AR; Dore GJ; Wiseman V; Grebely J, Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis,
    Preprints |
    Shih STF; Cheng Q; Carson J; Valerio H; Sheehan Y; Gray RT; Cunningham EB; Kwon J; Lloyd AR; Dore GJ; Wiseman V; Grebely J, Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis,

Major Category 1 Grants
  • NHMRC Investigator Grant (Leadership 3; 2022-2026: $1.92M)聽
  • NHMRC聽Practitioner Fellowships (2012-2016: $523K; 2017-2021: $569K).
  • NHMRC Program Grants as CI (2014-2018: $5.4M; CIA 2019-2023: $9.0M).
  • NHMRC Partnership Grants as CI (2014-2019:聽$1.49M; 2016-2020:聽$1,49M; 2018-2022: $2.1M; 2019-2022: $1.42M).
  • NIH R01 Grants as CI (2015-2020: $US 3.7M; 2011-2016: $2.3M).

2007, 2012, 2017 聽聽聽聽聽聽NHMRC Practitioner Fellowship

2007聽聽聽聽 聽聽聽聽聽聽聽聽聽聽聽 聽聽聽聽聽聽聽聽聽聽Frank Fenner ASID Award for Advanced Research in Infectious Diseases

2016聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽Fellow of Australian Academy of Health and Medical Science

2020聽 聽 聽 聽 聽 聽 聽 聽 聽 聽 聽 聽 聽 聽Australian Museum Eureka Prize in Infectious Diseases

2020, 2021聽 聽 聽 聽 聽 聽 聽 聽 聽Clarivate Highly Cited Researcher (clinical medicine)